

CITATION REPORT

List of articles citing

Proposals for the classification of the myelodysplastic syndrome

DOI: 10.1111/j.1365-2141.1982.tb08475.x

British Journal of Haematology, 1982, 51, 189-199.

Source: <https://exaly.com/paper-pdf/85738611/citation-report.pdf>

Version: 2024-04-28

This report has been generated based on the citations recorded by exaly.com for the above article. For the latest version of this publication list, visit the link given above.

The third column is the impact factor (IF) of the journal, and the fourth column is the number of citations of the article.

#	Paper	IF	Citations
2315	Myelodysplastic syndromes: is another classification necessary?. <i>British Journal of Haematology</i> , 1982 , 52, 343-4	4.5	16
2314	The diagnosis of preleukaemia. <i>British Journal of Haematology</i> , 1983 , 55, 1-6	4.5	16
2313	Myelodysplastic syndrome in polycythaemia vera. <i>British Journal of Haematology</i> , 1983 , 55, 193-4	4.5	20
2312	Refractory anaemia with excess of blasts in transformation: is a new category necessary?. <i>British Journal of Haematology</i> , 1983 , 55, 196-7	4.5	4
2311	Blood neutrophil function in primary myelodysplastic syndromes. <i>British Journal of Haematology</i> , 1983 , 55, 217-27	4.5	115
2310	Skin infiltration associated with chronic myelomonocytic leukaemia. <i>British Journal of Haematology</i> , 1983 , 53, 257-64	4.5	60
2309	Coexistent myelodysplasia and plasma cell neoplasia. <i>British Journal of Haematology</i> , 1983 , 54, 91-6	4.5	26
2308	Myeloid lymphoid node infiltration preceding acute myeloid leukaemia in a case of myelodysplastic syndrome. <i>British Journal of Haematology</i> , 1983 , 54, 321-3	4.5	1
2307	Chronic myelodysplastic syndrome: short survival with or without evolution to acute leukaemia. <i>British Journal of Haematology</i> , 1983 , 55, 691-700	4.5	118
2306	Low dose arabinosyl cytosine for treatment of myelodysplastic syndromes and subacute myeloid leukemia. 1983 , 7, 539-45		68
2305	Postleukemic dysmyelopoiesis. 1983 , 15, 321-34		13
2304	Flow cytometric DNA content in myelodysplastic syndromes. 1983 , 4, 238-43		26
2303	Quantitative cytochemistry of blood neutrophils in myelodysplastic syndromes and chronic granulocytic leukaemia. 1983 , 1, 92-6		8
2302	Use of bone-marrow culture in prediction of acute leukaemic transformation in preleukaemia. 1983 , 1, 1409-12		41
2301	Prevalence and distribution of ringed sideroblasts in primary myelodysplastic syndromes. 1983 , 36, 566-9		35
2300	Haematological features of primary myelodysplastic syndromes (PMDS) at initial presentation: a study of 118 cases. 1983 , 36, 1129-35		60
2299	Ring sideroblasts and myelodysplastic syndromes. 1983 , 36, 1413-4		1

2298	Leukemia and preleukemia after adjuvant treatment of gastrointestinal cancer with semustine (methyl-CCNU). 1983 , 309, 1079-84		188
2297	Response of preleukemic syndromes to continuous infusion of low-dose cytarabine. 1983 , 309, 1599-602		146
2296	Low doses of cytarabine in the treatment of myelodysplastic syndrome and acute myeloid leukemia. 1983 , 309, 1653-4		47
2295	Association of an inversion of chromosome 16 with abnormal marrow eosinophils in acute myelomonocytic leukemia. A unique cytogenetic-clinicopathological association. 1983 , 309, 630-6		438
2294	Defective neutrophil function and microbicidal mechanisms in the myelodysplastic disorders. 1983 , 36, 1120-8		57
2293	Chronic myelomonocytic leukemia: value of touch preps. 1984 , 10, 374-7		
2292	Progressive multifocal leukoencephalopathy, myelodysplastic syndrome type II and prostatic carcinoma. 1984 , 60, 157-8		2
2291	Natural killer (NK)-cell activity and antibody-dependent cellular cytotoxicity (ADCC) in primary preleukemic syndrome. 1984 , 8, 239-47		56
2290	Bone marrow histology in myelodysplastic syndromes. I. Histological findings in myelodysplastic syndromes and comparison with bone marrow smears. <i>British Journal of Haematology</i> , 1984 , 57, 423-30	4.5	124
2289	8;21 translocation in acute granulocytic leukaemia: cytological, cytochemical and clinical features. <i>British Journal of Haematology</i> , 1984 , 56, 199-213	4.5	204
2288	Myelodysplastic syndromes: is another classification necessary?. <i>British Journal of Haematology</i> , 1984 , 56, 515-7	4.5	19
2287	Serous effusions in monocytic leukaemias. <i>British Journal of Haematology</i> , 1984 , 58, 547-52	4.5	34
2286	The effect of low dose Ara-C in acute nonlymphoblastic leukaemias and atypical leukaemia. <i>British Journal of Haematology</i> , 1984 , 58, 9-18	4.5	42
2285	Sequential karyotypic evolutions and bone marrow aplasia preceding acute myelomonocytic transformation from myelodysplastic syndrome. <i>British Journal of Haematology</i> , 1984 , 58, 53-60	4.5	21
2284	Natural killer-interferon system in patients with preleukaemic states. <i>British Journal of Haematology</i> , 1984 , 58, 71-81	4.5	39
2283	Bone marrow histology in myelodysplastic syndromes. II. Prognostic value of abnormal localization of immature precursors in MDS. <i>British Journal of Haematology</i> , 1984 , 58, 217-25	4.5	142
2282	Neutrophils with ring-shaped nuclei in myeloproliferative disease. <i>British Journal of Haematology</i> , 1984 , 58, 227-30	4.5	35
2281	Low dose cytosine arabinoside (Ara C) in myelodysplastic syndromes. <i>British Journal of Haematology</i> , 1984 , 58, 231-40	4.5	98

2280	An analysis of prognostic factors in preleukemia: interest of bone marrow scintigraphy. 1984 , 16, 235-42	1
2279	Familial DiGuglielmo syndrome. 1984 , 54, 932-8	5
2278	Cytogenetic and in vitro culture studies on chronic myelomonocytic leukemia. 1984 , 54, 2468-74	9
2277	A reliable method with good cell preservation for the demonstration of peroxidase activity in human platelets and megakaryocytes. 1984 , 80, 79-84	4
2276	Cytarabine in pre-leukaemia. 1984 , 1, 1187	10
2275	Treatment of advanced myelodysplastic syndrome with alfacalcidol. 1984 , 2, 761	35
2274	Dysmyelopoietic syndrome. Current concepts. 1984 , 76, 122-8	15
2273	Associated abnormalities of chromosomes 1, 5, and 11 in dysmyelopoietic syndromes. 1984 , 12, 31-7	9
2272	Major karyotype aberrations, including t(3;12), in a patient with myelodysplastic syndrome. 1984 , 13, 267-73	2
2271	Empyema of the gallbladder. 1984 , 1, 1187	1
2270	Myelodysplastic syndromes in children: Observations on five cases. 1984 , 1, 71-75	6
2269	Acute nonlymphocytic leukemia. 1985 , 32, 653-68	19
2268	Primary refractory anemia: clinical and laboratory study of erythropoiesis in 16 patients. 1985 , 289, 229-35	5
2267	Low dose cytarabine in acute non-lymphoblastic leukemia or myelodysplastic syndrome: report of six cases and review of the literature. 1985 , 15, 10-5	7
2266	Primary acquired sideroblastic anaemia and myeloproliferative disease: a report on three cases. 1985 , 7, 113-8	3
2265	T lymphoblastic transformation of refractory anaemia with excess of blasts. 1985 , 7, 89-95	17
2264	Cytochemical examinations of cultivated unclassified leukaemic cells. 1985 , 17, 1377-80	3
2263	Synergistic interaction between differentiation inducers and DNA synthesis inhibitors: a new approach to differentiation induction in myelodysplasia and acute myeloid leukaemia. 1985 , 9, 573-81	54

2262	Treatment of acute myeloid leukemia developing after a myelodysplastic phase with low dose arabinosyl cytosine. 1985 , 9, 1293-8		5
2261	Acute eosinophilic leukemia: characterization by cytochemistry, chromosomal analysis, and in vitro colony formation. 1985 , 63, 133-7		7
2260	The effect of retinoids on CFU-GM from normal subjects and patients with myelodysplastic syndrome. <i>British Journal of Haematology</i> , 1985 , 59, 15-20	4.5	20
2259	The myelodysplastic syndrome: analysis of laboratory characteristics in relation to the FAB classification. <i>British Journal of Haematology</i> , 1985 , 59, 311-9	4.5	99
2258	Myelodysplastic syndromes: a study of 101 cases according to the FAB classification. <i>British Journal of Haematology</i> , 1985 , 61, 83-92	4.5	110
2257	Myelodysplastic syndromes: a scoring system with prognostic significance. <i>British Journal of Haematology</i> , 1985 , 59, 425-33	4.5	461
2256	The myelodysplastic syndromes: different evolution patterns based on sequential morphological and cytogenetic investigations. <i>British Journal of Haematology</i> , 1985 , 59, 659-70	4.5	145
2255	Prognostic factors in the myelodysplastic syndromes: importance of initial data on peripheral blood counts, bone marrow cytology, trephine biopsy and chromosomal analysis. <i>British Journal of Haematology</i> , 1985 , 60, 19-32	4.5	182
2254	Myelodysplastic syndromes in childhood: three case reports. <i>British Journal of Haematology</i> , 1985 , 60, 137-42	4.5	18
2253	Philadelphia chromosome-negative chronic myelogenous leukaemia: a morphological reassessment. <i>British Journal of Haematology</i> , 1985 , 60, 457-67	4.5	98
2252	Modifications in the classification of primary myelodysplastic syndromes: the addition of a scoring system. 1985 , 3, 55-63		101
2251	Chronic myelomonocytic leukemia: clinical features, cytogenetics, and prognosis in 30 consecutive cases. 1985 , 3, 147-55		25
2250	Increased numbers of marrow basophils may be associated with a t(6;9) in ANLL. 1985 , 18, 393-403		92
2249	Low-dose arabinosyl cytosine in acute leukemia after a myelodysplastic syndrome and in elderly leukemia. 1985 , 20, 191-3		13
2248	Acquisition of a Philadelphia chromosome concomitant with transformation of a refractory anemia into an acute leukemia. 1985 , 55, 1477-81		21
2247	Low-dose cytosine arabinoside treatment for acute nonlymphocytic leukemia in elderly patients. 1985 , 55, 1633-6		61
2246	Myelodysplastic syndrome or acute myeloid leukemia? A study of 28 cases presenting with borderline features. 1985 , 55, 2390-4		17
2245	Low-dose cytosine arabinoside (Ara-C) therapy in the myelodysplastic syndromes and acute leukemia. 1985 , 56, 443-9		58

2244	Myelodysplastic syndromes. A clinical and pathologic analysis of 109 cases. 1985 , 56, 553-61	210
2243	Low-dose cytosine arabinoside in the myelodysplastic syndromes and acute myelogenous leukemia. 1985 , 56, 1001-5	27
2242	Acute Leukemias, Myelodysplasia, and Lymphomas. 1985 , 1, 795-826	2
2241	Immune abnormalities in myelodysplastic syndromes. 1985 , 38, 908-11	46
2240	Refractory anaemia terminating in a combined lymphoproliferative and myeloproliferative disorder. 1985 , 38, 297-300	13
2239	Aplastic anaemia and the hypocellular myelodysplastic syndrome: histomorphological, diagnostic, and prognostic features. 1985 , 38, 1218-24	86
2238	Myelodysplastic syndromes: pathogenesis, functional abnormalities, and clinical implications. 1985 , 38, 1201-17	90
2237	Anemia in cancer. 1985 , 3, 249-60	29
2236	Progenitor cells and classification of myelodysplastic and myeloproliferative disorders. 1985 , 2, 885	4
2235	Myelodysplasia in cadaver renal allografts: a report of four cases. 1985 , 5, 251-7	8
2234	Specific cutaneous involvement in the course of chronic myelomonocytic leukemia simultaneously with blastic leukemic transformation. Report of a case with histologic and cytochemical study. 1985 , 12, 943-8	15
2233	Cytogenetic studies in 174 consecutive patients with preleukemic or myelodysplastic syndromes. 1985 , 60, 507-16	148
2232	Karyotypic evolution in patients with myelodysplastic syndromes. 1985 , 16, 157-67	55
2231	Loss of the Y chromosome in acute myelogenous leukemia: a report of 13 patients. 1985 , 17, 269-78	51
2230	Translocation 1;7 in preleukemic states. 1985 , 18, 189-92	30
2229	Translocation (1;7)(p11;p11): a new myeloproliferative hematologic entity. 1985 , 18, 199-206	30
2228	Involvement of chromosomes 4, 11, and 17 in a case of myelodysplastic syndrome. 1985 , 18, 265-73	7
2227	A 2p;11q chromosome translocation in dysmyelopoietic preleukemia. 1985 , 15, 143-50	23

2226	Increased sister chromatid exchange frequency in bone marrow cells of myelodysplastic syndromes. 1985 , 15, 151-8	3
2225	Long arm deletion of chromosome 5 in a case of chronic myelomonocytic leukemia. 1985 , 15, 269-75	1
2224	Heterochromatic variants and their association with neoplasias. II. Preleukemic states. 1985 , 14, 31-5	19
2223	Acute myeloblastic leukaemia in a dog. 1985 , 95, 619-32	11
2222	Management of myelodysplastic syndromes. 1986 , 80, 1149-57	30
2221	PROGNOSIS IN MYELOYDYSPLASIA. 1986 , 328, 436-437	
2220	Coexistence of S ⁺ zary syndrome and dysmyelopoiesis with an excess of myeloblasts. 1986 , 15, 1296-8	4
2219	The histological characterization of ALIP in the myelodysplastic syndromes. 1986 , 181, 402-7	13
2218	Cytogenetic studies in 18 patients with secondary blood disorders. 1986 , 22, 309-17	13
2217	Three cases of preleukemic myelodysplastic disorders with the same translocation t(1;3). 1986 , 19, 213-8	19
2216	Abnormalities of the short arm of chromosome 12 in acute nonlymphocytic leukemia and dysmyelopoietic syndrome. 1986 , 19, 281-9	50
2215	Specific minor chromosome deletions consistently occurring in myelodysplastic syndromes. 1986 , 23, 61-75	51
2214	Cytogenetic changes at 11q11, 11q23, and 17q11 in myelodysplastic syndrome. 1986 , 21, 287-95	9
2213	Translocation (2;3) in hematologic malignancies. 1986 , 21, 335-42	17
2212	Another case of myelodysplastic syndrome with a chromosome mode in the tetraploid range. 1986 , 23, 175-8	4
2211	Should refined chromosomal analysis be used routinely in acute leukemias and myelodysplastic syndrome?. 1986 , 315, 322-3	5
2210	Monocytic skin infiltration in chronic myelomonocytic leukaemia. 1986 , 8, 115-9	26
2209	Response of refractory anemia to low-dose cytosine arabinoside. 1986 , 16, 231-3	1

2208	Preleukemic changes in cases of nonlymphocytic leukemia secondary to cytotoxic therapy. Analysis of 105 cases. 1986 , 58, 630-4	19
2207	Clinical and prognostic features of Philadelphia chromosome-negative chronic myelogenous leukemia. 1986 , 58, 2023-30	54
2206	Chromosome studies in preleukemic states. V. Prognostic significance of single versus multiple abnormalities. 1986 , 58, 2571-5	57
2205	Hypocellular bone marrow with increased blasts. 1986 , 21, 15-22	12
2204	Acute myelocytic leukemia manifested by prominent generalized lymphadenopathy: report of two cases with immunological, ultrastructural, and cytochemical studies. 1986 , 21, 89-98	10
2203	Nuclear bridging of erythroblasts in acquired dyserythropoiesis: an early and transient preleukemic marker. 1986 , 21, 315-22	6
2202	Immunoregulatory abnormalities in myelodysplastic disorders. 1986 , 22, 17-26	36
2201	Association of chronic myelomonocytic leukemia and carcinoma: a possible paraneoplastic myelodysplasia. 1986 , 22, 109-10	8
2200	Trisomy 1q in polycythemia vera and its relation to disease transition. 1986 , 22, 155-67	49
2199	Myeloid cell surface phenotype in myelodysplasia: evidence for abnormal persistence of an early myeloid differentiation antigen. 1986 , 22, 251-7	16
2198	High-dose cytosine arabinoside in the treatment of preleukemic disorders: a leukemia intergroup study. 1986 , 23, 131-4	34
2197	Treatment of myelodysplastic syndrome with 1.25-dihydroxy-vitamin D3. 1986 , 23, 175-8	34
2196	Efficacy of danazol in pure red cell aplasia. 1986 , 23, 373-9	13
2195	Hypoplastic acute leukemia: review of 70 cases with multivariate regression analysis. 1986 , 4, 291-305	19
2194	Chromosomes in acute nonlymphocytic leukemia. 1986 , 73, 137-46	62
2193	Prognostic significance of some clinical, morphological and cytogenetic findings in refractory anaemia (RA) and RA with sideroblasts. 1986 , 52, 35-43	7
2192	Myelodysplastic syndromes: their history, evolution and relation to acute myeloid leukaemia. 1986 , 53, 423-36	25
2191	The nature of blast cells in myelodysplastic syndromes evolving to acute leukaemia. 1986 , 52, 357-63	15

2190	The concept of preleukemia: clinical and laboratory studies. 1986 , 4, 203-20		15
2189	Genomic diversity correlates with clinical variation in Ph ⁻ -negative chronic myeloid leukaemia. 1986 , 320, 281-3		123
2188	Ha-ras hypervariable alleles in myelodysplasia. 1986 , 321, 84-5		67
2187	Simple monosomy 7 and myelodysplastic syndrome in thirteen patients without previous cytostatic treatment. <i>British Journal of Haematology</i> , 1986 , 64, 425-33	4.5	31
2186	Progression of a myelodysplastic syndrome to pre-B acute lymphoblastic leukaemia with unusual phenotype. <i>British Journal of Haematology</i> , 1986 , 64, 487-91	4.5	35
2185	Cytogenetic evidence for involvement of erythroid progenitors in a child with therapy linked myelodysplasia. <i>British Journal of Haematology</i> , 1986 , 64, 513-9	4.5	9
2184	Cytogenetic evidence for partially committed myeloid progenitor cell origin of chronic myelomonocytic leukaemia and juvenile chronic myeloid leukaemia: both granulocyte-macrophage precursors and erythroid precursors carry identical marker chromosome. <i>British Journal of Haematology</i> , 1986 , 64, 539-46	4.5	42
2183	Multiple chromosomally distinct cell populations in myelodysplastic syndromes and their possible significance in the evolution of the disease. <i>British Journal of Haematology</i> , 1986 , 64, 699-706	4.5	60
2182	Acute megakaryoblastic leukaemia: a prospective study of its identification and treatment. <i>British Journal of Haematology</i> , 1986 , 62, 55-63	4.5	52
2181	An identical translocation between chromosome 1 and 15 in two patients with myelodysplastic syndromes. <i>British Journal of Haematology</i> , 1986 , 62, 439-45	4.5	16
2180	Immunological abnormalities in myelodysplastic syndromes. I. Serum immunoglobulins and autoantibodies. <i>British Journal of Haematology</i> , 1986 , 63, 143-7	4.5	165
2179	Immunological abnormalities in myelodysplastic syndromes. II. Coexistent lymphoid or plasma cell neoplasms: a report of 20 cases unrelated to chemotherapy. <i>British Journal of Haematology</i> , 1986 , 63, 149-59	4.5	98
2178	The role of aggressive chemotherapy in the treatment of the myelodysplastic syndromes. <i>British Journal of Haematology</i> , 1986 , 63, 477-83	4.5	108
2177	Diagnostic significance of detecting pseudo-Pelger-Huët anomalies and micro-megakaryocytes in myelodysplastic syndrome. <i>British Journal of Haematology</i> , 1986 , 63, 665-9	4.5	84
2176	Histopathology of canine nonneoplastic bone marrow. 1986 , 15, 7-11		12
2175	Management of chronic myeloid leukaemia. 1986 , 37, 269-79		1
2174	Prognostic significance of the morphological dysplastic changes in chronic myelogenous leukemia. 1986 , 10, 331-7		10
2173	Morphometric study of megakaryocytes size and prognosis in adults with acute non-lymphocytic leukemia. 1986 , 10, 475-80		4

2172	Prognostic factors for survival of 194 patients with low infiltrate leukemia. 1986 , 10, 995-1006	10
2171	Oral manifestations in myelodysplastic syndrome. Review of the literature and report of a case. 1986 , 61, 466-70	11
2170	Increased alpha:non-alpha globin chain synthesis ratios in myelodysplastic syndromes and myeloid leukaemia. 1986 , 39, 1233-5	10
2169	Prognostic importance of hypodiploid hemopoietic precursors in myelodysplastic syndromes. 1986 , 314, 1472-5	46
2168	Primary myelodysplastic syndrome with complex chromosomal rearrangements in a patient with Klinefelter's syndrome. 1986 , 23, 183-5	6
2167	Myelodysplastic syndrome coexisting with acute lymphoblastic leukaemia. 1986 , 39, 728-30	13
2166	Monosomy 7 in granulocytes and monocytes in myelodysplastic syndrome. 1987 , 316, 499-503	79
2165	Myeloid surface antigen abnormalities in myelodysplasia: relation to prognosis and modification by 13-cis retinoic acid. 1987 , 40, 652-6	19
2164	A point mutation at codon 13 of the N-ras oncogene in myelodysplastic syndrome. 1987 , 327, 430-2	190
2163	Circulating micromegakaryocytes in myelodysplasia. 1987 , 40, 1349-52	26
2162	Effects of recombinant human granulocyte-macrophage colony-stimulating factor in patients with myelodysplastic syndromes. 1987 , 317, 1545-52	514
2161	The effect of cytosine arabinoside on CFU-GM from patients with myelodysplastic syndrome. 1987 , 9, 23-6	
2160	Isodicentric X chromosome in a patient with myelodysplastic syndrome. 1987 , 27, 215-8	9
2159	Cytogenetic findings in siblings with a myelodysplastic syndrome. 1987 , 27, 241-9	8
2158	Leukemic transformation in patients with the 5q- alteration: analysis of the behavior of the 5q-clones in preleukemic to leukemic phases. 1987 , 26, 199-207	12
2157	Specific minor chromosome deletions in myelodysplastic syndromes: clinical and morphologic correlations. 1987 , 26, 227-34	9
2156	Translocation (1;7) in a case of secondary chronic myelomonocytic leukemia. 1987 , 24, 355-7	12
2155	Presence of isochromosomes in hematologic diseases. 1987 , 25, 47-54	25

2154	Duplication of one of the products of the t(8;21) translocation in a patient with refractory anemia with excess blasts in transformation. 1987 , 25, 175-7	16
2153	A chromosomal profile of polycythemia vera. 1987 , 25, 233-45	98
2152	Refractory anemia with monosomy 2 and a double minute chromosome. 1987 , 28, 367-71	3
2151	Trisomy 14 in refractory anemia with excess of blasts in transformation. 1987 , 29, 315-8	12
2150	11q-chromosome is associated with abnormal iron stores in myelodysplastic syndromes. 1987 , 27, 39-44	40
2149	Treatment for Myelodysplastic Syndromes. 1987 , 330, 717-719	
2148	Immunoglobulin synthesis in myelodysplastic syndromes: normal B-cell and immunoregulatory T-cell functions. 1987 , 42, 195-201	4
2147	Cytochemical characterization of leukemic cells with numerous cytoplasmic granules. 1987 , 62, 978-85	9
2146	Effect of 13-cis-retinoic acid on survival of patients with myelodysplastic syndrome. 1987 , 1, 763-5	61
2145	Detection of a multidrug resistant phenotype in acute non-lymphoblastic leukaemia. 1987 , 1, 135-7	175
2144	The myelodysplastic syndromes. 1987 , 295, 227-8	4
2143	Refractory cytopenias: clinical course according to bone marrow cytology and cellularity. 1987 , 54, 153-63	18
2142	Allogeneic bone marrow transplantation as primary therapy for chronic myelomonocytic leukemia. 1987 , 54, 189-92	2
2141	Leukocyte-derived inhibitory activity in patients with myelodysplastic syndrome. 1987 , 55, 165-71	4
2140	In vitro exposure of leukemic cells to low concentration Arabinosyl Cytosine: no evidence of differentiation inducing activity. 1987 , 54, 299-306	
2139	Histopathology of bone marrow in human immunodeficiency virus infection. 1987 , 411, 543-51	50
2138	The prognostic significance of cytological, histological and cytogenetic findings in refractory anaemia (RA) and RA with sideroblasts. A follow up study. 1987 , 54, 231-8	5
2137	French registry of acute leukemia and myelodysplastic syndromes. Age distribution and hemogram analysis of the 4496 cases recorded during 1982-1983 and classified according to FAB criteria. 1987 , 60, 1385-1394	49

2136	Myelodysplastic syndromes. A multiparametric study of prognostic factors in 336 patients. 1987 , 60, 3029-32		34
2135	The myelodysplastic syndrome--a practical guide. 1987 , 5, 19-34		55
2134	Treatment-related leukemia in Hodgkin's disease: a multi-institution study on 75 cases. 1987 , 5, 83-98		23
2133	In vitro correlates of low dose ara-C efficacy: clinical, cytogenetic, and bone marrow culture analysis. 1987 , 25, 43-53		6
2132	Acute myelomonocytic leukemia (AML-M4) and translocation t(6;9)(p23);q34): two additional patients with prominent myelodysplasia. 1987 , 26, 77-82		15
2131	The myelodysplastic syndromes. 1987 , 1, 34-43		22
2130	Biology of myelodysplastic syndromes. 1987 , 5, 356-75		14
2129	Balloon-like platelets in myelodysplastic syndromes--a feature of dysmegakaryopoiesis?. 1987 , 11, 747-52		9
2128	Production of human pluripotent progenitor cell colony stimulating activity (CFU-GEMMCSA) in patients with myelodysplastic syndromes. 1987 , 11, 273-9		5
2127	13-cis retinoic acid treatment of myelodysplastic syndromes. 1987 , 11, 7-16		28
2126	Combination of low-dose cytarabine and 13-cis retinoic acid in the treatment of myelodysplastic syndromes. 1987 , 11, 1041-4		19
2125	The effect of low dose ARA-C on in-vitro haemopoiesis of marrow cells from myelodysplastic patients. 1987 , 11, 379-84		4
2124	Clinical and laboratory features of de novo acute myeloid leukaemia with trilineage myelodysplasia. <i>British Journal of Haematology</i> , 1987 , 66, 445-50	4.5	157
2123	Dysmegakaryocytopenia in acute leukaemias: its predominance in myelomonocytic (M4) leukaemia and implication for poor response to chemotherapy. <i>British Journal of Haematology</i> , 1987 , 66, 467-72	4.5	46
2122	Enzyme cytochemistry of neutrophil granulocytes. <i>British Journal of Haematology</i> , 1987 , 65, 127-9	4.5	3
2121	Erythroid and myeloid maturation patterns related to progenitor assessment in the myelodysplastic syndromes. <i>British Journal of Haematology</i> , 1987 , 67, 61-6	4.5	18
2120	Mechanisms and prognostic value of cell kinetics in the myelodysplastic syndromes. <i>British Journal of Haematology</i> , 1987 , 67, 147-52	4.5	19
2119	Haem arginate as a treatment for myelodysplastic syndromes. <i>British Journal of Haematology</i> , 1987 , 65, 425-8	4.5	23

2118	RAEB in a patient with chronic granulated T-lymphocytosis. <i>British Journal of Haematology</i> , 1987 , 65, 503-4	4.5	5
2117	Utility of the FAB classification for myelodysplastic syndromes: investigation of prognostic factors in 237 cases. <i>British Journal of Haematology</i> , 1987 , 65, 73-81	4.5	163
2116	Chronic and subacute myelomonocytic leukaemia in the adult: a report of 60 cases with special reference to prognostic factors. <i>British Journal of Haematology</i> , 1987 , 65, 101-6	4.5	74
2115	Significance of ring sideroblasts in refractory anaemia with excess of blasts. <i>British Journal of Haematology</i> , 1987 , 65, 119-20	4.5	4
2114	Familial myelodysplasia: progressive disease associated with emergency of monosomy 7. <i>British Journal of Haematology</i> , 1987 , 65, 321-3	4.5	31
2113	A randomized trial of 13-cis retinoic acid with or without cytosine arabinoside in patients with the myelodysplastic syndrome. <i>British Journal of Haematology</i> , 1987 , 66, 77-83	4.5	76
2112	Ph-negative chronic myeloid leukaemia. <i>British Journal of Haematology</i> , 1987 , 66, 311-4	4.5	26
2111	Myelodysplastic syndromes. 1987 , 1, 389-426		42
2110	Haematological classification of the chronic myeloid leukaemias. 1987 , 1, 887-906		45
2109	Chromosome abnormalities in CML. 1987 , 1, 963-81		23
2108	Natural killer cell-mediated inhibition of bone marrow colony formation (CFU-GM) in refractory anaemia (preleukaemia): evidence for patient-specific cell populations. <i>British Journal of Haematology</i> , 1988 , 69, 457-62	4.5	7
2107	The syndrome of abnormal chromatin clumping in leucocytes: a myelodysplastic disorder with proliferative features?. <i>British Journal of Haematology</i> , 1988 , 70, 49-54	4.5	47
2106	Evolution of acquired severe aplastic anaemia to myelodysplasia and subsequent leukaemia in adults. <i>British Journal of Haematology</i> , 1988 , 70, 55-62	4.5	107
2105	Prognostic features of chronic myelomonocytic leukaemia: a modified Bournemouth score gives the best prediction of survival. <i>British Journal of Haematology</i> , 1988 , 68, 17-21	4.5	139
2104	An acquired Bernard-Soulier-like platelet defect associated with juvenile myelodysplastic syndrome. <i>British Journal of Haematology</i> , 1988 , 68, 97-101	4.5	33
2103	Morphologic, immunologic and cytogenetic (MIC) working classification of the acute myeloid leukaemias. Second MIC Cooperative Study Group. <i>British Journal of Haematology</i> , 1988 , 68, 487-94	4.5	144
2102	Enrichment of haemopoietic progenitor cells from the marrow of patients with myelodysplasia. <i>British Journal of Haematology</i> , 1988 , 68, 159-64	4.5	7
2101	Refined chromosome study helps define prognostic subgroups in most patients with primary myelodysplastic syndrome and acute myelogenous leukaemia. <i>British Journal of Haematology</i> , 1988 , 68, 189-94	4.5	205

2100	Thrombopoietic inhibitory activity in serum of patients with refractory anaemia. <i>British Journal of Haematology</i> , 1988 , 68, 265-6	4.5	
2099	Bone marrow transplantation for myelodysplastic syndromes. <i>British Journal of Haematology</i> , 1988 , 69, 29-33	4.5	32
2098	Childhood monosomy 7 revisited. <i>British Journal of Haematology</i> , 1988 , 69, 41-5	4.5	43
2097	Asparaginase-induced derangements of glutamine metabolism: the pathogenetic basis for some drug-related side-effects. 1988 , 18, 512-6		93
2096	Prognostic factors in chronic myelodysplastic syndromes: a multivariate analysis in 107 cases. 1988 , 27, 163-8		37
2095	Prognostic value of clonal chromosomal abnormalities in patients with primary myelodysplastic syndromes. 1988 , 28, 13-20		29
2094	Absence of immunoglobulin and T-cell receptor gene rearrangements in myelodysplastic syndromes and acute nonlymphocytic leukemias. 1988 , 28, 95-7		11
2093	Simultaneous expression of lymphoid and myeloid phenotypes in acute leukemia arising from myelodysplastic syndrome. 1988 , 28, 103-6		16
2092	Treatment of "poor risk" acute nonlymphocytic leukemia with continuously infused low-dose cytosine arabinoside. 1988 , 29, 79-84		7
2091	Hematologic aspects of human immunodeficiency virus infection: laboratory and clinical considerations. 1988 , 29, 94-105		86
2090	Acute leukemia and myelodysplasia in polycythemia vera. A clinical study with long-term follow-up. 1988 , 61, 89-95		58
2089	Immunologic indices in myelodysplastic syndromes. 1988 , 61, 1075-81		52
2088	Prognostic significance of blood and marrow findings in acute myelogenous leukemia in remission. A Southeastern Cancer Study Group report. 1988 , 61, 2481-6		5
2087	Hypoplastic myelodysplastic syndrome. 1988 , 62, 958-64		72
2086	Significance of systemic mast cell disease with associated hematologic disorders. 1988 , 62, 965-72		201
2085	Chromosome abnormalities and karyotypic evolution in 83 patients with myelodysplastic syndrome and predictive value for prognosis. 1988 , 62, 1129-38		113
2084	Treatment of myelodysplastic syndromes with low-dose oral 6-thioguanine. 1988 , 16, 17-20		6
2083	Hematologic and clinical features of patients with chromosome 5 monosomy or deletion (5q). 1988 , 16, 88-94		17

2082	Effectiveness of attenuated chemotherapy in myelodysplastic syndromes: a preliminary report. 1988 , 16, 107-10	2
2081	Intensive chemotherapy for acute non-lymphoblastic leukemia after primary myelodysplastic syndrome. 1988 , 6, 299-305	15
2080	Chronic myelomonocytic leukemia and primary Sjögren's syndrome. 1988 , 7, 110-3	5
2079	Secondary leukemia after severe aplastic anemia. 1988 , 56, 79-81	7
2078	Aggressive chemotherapy in adult primary myelodysplastic syndromes. A report on 29 cases. 1988 , 57, 297-302	36
2077	Deficiency of pluripotent hemopoietic progenitor cells in myelodysplastic syndromes. 1988 , 57, 45-9	19
2076	Clinicopathological study of hematological disorders after Thorotrast administration in Japan. 1988 , 56, 153-60	6
2075	Low dose cytosine arabinoside in refractory anemia with excess of blasts in transformation. 1988 , 57, 357-60	2
2074	Sweet's syndrome and myelodysplasia. 1988 , 56, 47-8	13
2073	Classification of acute leukaemias. 1988 , 2, 186-93	26
2072	Colony growth characteristics in chronic myelomonocytic leukemia. 1988 , 12, 373-7	47
2071	The Ha-ras polymorphism in myelodysplasia and acute myeloid leukaemia. 1988 , 12, 385-91	12
2070	Heme arginate treatment for myelodysplastic syndromes. 1988 , 12, 423-31	31
2069	Acute myeloblastic leukaemia in the elderly. 1988 , 12, 617-25	17
2068	Heterogeneous colony forming ability in vitro of the abnormal clone-derived granulocyte-macrophage precursors in myelodysplastic syndromes. 1988 , 12, 687-92	2
2067	Alpha-interferon in myelodysplasia; clinical observations and effects on NK cells. 1988 , 12, 257-62	23
2066	Abnormal neutrophils in acute myeloid leukemia and myelodysplastic syndrome. 1988 , 19, 454-9	31
2065	Chromosome study of 85 patients with myelodysplastic syndrome. 1988 , 33, 39-50	60

2064	Translocation t(1;7) revisited. Report of three further cases and review. 1988 , 36, 45-54	18
2063	Morphologic, immunologic, and cytogenetic (MIC) working classification of the acute myeloid leukemias. 1988 , 30, 1-15	109
2062	Four patients with myelodysplastic syndrome with translocation (1;7)(p11;p11) including one patient with independent clones del(7)q22) [corrected] and t(1;7)(q21;q11). 1988 , 30, 83-90	11
2061	Translocation t(11;21)(q24;q11.2) is a new nonrandomly occurring chromosome change in myelodysplastic syndromes. 1988 , 34, 33-40	7
2060	Childhood myelodysplastic syndromes with 11p15 translocation. 1988 , 34, 41-6	13
2059	Myelodysplastic syndrome with Philadelphia-like chromosome without bcr rearrangement. 1988 , 35, 151-8	5
2058	Cytogenetic findings in leukemic cells of 56 patients with constitutional chromosome abnormalities. A cooperative study. Groupe Franais de Cytog ⁿ n ^e tique H ^m matologique. 1988 , 35, 243-52	38
2057	An identical t(Y;1)(q12;q21) in two patients with myelodysplastic syndromes. 1988 , 34, 285-93	21
2056	Cytogenetics of acutely transformed chronic myeloproliferative syndromes without a Philadelphia chromosome. A multicenter study of 55 patients. Groupe Franais de Cytog ⁿ n ^e tique H ^m matologique. 1988 , 32, 157-68	52
2055	Chronic myelomonocytic leukemia with trisomy 8 and a related clone with trisomy 8 and t(15;17). 1988 , 32, 287-92	2
2054	Recommendations for a morphologic, immunologic, and cytogenetic (MIC) working classification of the primary and therapy-related myelodysplastic disorders. 1988 , 32, 1-10	127
2053	Systemic treatment of cancer in the elderly. 1988 , 7, 119-50	19
2052	The effect of a calf thymus acid lysate on bone marrow cell growth in vitro. 1988 , 10, 523-36	
2051	Therapeutic efficacy of danazol in myelodysplastic syndromes. 1988 , 24, 1481-9	16
2050	Sickle-cell trait as a risk factor for sudden death in physical training. 1988 , 318, 787	12
2049	Diagnostic and prognostic value of DNA image cytometry in myelodysplasia. 1988 , 41, 604-8	8
2048	Refractory myelodysplastic anaemias with hypocellular bone marrow. 1988 , 41, 763-7	41
2047	The Philadelphia chromosome: a brief review. 1988 , 18, 617-23	1

2046	Preleukemic syndromes and other syndromes predisposing to leukemia. 1988 , 35, 853-71	9
2045	Bone Marrow in Megakaryocytic Disorders. 1988 , 2, 695-733	19
2044	The Bone Marrow in Myeloproliferative and Dysmyelopoietic Syndromes. 1988 , 2, 669-694	8
2043	Erythropoietin: Biology and Clinical Use. 1989 , 3, 369-400	39
2042	Granulocytic sarcoma presenting as bleeding gastric polyp. 1989 , 21, 63-4	4
2041	Bone marrow biopsy and evaluation. 1989 , 19, 669-96	19
2040	DNA index and karyotype analysis in myelodysplasia. 1989 , 42, 498-501	9
2039	In Vivo Measurements of the T1 Relaxation Processes in the Bone Marrow in Patients with Myelodysplastic Syndrome: A Magnetic Resonance Imaging Study. 1989 , 30, 365-368	13
2038	Acute non-lymphoblastic leukemias in childhood. 1989 , 56, 683-92	
2037	Prognostic implication of sequential bone marrow cultures in the myelodysplastic syndromes. 1989 , 13, 967-72	7
2036	Characterization of clonogenic cells in refractory anemia with excess of blasts (RAEB-CFU): response to recombinant hematopoietic growth factors and maturation phenotypes. 1989 , 13, 245-51	12
2035	Phase II trial of fenretinide [N-(4-hydroxyphenyl) retinamide] in myelodysplasia: possible retinoid-induced disease acceleration. 1989 , 13, 339-43	19
2034	Correlation of bone marrow colony growth in the myelodysplastic syndromes with the FAB classification and the Bournemouth score. 1989 , 13, 833-9	18
2033	Diagnostic significance of dysplastic features of peripheral blood polymorphs in myelodysplastic syndromes. 1989 , 13, 173-8	36
2032	Effects of retinoic acid, 1,25-dihydroxyvitamin D3, cytosine arabinoside and alpha-interferon on bone marrow cells from patients with myelodysplastic syndromes. 1989 , 13, 1113-21	13
2031	Delayed maturation of skin window macrophages in myelodysplastic syndromes. 1989 , 13, 433-5	11
2030	Bone marrow analysis of the myelodysplastic syndromes: histological and immunohistochemical features related to the evolution of overt leukemia. 1989 , 57, 47-53	32
2029	Alpha-smooth muscle actin is expressed in a subset of bone marrow stromal cells in normal and pathological conditions. 1989 , 57, 291-302	53

2028	Abnormal megakaryopoiesis in patients with myelodysplastic syndromes: analysis of cellular and humoral defects. <i>British Journal of Haematology</i> , 1989 , 73, 29-35	4.5	9
2027	Circulating erythropoietin in patients with myelodysplastic syndromes. <i>British Journal of Haematology</i> , 1989 , 73, 36-9	4.5	80
2026	Absence of rearrangement of proto-oncogene MET in 88 cases of myelodysplastic syndromes (MDS). <i>British Journal of Haematology</i> , 1989 , 73, 40-2	4.5	6
2025	Acute febrile neutrophilic dermatosis (Sweet's syndrome) in association with myelodysplastic syndromes: a report of three cases and a review of the literature. <i>British Journal of Haematology</i> , 1989 , 73, 43-7	4.5	65
2024	A case of myelodysplastic syndrome with abnormal chromatin clumping in leucocytes. <i>British Journal of Haematology</i> , 1989 , 73, 135	4.5	4
2023	Regulatory abnormalities in the marrow of patients with myelodysplastic syndromes. <i>British Journal of Haematology</i> , 1989 , 73, 158-64	4.5	21
2022	Abnormal calcium transport of acanthocytes in acute myelodysplasia with myelofibrosis. <i>British Journal of Haematology</i> , 1989 , 73, 568-70	4.5	3
2021	Ras genes and acute myeloid leukaemia. <i>British Journal of Haematology</i> , 1989 , 71, 1-6	4.5	28
2020	Characterization of deletions of chromosome 7 short arm occurring as primary karyotypic anomaly in acute myeloid leukaemia. <i>British Journal of Haematology</i> , 1989 , 71, 13-7	4.5	17
2019	HRAS1 and INS genes are relocated but not structurally altered as a result of the t(7;11)(p15;p15) in a clone from a patient with acute myeloid leukaemia (M4). <i>British Journal of Haematology</i> , 1989 , 71, 481-6	4.5	10
2018	Myelofibrosis in primary myelodysplastic syndromes: a clinico-morphological study of 10 cases. <i>British Journal of Haematology</i> , 1989 , 71, 499-504	4.5	86
2017	AML associated with previous cytotoxic therapy, MDS or myeloproliferative disorders: results from the MRC's 9th AML trial. <i>British Journal of Haematology</i> , 1989 , 72, 45-53	4.5	127
2016	Bone marrow histopathology of patients with severe aplastic anaemia before treatment and at follow-up. <i>British Journal of Haematology</i> , 1989 , 72, 439-44	4.5	19
2015	Lactic dehydrogenase estimation in haematological malignancies. 1989 , 11, 17-26		4
2014	Laryngeal infiltration in chronic myelomonocytic leukaemia. 1989 , 11, 403-6		2
2013	Idiopathic dyserythropoiesis in a dog. 1989 , 18, 43-6		16
2012	Cytologic evaluation of Papanicolaou-stained bone marrow aspirates. 1989 , 5, 383-7		
2011	Prognostic significance of Auer rods in childhood acute myelogenous leukemia: results of the studies AML-BFM-78 and -83. 1989 , 17, 202-9		12

2010	Myelodysplastic syndrome and secondary acute leukemia after treatment of essential thrombocythemia with melphalan. 1989 , 30, 47-8	11
2009	Erythrocyte enzyme activities in myelodysplastic syndromes: elevated pyruvate kinase activity. 1989 , 30, 97-103	2
2008	8;21 translocation in myelodysplasia secondary to essential thrombocythemia. 1989 , 30, 233-5	3
2007	Congenital erythroleukemia: a case report with morphological, immunophenotypic, and cytogenetic findings. 1989 , 31, 114-21	26
2006	Myelodysplastic syndrome with trisomy 11 associated with polycythemia vera. 1989 , 31, 122-5	7
2005	Porphyria cutanea tarda and chronic myelomonocytic leukemia. 1989 , 31, 299	7
2004	Dominantly transmitted hematologic dysfunction clinically similar to Fanconi's anemia. 1989 , 32, 241-7	2
2003	Acute nonlymphocytic leukemias of childhood. Inter-observer variability and problems in the use of the FAB classification. 1989 , 63, 295-301	29
2002	The role of low-dose cytosine arabinoside and aggressive chemotherapy in advanced myelodysplastic syndromes. 1989 , 64, 1812-8	66
2001	Pathogenetic implications of internuclear bridging in myelodysplastic syndrome. An Eastern Cooperative Oncology Group/Southwest Oncology Group Cooperative Study. 1989 , 64, 2199-2202	12
2000	Refractory anemia with excess of blasts in transformation hematologic and clinical study of 52 patients. 1989 , 64, 2340-6	62
1999	Chronic pure thrombocytopenia in elderly patients. An aspect of the myelodysplastic syndrome. 1989 , 64, 2506-10	31
1998	Oncogenes in the myelodysplastic syndrome. 1989 , 3, 105-9	10
1997	Acute myelogenous leukaemia in children. 1989 , 148, 382-8	14
1996	Progress in the therapy of myelodysplastic syndromes. 1989 , 58, 265-70	10
1995	Cooperative effects of gamma-interferon and 1 alpha, 25-dihydroxyvitamin D3 on in vitro differentiation of the blast cells of RAEB and RAEB-T. 1989 , 58, 181-6	7
1994	Analysis of human dysplastic haematopoiesis in long-term bone marrow culture. 1989 , 59, 442-8	10
1993	Hematologic and cytogenetic findings in myelodysplastic syndromes treated with recombinant human granulocyte colony-stimulating factor. 1989 , 80, 848-54	22

1992	Xeroderma pigmentosum and refractory anaemia in two first cousins. 1989 , 121, 767-71	5
1991	Chronic myelomonocytic leukemia: natural history and prognostic determinants. 1989 , 64, 1246-54	56
1990	Prognostic significance of single chromosome abnormalities in preleukemic states. 1989 , 42, 1-7	37
1989	Refractory anemia with excess of blasts in transformation. Clinical, hematologic, and cytogenetic findings in nine patients. 1989 , 42, 55-65	7
1988	General Report of the Sixth International Workshop on Chromosomes in Leukemia. 1989 , 40, 141-147	3
1987	Clinical-cytogenetic correlations in myelodysplasia (preleukemia). 1989 , 40, 149-61	97
1986	Cytogenetic and clinical investigations in 76 cases with therapy-related leukemia and myelodysplastic syndrome. 1989 , 43, 227-41	64
1985	Der(5)t(5;7)(q11.2;p11.2): a new recurring abnormality in malignant myeloid disorders. 1989 , 37, 1-8	12
1984	Cytogenetic analysis of different cellular populations in chronic myelomonocytic leukemia. 1989 , 37, 29-37	11
1983	Twenty-six patients with hematologic disorders and X chromosome abnormalities. Frequent idic(X)(q13) chromosomes and Xq13 anomalies associated with pathologic ringed sideroblasts. 1989 , 42, 173-85	47
1982	Translocation t(6;9) occurring in acute myelofibrosis, myelodysplastic syndrome, and acute nonlymphocytic leukemia suggests multipotent stem cell involvement. 1989 , 42, 209-19	36
1981	A dysmorphic child with myelodysplasia characterized by a duplication of 1q and multiple duplications of 3q. 1989 , 38, 9-12	17
1980	Acute leukemia with abnormal thrombopoiesis and inversions of chromosome 3. 1989 , 39, 167-79	56
1979	Loss of the Y chromosome associated with translocation t(6;9)(p23;q34) in a patient with acute nonlymphocytic leukemia. 1989 , 39, 81-7	10
1978	Imprint cytology of non-Hodgkin's lymphomas based on a study of 212 immunologically characterized cases: correlation of touch imprints with tissue sections. 1989 , 20, 1-137	43
1977	Treatment of myelodysplastic syndromes with recombinant human granulocyte colony-stimulating factor: a preliminary report. 1989 , 86, 178-82	92
1976	Treatment of cutaneous granulocytic sarcoma in a patient with myelodysplasia. 1989 , 86, 477-80	14
1975	[Acquired idiopathic sideroblastic anemia. Apropos of 39 cases]. 1989 , 10, 323-9	

1974	Subcutaneous eosinophilic necrosis associated with refractory anemia with an excess of myeloblasts. 1989 , 20, 320-3		10
1973	Detection of rearrangement within the breakpoint cluster region of chromosome 22 in the diagnosis of chronic myeloid leukemia. 1989 , 19, 443-8		
1972	Primary chromosome abnormalities in human neoplasia. 1989 , 52, 1-43		53
1971	The myelodysplastic syndrome. 1989 , 299, 582		6
1970	Bestatin treatment of myelodysplastic syndromes (MDS) and the effects of bestatin on hematopoiesis in MDS. 1990 , 29, 803-7		4
1969	Sweet's syndrome associated with sideroblastic anaemia. 1990 , 20, 179-81		2
1968	Myelodysplastic Syndrome with Multilineage Blast Transformation: Special Stains for Optimal Cytodiagnosis. 1990 , 13, 67-70		
1967	Characteristics of granulocyte-macrophage colony formation in chronic myelomonocytic leukemia: a comparative study with other myelodysplastic and myeloproliferative disorders. 1990 , 81, 820-6		5
1966	Megakaryocytes in myelodysplasia: an immunohistochemical study on bone marrow trephines. 1990 , 17, 69-74		17
1965	Epidermal Langerhans cells in myelodysplastic syndromes are abnormal. 1991 , 96, 932-6		4
1964	Two types of acquired idiopathic sideroblastic anaemia (AISA). <i>British Journal of Haematology</i> , 1990 , 74, 45-52	4.5	77
1963	Allogeneic bone marrow transplantation for secondary leukaemia and myelodysplastic syndrome: a survey by the Leukaemia Working Party of the European Bone Marrow Transplantation Group (EBMTG). <i>British Journal of Haematology</i> , 1990 , 74, 151-5	4.5	149
1962	Myelodysplastic syndrome (MDS)-associated inhibitory activity on haemopoietic progenitor cells. <i>British Journal of Haematology</i> , 1990 , 74, 179-84	4.5	15
1961	Cutaneous vasculitis in patients with myelodysplasia. <i>British Journal of Haematology</i> , 1990 , 74, 364-5	4.5	47
1960	A case of myelodysplastic syndrome and myelofibrosis. <i>British Journal of Haematology</i> , 1990 , 74, 373-5	4.5	9
1959	Functional studies of bone marrow haemopoietic and stromal cells in the myelodysplastic syndrome (MDS). <i>British Journal of Haematology</i> , 1990 , 75, 16-25	4.5	63
1958	Bone marrow biopsy in myelodysplastic syndromes: morphological characteristics and contribution to the study of prognostic factors. <i>British Journal of Haematology</i> , 1990 , 75, 26-33	4.5	66
1957	Long-term bone marrow damage after chemotherapy for acute myeloid leukaemia does not improve with time. <i>British Journal of Haematology</i> , 1990 , 75, 68-72	4.5	36

1956	Ras activation in myelodysplastic syndromes: clinical and molecular study of the chronic phase of the disease. <i>British Journal of Haematology</i> , 1990 , 74, 408-13	4.5	27
1955	Immunocytochemical detection of ferritin in human bone marrow and peripheral blood cells using monoclonal antibodies specific for the H and L subunit. <i>British Journal of Haematology</i> , 1990 , 76, 427-32	4.5	22
1954	Contrasting patterns of neoplastic cell behaviour in long-term culture of bone marrow from patients with acute leukaemia and myelodysplastic disorders. A survey of responses in 31 cases with cytogenetic determination of neoplastic status of cultured cells in 17 studies. <i>British Journal of Haematology</i> , 1990 , 75, 476-84	4.5	9
1953	Systemic vasculitis and myelodysplasia. <i>British Journal of Haematology</i> , 1990 , 75, 627-9	4.5	12
1952	Clonal karyotype abnormalities and clinical progress in the myelodysplastic syndrome. <i>British Journal of Haematology</i> , 1990 , 76, 194-202	4.5	90
1951	Development of acute myelocytic leukemia in patients with Crohn's disease. 1990 , 35, 1553-6		18
1950	Improvement of anemia by recombinant erythropoietin in patients with myelodysplastic syndromes and aplastic anemia. 1990 , 8, 445-58		77
1949	Effects of prolonged treatment of myelodysplastic syndromes with recombinant human granulocyte colony-stimulating factor. 1990 , 8 Suppl 1, 293-300; discussion 300-2		17
1948	p75c-myb expression in leukemia-lymphoma cells correlated with proliferation and differentiation. 1990 , 14, 423-32		5
1947	Cytosine arabinoside does not cause differentiation in vitro of CFU-GM in marrow from normal, myelodysplastic or ANLL subjects. 1990 , 14, 185-93		2
1946	The combined effects of IL-3, GM-CSF and G-CSF on the in vitro growth of myelodysplastic myeloid progenitor cells. 1990 , 14, 1019-25		11
1945	de novo myelodysplastic syndromes in adults aged 50 or less. A report on 37 cases. 1990 , 14, 1053-9		25
1944	Dysplastic features of peripheral blood polymorphs in myelodysplastic syndrome in children. 1990 , 14, 1069-70		4
1943	Clonal growth of haemopoietic progenitor cells from myelodysplastic marrow in response to recombinant haemopoietins. 1990 , 14, 247-53		10
1942	Prognostic factors of myelodysplastic syndromes--a simplified 3-D scoring system. 1990 , 14, 255-62		67
1941	Bone marrow cultures and prognosis in primary myelodysplastic syndromes. 1990 , 14, 85-9		4
1940	The myelodysplastic syndromes. Case report and review. 1990 , 70, 579-83		10
1939	Acute nonlymphocytic leukemia following chemotherapy with cisplatin and etoposide for non-small-cell carcinoma of the lung: case report. 1990 , 26, 235-6		7

1938	Successful treatment for perinephric abscess with recombinant human granulocyte colony-stimulating factor following nephrectomy in a patient of myelodysplastic syndrome: a case report. 1990 , 2, 223-6	2
1937	Common variable immunodeficiency and malignancy: a report of two cases and possible explanation for the association. 1990 , 31, 250-4	13
1936	Plasma cyclic nucleotide levels in patients with refractory anaemia with excess of blasts. 1990 , 60, 177-80	1
1935	Correlations between cytogenetics and morphology in myelodysplastic syndromes. 1990 , 60, 223-7	17
1934	Myelodysplastic syndrome and secondary acute leukemia after treatment of essential thrombocythemia with hydroxyurea. 1990 , 33, 152	21
1933	Myelodysplastic syndromes: a study of surface markers and in vitro growth patterns. 1990 , 34, 26-31	47
1932	Neutrophilic myelofibrosis presenting as Philadelphia chromosome negative BCR non-rearranged chronic myeloid leukemia. 1990 , 34, 59-63	16
1931	Recurrent spleen enlargement during cyclic granulocyte-macrophage colony-stimulating factor therapy for myelodysplastic syndrome. 1990 , 34, 73-4	16
1930	Application of the avidin-biotin-peroxidase complex technique for ultraimmunocytochemical characterization of leukemic cells. 1990 , 34, 140-8	2
1929	Structure of the granulocyte macrophage colony-stimulating factor gene in patients with the myelodysplastic syndromes. 1990 , 34, 157-8	3
1928	Bone marrow in vitro growth and cytogenetic studies in patients with FAB-classified primary myelodysplastic syndromes. 1990 , 34, 175-80	12
1927	Target cell of leukemic transformation in acute megakaryoblastic leukemia. 1990 , 34, 252-8	13
1926	Chronic myelomonocytic leukemia: a test of a proposed staging system. 1990 , 35, 129-30	4
1925	Cytogenetic findings in adult acute leukemia and myeloproliferative disorders with an involvement of megakaryocyte lineage. 1990 , 65, 940-8	20
1924	The unbalanced 1;7 translocation in de novo myelodysplastic syndrome and its clinical implication. 1990 , 65, 1350-4	39
1923	Myelodysplastic syndromes presenting in pregnancy. A report of five cases and the clinical outcome. 1990 , 66, 377-81	20
1922	Intensive antileukemic treatment of patients younger than 65 years with myelodysplastic syndromes and secondary acute myelogenous leukemia. 1990 , 66, 831-7	94
1921	Immunoreactive Calcitonin: A Tumor Marker for Myelogenous Leukemias. 1990 , 5, 27-30	1

1920	Philadelphia Chromosome-Negative Chronic Myelogenous Leukemia and Chronic Myelomonocytic Leukemia. 1990 , 4, 389-404	38
1919	Cytogenetics and Occupational Exposure to Solvents: A Pilot Study on Leukemias and Myelodysplastic Disorders. 1990 , 76, 350-352	8
1918	Breakpoints Involved in Deletions of the Long Arm of Chromosome 5 in Myelodysplasia and Acute Non-Lymphoblastic Leukemia do not Correlate with the Morphological Diagnosis. 1990 , 3, 195-200	1
1917	Apoptosis is a Common Histopathological Finding in Myelodysplasia: the Correlate of Ineffective Haematopoiesis. 1990 , 2, 415-8	81
1916	Prognostic Features in the Myelodysplastic Syndromes: Importance of Morphological Atypia in the Marrow Cell Lineages. 1990 , 1, 141-6	2
1915	Immunophenotype of Abnormal Metaphases Demonstrating Multilineage Involvement in Myelodysplastic Syndromes. 1990 , 2, 201-5	2
1914	New stains for blood and bone marrow cells. 1990 , 65, 211-30	1
1913	Anémie r ^h fractaire et connectivite, ¶propos d'une cas. 1990 , 11, 403-404	
1912	Flow cytometric analysis of acute leukemias. 1990 , 10, 43-50	5
1911	Pathobiology of myelodysplastic syndromes. 1990 , 44, 69-83	4
1910	The myelodysplastic syndrome. 1990 , 26, 1113-5	4
1909	Karyotypically unrelated clones in acute leukemias and myelodysplastic syndromes. 1990 , 47, 171-8	27
1908	ETS1 gene in myelodysplastic syndrome with chromosome change at 11q23. 1990 , 45, 73-80	7
1907	Translocations (5;17) and (7;17) in patients with de novo or therapy-related myelodysplastic syndromes or acute nonlymphocytic leukemia. A possible association with acquired pseudo-Pelger-HuÈ anomaly and small vacuolated granulocytes. 1990 , 46, 173-83	28
1906	In vitro cytogenetic effects of recombinant human hematopoietic growth factors on cells derived from myelodysplastic syndromes. 1990 , 48, 169-78	4
1905	Translocation (3;21) in a patient with secondary hematological malignancy. 1990 , 50, 227-9	6
1904	Results of chromosome studies and their relation to morphology, course, and prognosis in 120 patients with de novo myelodysplastic syndrome. 1990 , 44, 15-26	105
1903	Deletion of 5q by t(5;17) in therapy-related myelodysplastic syndrome. 1990 , 48, 49-52	11

1902	Cytogenetic abnormalities in acute leukemia complicating melphalan-treated multiple myeloma. 1990 , 48, 67-73	15
1901	Myelodysplastic syndromes. 1990 , 6, 9-16	
1900	Treatment with 13-cis-retinoic acid in transfusion-dependent patients with myelodysplastic syndrome and decreased toxicity with addition of alpha-tocopherol. 1990 , 89, 739-47	63
1899	Monoclonal antibody ratios in malignant myeloid diseases: diagnostic and prognostic use in myelodysplastic syndromes. <i>British Journal of Haematology</i> , 1990 , 74, 270-6	4.5 30
1898	Neuropsychiatric disturbances in a patient with a nonmosaic isodicentric (X) (q21.32) chromosome. 1990 , 44, 563-70	
1897	Chromosome studies in 104 patients with polycythemia vera. 1991 , 66, 287-99	120
1896	Bestatin treatment of myelodysplastic syndromes and chronic myelogenous leukemia. 1991 , 45, 87-93	3
1895	Urticaria pigmentosa and preleukemia: evidence for reactive mast cell proliferation. 1991 , 24, 893-7	3
1894	Management of patients with myelodysplastic syndromes. 1991 , 66, 485-97	12
1893	Retinoic acid in mono- or combined differentiation therapy of myelodysplasia and acute promyelocytic leukemia. 1991 , 45, 169-77	8
1892	Dysmegakaryopoiesis predicting response to therapy in acute myeloid leukaemia. A histologic and clinical study. 1991 , 187, 290-5	1
1891	Therapy related myelodysplastic syndrome and leukemia with no "unfavourable" cytogenetic findings have a good response to intensive chemotherapy: a report on 15 cases. 1991 , 5, 117-25	18
1890	Infection in the myelodysplastic syndromes. 1991 , 90, 338-344	37
1889	Granulocytic sarcoma in myelodysplastic syndromes: clinical marker of disease acceleration. 1991 , 90, 274-276	2
1888	Hematologic manifestations of systemic mast cell disease: a prospective study of laboratory and morphologic features and their relation to prognosis. 1991 , 91, 612-24	142
1887	Granulocytic sarcoma in myelodysplastic syndromes: clinical marker of disease acceleration. 1991 , 90, 274-6	27
1886	Infection in the myelodysplastic syndromes. 1991 , 90, 338-344	74
1885	Reciprocal translocation involving 3q21 in an unusual myeloproliferative disorder with myelodysplastic features and prominent dysmegakaryopoiesis. 1991 , 51, 73-8	3

1884	8;21 translocation with duplication of the der(21) in a patient with myelomonocytic leukemia. 1991 , 51, 139-41	8
1883	Isochromosome 14q in chronic myelomonocytic leukemia. 1991 , 52, 139-40	10
1882	Effect of recombinant human IL-3 on the mitotic index and karyotype of hemopoietic cells. 1991 , 55, 235-41	4
1881	Prognostic value of complex karyotypes in patients with simple refractory anemia. 1991 , 53, 279-80	5
1880	Partial trisomy 1q. A nonrandom primary chromosomal abnormality in myelodysplastic syndromes?. 1991 , 56, 243-53	49
1879	A case of myelodysplastic syndrome with abnormal megakaryocytes and ins(8;3)(q24;q21q26). 1991 , 55, 31-4	1
1878	Genetic abnormalities in myelodysplastic syndrome. 1991 , 56, 1-6	12
1877	Review of clinical, cytogenetic, and molecular aspects of Ph-negative CML. 1991 , 52, 143-56	68
1876	Role of interleukin-4 in the negative regulation of proliferation of chronic myelomonocytic leukemia cells. 1991 , 628, 156-64	4
1875	Low-dose cytarabine for acute myeloid leukaemia and myelodysplastic syndromes: in vivo and in vitro cytotoxicity. 1991 , 27, 842-5	6
1874	Granulocyte-monocyte and Granulocyte-Colony Stimulating Factors in Myelodysplastic Syndromes. 1991 , 5, 219-30	2
1873	Treatment of myelodysplastic syndromes. 1991 , 5, 42-50	12
1872	Absence of allelic loss on chromosome 5q by RFLP analysis in preleukemia. 1991 , 15, 297-303	5
1871	Serum erythropoietin concentrations in patients with myelodysplastic syndromes. 1991 , 15, 571-5	24
1870	The occurrence subtype and significance of haemopoietic inhibitory T cells (HIT cells) in myelodysplasia: an in vitro study. 1991 , 15, 597-601	55
1869	In vitro effects of recombinant hemopoietic growth factors on progenitor cells from patients with myelodysplastic syndromes. 1991 , 15, 29-36	9
1868	Interleukin 1 production by monocytic leukemia cells and its possible role in coagulation abnormalities. 1991 , 15, 1133-7	6
1867	Prognostic implication and characterization of the blast cell population in the myelodysplastic syndrome. 1991 , 15, 1159-65	28

1866	Ineffective hemopoiesis in the myelodysplastic syndromes (MDS) as studied by daily in situ observation of colony-cluster formation. 1991 , 9, 521-30		15
1865	Clinical use of cytokines in the treatment of myelodysplastic syndrome (MDS): A review. 1991 , 9, 21-30		
1864	Bone marrow trephine interpretation: diagnostic utility and potential pitfalls. 1991 , 18, 489-93		12
1863	Lobular panniculitis terminating in acute myeloid leukemia. 1991 , 30, 503-4		4
1862	Recurrent oral condylomata acuminata and hairy leukoplakia: an early sign of myelodysplastic syndrome in an HIV-seronegative patient. 1991 , 20, 398-402		18
1861	Myelodysplasia. 1991 , 4, 459-82		17
1860	In vitro growth pattern and differentiation predict for progression of myelodysplastic syndromes to acute nonlymphocytic leukaemia. <i>British Journal of Haematology</i> , 1991 , 78, 35-41	4.5	28
1859	Molecular analysis of BCR/ABL products in a case of myelodysplastic syndrome with late appearing Philadelphia chromosome. <i>British Journal of Haematology</i> , 1991 , 78, 130-2	4.5	22
1858	A phase II trial of recombinant human granulocyte colony-stimulating factor in the myelodysplastic syndromes. <i>British Journal of Haematology</i> , 1991 , 78, 378-84	4.5	80
1857	Effect of subcutaneously administered human recombinant erythropoietin on erythropoiesis in patients with myelodysplasia. <i>British Journal of Haematology</i> , 1991 , 78, 488-93	4.5	48
1856	In vivo administration of granulocyte-macrophage colony stimulating factor enhances neutrophil function in patients with myelodysplastic syndromes. <i>British Journal of Haematology</i> , 1991 , 79, 177-84	4.5	40
1855	Congenital myelodysplasia: a newly described disease entity?. <i>British Journal of Haematology</i> , 1991 , 79, 340-2	4.5	6
1854	Prognostic importance of Sudan Black positivity: a study of bone marrow slides from 1,386 patients with de novo acute myeloid leukaemia. <i>British Journal of Haematology</i> , 1991 , 79, 398-407	4.5	20
1853	Detection of soluble IL-2 receptor in the serum of patients with myelodysplastic syndromes: induction under therapy with GM-CSF. <i>British Journal of Haematology</i> , 1991 , 79, 438-43	4.5	26
1852	Clonality of cell populations in refractory anaemia using combined approach of gene loss and X-linked restriction fragment length polymorphism-methylation analyses. <i>British Journal of Haematology</i> , 1991 , 79, 550-5	4.5	58
1851	Shift in the megakaryocyte ploidy in MDS patients: microcytofluorometry with DAPI staining after destaining of Wright-Giemsa stain. <i>British Journal of Haematology</i> , 1991 , 79, 556-61	4.5	9
1850	Effects of low doses of recombinant human granulocyte-macrophage colony stimulating factor (GM-CSF) in patients with myelodysplastic syndromes. <i>British Journal of Haematology</i> , 1991 , 77, 291-5	4.5	69
1849	Colony-cluster ratio and cluster number in cultures of circulating myeloid progenitors as indicators of high-risk myelodysplasia. <i>British Journal of Haematology</i> , 1991 , 77, 296-300	4.5	21

1848	The treatment of anaemia in the myelodysplastic syndromes with recombinant human erythropoietin. <i>British Journal of Haematology</i> , 1991 , 77, 419-23	4.5	102
1847	Proposed criteria for classification of acute myeloid leukemia in dogs and cats. 1991 , 20, 63-82		93
1846	Chromosome 16 abnormalities associated with myeloid malignancies. 1991 , 3, 55-61		44
1845	Arsenic intoxication presenting as a myelodysplastic syndrome: a case report. 1991 , 36, 291-3		36
1844	Myelodysplastic transformation of polycythemia vera: case report and review of the literature. 1991 , 37, 45-8		10
1843	Evaluation of continuous infusion low-dose 5-azacytidine in the treatment of myelodysplastic syndromes. 1991 , 37, 100-4		49
1842	The effect of 1-hydroxyvitamin D3 for prolongation of leukemic transformation-free survival in myelodysplastic syndromes. 1991 , 38, 67-8		45
1841	Exposure histories in acute nonlymphocytic leukemia patients with a prior preleukemic condition. 1991 , 67, 2211-4		21
1840	Superoxide anion hyperproduction by neutrophils in a case of myelodysplastic syndrome. Association with Sweet's syndrome and interstitial pneumonia. 1991 , 67, 2337-41		30
1839	Interleukin-3. Biologic effects and clinical impact. 1991 , 67, 2712-7		17
1838	Clinical and cytogenetic characteristics of myelodysplastic syndromes developing myelofibrosis. 1991 , 68, 178-83		42
1837	Polyneuropathy in acute megakaryoblastic leukemia. 1991 , 68, 2033-6		21
1836	Megakaryocytopoiesis in haematological disorders: diagnostic features of bone marrow biopsies. An overview. 1991 , 418, 87-97		31
1835	Myelodysplastic syndromes with bone marrow fibrosis: a myelodysplastic disorder with proliferative features. 1991 , 63, 235-41		54
1834	Superoxide anion production and expression of cytochrome b 558 by neutrophils are impaired in some patients with myelodysplastic syndrome. 1991 , 63, 270-5		15
1833	Granulocyte-macrophage colony-stimulating factor and interleukin-3 in combination: a potent and consistent myelodysplastic syndrome bone marrow stimulant in vitro. 1991 , 63, 297-301		9
1832	The effect of recombinant alpha-interferon on natural killer cell activity and clinical course in patients with myelodysplastic syndrome. 1991 , 62, 225-9		3
1831	Early Pre-B Lymphoblastic Transformation in A Patient with Refractory Anemia. 1991 , 3, 301-3		

1830	Comparative ferrokinetic study with initial and extended iron clearance models. 1991 , 44, 395-9	4
1829	Dysmegakaryopoiesis in myelodysplastic syndromes (MDS): an immunomorphometric study of bone marrow trephine biopsy specimens. 1991 , 44, 300-5	24
1828	Successful treatment with hydroxyurea of ocular involvement in chronic myelomonocytic leukemia. 1991 , 325, 209-10	7
1827	Globin chain synthesis in myelodysplastic syndromes. 1991 , 44, 134-8	5
1826	Two Cases of Translocation t(3;6)(p14;p22): A Non Random Chromosomal Abnormality?. 1991 , 5, 423-9	
1825	Dysmyelopoietic Features and Bone Marrow Histology in 30 Cases of Primary Myelodysplastic Syndromes. 1991 , 3, 419-22	2
1824	Cytogenetic Studies in Patients with Acute Myeloid Leukemia Following a Myelodysplastic Syndrome. 1991 , 3, 423-7	3
1823	Monocyte counting: discrepancies in results obtained with different automated instruments. 1991 , 44, 224-7	26
1822	Basic blue 75: a new stain for erythroblasts. 1991 , 66, 259-65	
1821	Granulocyte colony-stimulating factor and granulocyte-macrophage colony-stimulating factor (2). 1992 , 327, 99-106	403
1820	Haematological differences between chronic granulocytic leukaemia, atypical chronic myeloid leukaemia, and chronic myelomonocytic leukaemia. 1992 , 7, 343-50	27
1819	Further evidence for differential regulation of follicle-stimulating hormone (FSH) and luteinizing hormone (LH): increased FSH and decreased LH levels in a patient with familial pure gonadal dysgenesis. 1992 , 68, 925-7	1
1818	Complex Karyotype with PH1 Chromosome in Myelodysplasia: Cytogenetic and Molecular Studies. 1992 , 6, 401-406	7
1817	Myelodysplastic syndromes. 1992 , 67, 962-6	17
1816	Pathogenesis of Anaemia in the Myelodysplastic Syndrome. 1992 , 20-24	
1815	Oncogene expression in primary myelodysplasia: correlation with haematological, karyotypic, and clinical progression. 1992 , 45, 339-43	7
1814	Bone marrow histology. 3: Value of bone marrow core biopsy in acute leukaemia, myelodysplastic syndromes, and chronic myeloid leukaemia. 1992 , 45, 855-9	16
1813	A case of neutrophilic dermatosis (ND) complicated by cryofibrinogenemia (CFGN) and myelodysplastic syndrome (MDS). 1992 , 19, 181-5	8

1812	Cytogenetic analysis of bone marrow from patients with primary myelodysplastic syndrome. 1992 , 20, 254-66	4
1811	Increased tyrosine protein kinase activity in hairy cell and monocytic leukemias. 1992 , 303, 387-91	8
1810	Myelodysplastic syndromes (refractory anemia). A perspective of the biologic, clinical, and therapeutic issues. 1992 , 76, 599-617	8
1809	Ph-Negative Chronic Myeloid Leukemia: The Nature of the Breakpoint Junctions and Mechanism of ABL Transposition. 1992 , 6, 277-287	3
1808	Myelodysplastic syndromes in the elderly. 1992 , 40, 386-91	2
1807	A two step stain for normal and leukemic monocytes using two different dyes applied in sequence. 1992 , 67, 68-72	2
1806	Decreased level of transforming growth factor-beta in blood lymphocytes of patients with aplastic anemia. 1992 , 6, 85-90	11
1805	Basic blue 54: a new colorant for monocytes. 1992 , 67, 21-6	1
1804	Acquired amegakaryocytic thrombocytopaenia in a child. 1992 , 28, 263-6	5
1803	Myelodysplastic syndrome with partial deletion of the long arm of chromosome 5: first report of a case in a child. 1992 , 34, 539-42	9
1802	Indications for the presence of antibodies cross-reactive with HTLV-I/II, but not HIV, in patients with myelodysplastic syndrome. 1992 , 65, 75-9	1
1801	Therapy of 'high risk' myelodysplastic syndromes with an association of low-dose Ara-C, retinoic acid and 1,25-dihydroxyvitamin D3. 1992 , 46, 211-7	10
1800	In vitro growth of erythroid progenitor cells (BFU-E) and production of burst-promoting activity (BPA) by T lymphocytes in patients with myelodysplastic syndromes. 1992 , 46, 393-9	1
1799	Macrophages (phagocytic-histiocytic reticular cells) in reactive-inflammatory lesions of the bone marrow and in myelodysplastic syndromes (MDS). An immunohistochemical and morphometric study by use of a new monoclonal antibody (PG-M1). 1992 , 188, 995-1001	9
1798	Cell-cycle progression rates and sister chromatid exchange frequencies in the bone marrow of patients with myelodysplastic syndrome and acute myeloid leukemia. 1992 , 62, 66-9	8
1797	Trisomy of chromosome 8 in myelodysplastic syndrome. Significance of the fluctuating trisomy 8 population. 1992 , 62, 70-4	30
1796	Trisomy 8 and 11 in refractory anemia with excess blasts in transformation (RAEB-T). 1992 , 62, 98-9	1
1795	Cytohematologic and cytogenetic prognostic factors at diagnosis and in the evolution in 46 primary myelodysplastic syndromes. 1992 , 61, 174-82	16

1794	Loss of chromosome 22 in patients with refractory anemia with excess of blasts (RAEB) in transformation and acute leukemia after RAEB. 1992 , 61, 210-2	4
1793	Predominance of chromosome 5 deletions in myeloid neoplasia associated with solid tumors managed by surgical excision. 1992 , 58, 125-9	
1792	Leukemia and preleukemia in Fanconi's anemia. 1992 , 58, 206-8; discussion 209	19
1791	Translocation (8;21) in two cases of refractory anemia with excess of blasts in transformation. 1992 , 58, 76-8	17
1790	Trisomy 14 in refractory anemia with excess blasts in transformation. 1992 , 59, 9-11	5
1789	Three new cases of chromosome 3 rearrangement in bands q21 and q26 with abnormal thrombopoiesis bring further evidence to the existence of a 3q21q26 syndrome. 1992 , 59, 138-60	92
1788	Cytogenetic and molecular studies of the Philadelphia translocation in myelodysplastic syndromes. Report of two cases and review of the literature. 1992 , 59, 161-6	28
1787	Cytogenetic analysis of hematologic malignancies in Hong Kong. A study of 98 cases. 1992 , 62, 154-9	32
1786	Cytogenetic studies in 112 cases of untreated myelodysplastic syndromes. 1992 , 64, 12-20	69
1785	Deletion of the long arm of chromosome 5 in essential thrombocythemia. 1992 , 61, 93-5	9
1784	The Value of Cytochemical Investigations in the Diagnosis of the Myelodysplastic Syndrome*. 1992 , 44-50	1
1783	Acute Myelocytic Leukemia and Chronic Myelomonocytic Leukemia Simultaneously with Resectable Breast Cancer: A Report of two Cases. 1992 , 78, 356-358	2
1782	Biologic Relevance of Elevated Red Cell Adenosine Deaminase Activity in Myelodysplastic Syndromes and Paroxysmal Nocturnal Hemoglobinuria. 1992 , 78, 370-373	1
1781	A Guide to Risk Assessment in the Primary Myelodysplastic Syndrome. 1992 , 6, 587-606	41
1780	Morphology and Classification of Myelodysplastic Syndromes. 1992 , 6, 485-499	38
1779	Experience in Pediatric Myelodysplastic Syndromes. 1992 , 6, 655-672	49
1778	Clinical Course of Myelodysplastic Syndromes. 1992 , 6, 607-618	38
1777	Treatment of Myelodysplastic Syndromes with Hematopoietic Growth Factors. 1992 , 6, 633-653	23

1776	Japanese Experience in the Treatment of Myelodysplastic Syndromes. 1992 , 6, 673-685	4
1775	Molecular Genetic Aspects of Myelodysplastic Syndromes. 1992 , 6, 557-570	35
1774	Issues in the Pathology of the Myelodysplastic Syndromes. 1992 , 6, 501-522	17
1773	Therapy-related myelodysplastic syndrome in children with medulloblastoma following MOPP chemotherapy. 1992 , 14, 57-62	14
1772	Unusual cutaneous lesions associated with chronic myelomonocytic leukaemia. 1992 , 17, 121-4	17
1771	Acute febrile neutrophilic dermatosis (Sweet's syndrome) associated with prostate adenocarcinoma and a myelodysplastic syndrome. 1992 , 31, 647-8	10
1770	Myelodysplastic syndromes. Pathogenesis, diagnosis and treatment. 1992 , 12, 193-215	32
1769	Childhood myelodysplastic syndromes: clinical features, cytogenetics and prognosis. 1992 , 59, 443-8	7
1768	Seronegative inflammatory arthritis in the myelodysplastic syndromes. 1992 , 21, 345-54	53
1767	Increased serum interleukin 6 levels in patients with myelodysplastic syndromes. 1992 , 16, 585-8	26
1766	Minimal diagnostic criteria for the myelodysplastic syndrome. 1992 , 16, 4-5	9
1765	Minimal diagnostic criteria for the myelodysplastic syndrome in clinical practice. 1992 , 16, 5-6	10
1764	Minimal diagnostic criteria for the myelodysplastic syndrome in clinical practice. 1992 , 16, 8-9	1
1763	Minimal diagnostic criteria for the myelodysplastic syndrome. 1992 , 16, 9-11	20
1762	Morphologic classification of the myelodysplastic syndromes (MDS): combined utilization of bone marrow aspirates and trephine biopsies. 1992 , 16, 15-33	41
1761	Myelodysplastic syndromes (MDS) and acute myeloid leukemias (AML) with myelofibrosis. 1992 , 16, 51-4	26
1760	Bone marrow dysfunctions preceding acute leukemia in children: a clinical study. 1992 , 16, 71-6	20
1759	Prognostic factors in myelodysplastic syndromes. 1992 , 16, 77-86	45

1758	Therapeutic aspects of myelodysplastic syndromes in chronic phase. 1992 , 16, 95-100	5
1757	Endogenous serum levels and surface receptor expression of GM-CSF and IL-3 in patients with myelodysplastic syndromes. 1992 , 16, 1181-6	20
1756	A hematological remission by clonal hematopoiesis after treatment with recombinant human granulocyte-macrophage colony-stimulating factor and erythropoietin in a patient with therapy-related myelodysplastic syndrome. 1992 , 16, 123-31	11
1755	Clinical features of long-term survivors of refractory myelodysplastic anemias. A Japanese cooperative study. 1992 , 16, 775-9	5
1754	Morphologic, immunologic and cytogenetic studies in acute myeloid leukemia following occupational exposure to pesticides and organic solvents. 1992 , 16, 789-96	47
1753	Heterogeneity of acquired idiopathic sideroblastic anaemia (AISA). 1992 , 16, 463-8	34
1752	In vitro suspension culture reactions to 1,25 dihydroxyvitamin D3 in relation to bone marrow morphology and prognosis in patients with myelodysplastic syndromes. 1992 , 16, 529-35	4
1751	Clinical trials of bestatin for leukemia and solid tumors. 1992 , 4, 205-14	30
1750	Interleukin-3 in the treatment of myelodysplastic syndromes. 1992 , 22, 125-8	2
1749	Atypical micromegakaryocytes, promegakaryoblasts and megakaryoblasts: a critical evaluation by immunohistochemistry, cytochemistry and morphometry of bone marrow trephines in chronic myeloid leukemia and myelodysplastic syndromes. 1992 , 62, 275-82	16
1748	Chromosome analyses in patients with myelodysplastic syndromes: correlation with bone marrow histopathology and prognostic significance. 1992 , 421, 47-52	9
1747	Recombinant human erythropoietin for the treatment of anemia in the myelodysplastic syndromes: a clinical and erythrokinetic assessment. 1992 , 64, 16-21	44
1746	Acute parvovirus B19 infection mimicking myelodysplastic syndrome of the bone marrow. 1992 , 64, 43-5	36
1745	Hypoplastic acute leukemia: description of eight cases and search for hematopoietic inhibiting activity. 1992 , 65, 247-52	5
1744	Expression of the Tn antigen on erythroid cells from a patient with Tn syndrome. 1992 , 37, 271-83	1
1743	A randomized phase-I/II multicenter study of recombinant human granulocyte-macrophage colony-stimulating factor (GM-CSF) therapy for patients with myelodysplastic syndromes and a relatively low risk of acute leukemia. EORTC Leukemia Cooperative Group. 1992 , 64, 173-80	44
1742	The evaluation of low-dose cytarabine in the treatment of myelodysplastic syndromes: a phase-III intergroup study. 1992 , 65, 162-8	114
1741	Treatment of myelodysplastic syndromes (MDS) and high leukaemic risk with low-dose cytosine arabinoside (LD-AraC) plus granulocyte-macrophage colony-stimulating factor (rh GM-CSF). The EORTC Leukaemia Group. 1992 , 20 Suppl 2, S116-23	3

1740	Ph-negative and bcr-negative atypical chronic myelogenous leukemia: biological features and clinical outcome. 1992 , 65, 17-21		18
1739	Myelodysplastic syndromes in childhood: a population based study of nine cases. <i>British Journal of Haematology</i> , 1992 , 81, 495-8	4.5	48
1738	Extended cytogenetic follow-up of patients with myelodysplastic syndrome (MDS). <i>British Journal of Haematology</i> , 1992 , 81, 499-502	4.5	23
1737	A predictive model for the clinical response to low dose ara-C: a study of 102 patients with myelodysplastic syndromes or acute leukaemia. <i>British Journal of Haematology</i> , 1992 , 81, 503-11	4.5	71
1736	Abstracts of the State of the Art Symposia Presented at the 24th Congress of the International Society of Haematology, London, 23-27 August 1992. <i>British Journal of Haematology</i> , 1992 , 82, 181-271	4.5	
1735	Desferrioxamine treatment reduces blood transfusion requirements in patients with myelodysplastic syndrome. <i>British Journal of Haematology</i> , 1992 , 80, 121-4	4.5	39
1734	Primary myelodysplastic syndrome in children: the clinical experience in 33 cases. <i>British Journal of Haematology</i> , 1992 , 82, 347-53	4.5	53
1733	Low-dose etoposide: a potential therapy for myelodysplastic syndromes. <i>British Journal of Haematology</i> , 1992 , 82, 354-7	4.5	14
1732	Age-related incidence and other epidemiological aspects of myelodysplastic syndromes. <i>British Journal of Haematology</i> , 1992 , 82, 358-67	4.5	171
1731	Remission with morphological myelodysplasia in de novo acute myeloid leukaemia: implications for early relapse. <i>British Journal of Haematology</i> , 1992 , 81, 33-9	4.5	10
1730	Myelodysplastic syndrome (MDS)-associated inhibitory activity on haematopoietic progenitor cells: contribution of monocyte-derived lipid containing macrophages (MDLM). <i>British Journal of Haematology</i> , 1992 , 81, 67-72	4.5	6
1729	Mutations of the p53 tumour suppressor gene in haematologic neoplasms. <i>British Journal of Haematology</i> , 1992 , 81, 235-40	4.5	43
1728	Clonal lymphocytes are detectable in only some cases of MDS. <i>British Journal of Haematology</i> , 1992 , 81, 346-52	4.5	77
1727	Detection of latent subclones with abnormal karyotypes by long-term bone marrow cultures in cases of myelodysplastic syndrome. <i>British Journal of Haematology</i> , 1992 , 81, 353-61	4.5	7
1726	The cytogenetics of haematological malignancies. 1992 , 5, 791-814		5
1725	Myeloid malignancies and chromosome 5 deletions. 1992 , 5, 931-42		12
1724	The management of acute myelogenous leukemia in the elderly: ten-year experience in 118 patients. 1992 , 10, 251-60		15
1723	Successful treatment with vincristine by slow infusion in a patient with refractory anemia and excess of blasts. 1992 , 39, 73-4		1

- 1722 Circulating CD34+ cells: an adverse prognostic factor in the myelodysplastic syndromes. **1992**, 39, 96-101 39
- 1721 Relapsing polychondritis: a paraneoplastic syndrome associated with myelodysplastic syndromes. **1992**, 40, 47-50 31
- 1720 Myelodysplastic syndromes and malignant solid tumors: analysis of 21 cases. **1992**, 41, 1-4 18
- 1719 Cytogenetic characterization of primary refractory anemia. **1992**, 41, 241-8 7
- 1718 No large deletions of mitochondrial DNA in acquired idiopathic sideroblastic anemia (AISA). **1992**, 41, 297 8
- 1717 T cell-mediated inhibition of erythropoiesis in myelodysplastic syndromes. **1992**, 41, 304-5 36
- 1716 Distinct cytogenetic and clinicopathologic features in acute myeloid leukemia after occupational exposure to pesticides and organic solvents. **1992**, 70, 77-85 40
- 1715 Cytogenetic and clinical findings of myelodysplastic syndromes with a poor prognosis. An experience with 97 cases. **1992**, 70, 94-9 16
- 1714 Spontaneous remission of infantile acute nonlymphocytic leukemia for 11 years in a child with normal karyotype. **1993**, 71, 1928-30 16
- 1713 Treatment of myelodysplastic syndromes with daily oral idarubicin. A phase I-II study. **1993**, 71, 1989-92 9
- 1712 Myelodysplastic syndrome after cisplatin therapy. **1993**, 72, 213-8 16
- 1711 Bilateral tumoral infiltration of the Achilles tendons revealing chronic myelomonocytic leukemia. **1993**, 36, 852-6 8
- 1710 Comparison of cytogenetic and restriction fragment length polymorphism analyses for the detection of loss of chromosome material in clonal hemopoietic disorders. **1993**, 42, 171-6 11
- 1709 High Ia (HLA-DR) and low CD11b (Mo1) expression may predict early conversion to leukemia in myelodysplastic syndromes. **1993**, 43, 165-71 17
- 1708 8;21 translocation and multilineage involvement. **1993**, 43, 211-215
- 1707 *Saccharomyces cerevisiae* septicemia in a patient with myelodysplastic syndrome. **1993**, 43, 325-6 34
- 1706 Inversion of chromosome 16 and eosinophilia in refractory anemia with ring sideroblasts: report of a case. **1993**, 44, 134-8 6
- 1705 Recombinant human granulocyte-macrophage colony-stimulating factor plus recombinant human erythropoietin may improve anemia in selected patients with myelodysplastic syndromes. **1993**, 44, 229-36 33

1704	Karyotypic analysis in primary myelodysplastic syndromes. 1993 , 7, 10-8		19
1703	Recombinant human interleukin-8 restores function in neutrophils from patients with myelodysplastic syndromes without stimulating myeloid progenitor cells. 1993 , 37, 322-8		13
1702	Myelodysplastic syndromes in children. <i>British Journal of Haematology</i> , 1993 , 84, 185-6	4.5	23
1701	Management of myelodysplastic syndromes. <i>British Journal of Haematology</i> , 1993 , 84, 191-6	4.5	15
1700	Clonal evolutions during long-term cultures of bone marrow from de novo acute myeloid leukaemia with trilineage myelodysplasia and with myelodysplastic remission marrow. <i>British Journal of Haematology</i> , 1993 , 84, 219-26	4.5	17
1699	High doses of intravenous recombinant erythropoietin for the treatment of anaemia in myelodysplastic syndrome. <i>British Journal of Haematology</i> , 1993 , 84, 232-7	4.5	39
1698	Immunotyping of blasts in refractory anaemia with excess of blasts. <i>British Journal of Haematology</i> , 1993 , 84, 305-9	4.5	15
1697	Bone marrow transplantation for myelodysplastic syndrome and secondary leukaemias. <i>British Journal of Haematology</i> , 1993 , 84, 361-4	4.5	9
1696	Immunophenotypic characterization of myelomonocytic cells in patients with myelodysplastic syndrome. <i>British Journal of Haematology</i> , 1993 , 84, 428-35	4.5	26
1695	Myelodysplastic syndrome with eosinophilia in bone marrow. Gunma Haematology Study Group. <i>British Journal of Haematology</i> , 1993 , 84, 636-8	4.5	17
1694	Clonal remissions in acute myeloid leukaemia are commonly associated with features of trilineage myelodysplasia during remission. <i>British Journal of Haematology</i> , 1993 , 85, 698-705	4.5	13
1693	Long-standing remission after 25-OH D3 treatment in a case of chronic myelomonocytic leukaemia. <i>British Journal of Haematology</i> , 1993 , 85, 811-2	4.5	9
1692	Clinical, haematological and cytogenetic features in 24 patients with structural rearrangements of the Q arm of chromosome 3. <i>British Journal of Haematology</i> , 1993 , 83, 158-65	4.5	61
1691	Proliferation and differentiation of myelodysplastic CD34+ cells in serum-free medium: response to individual colony-stimulating factors. <i>British Journal of Haematology</i> , 1993 , 83, 349-58	4.5	20
1690	MDS-macrophage derived inhibitory activity on myelopoiesis of MDS abnormal clones. <i>British Journal of Haematology</i> , 1993 , 83, 388-91	4.5	13
1689	Clonality in myelodysplastic syndromes: demonstration of pluripotent stem cell origin using X-linked restriction fragment length polymorphisms. <i>British Journal of Haematology</i> , 1993 , 83, 589-94	4.5	62
1688	The CD11/CD18 granulocyte adhesion molecules in myelodysplastic syndromes. <i>British Journal of Haematology</i> , 1993 , 83, 245-52	4.5	10
1687	The prognostic significance of auer rods in myelodysplasia. <i>British Journal of Haematology</i> , 1993 , 85, 67-76	4.5	26

1686	De novo myelodysplastic syndrome (MDS) with deletion of the long arm of chromosome 20: a subtype of MDS with distinct hematological and prognostic features?. 1993 , 17, 921-6	50
1685	Variable growth in vitro of chromosomally different stem cells in myelodysplastic syndromes. 1993 , 17, 927-32	3
1684	Effects of interleukin 2 on myelodysplastic syndromes. 1993 , 17, 137-42	7
1683	The role of integrins in granulocyte dysfunction in myelodysplastic syndrome. 1993 , 17, 609-19	14
1682	Long-term survivors in myelodysplastic syndromes: a report on 63 cases and comparison with short and intermediate survivors. 1993 , 17, 733-9	9
1681	Expression of the DCC gene in myelodysplastic syndromes and overt leukemia. 1993 , 17, 785-8	17
1680	A quantitative evaluation of erythropoiesis in myelodysplastic syndromes using multiparameter flow cytometry. 1993 , 17, 839-46	10
1679	The effects of GM-CSF on myeloperoxidase release in normal and myelodysplastic neutrophils. 1993 , 17, 1037-44	13
1678	Recombinant human erythropoietin (rHuEPO) for treatment of myelodysplastic syndrome. 1993 , 11, 49-55	23
1677	Classification of myeloproliferative disorders in cats using criteria proposed by the animal leukaemia study group: A retrospective study of 181 cases (1969-1992). 1993 , 3, 125-134	28
1676	Clinico-hematological profile and natural history of childhood myelodysplastic syndromes. 1993 , 60, 573-81	8
1675	Prognostic relevance of histological findings on bone marrow biopsy in myelodysplastic syndromes. 1993 , 66, 85-91	30
1674	Biology and treatment of myelodysplastic syndromes--developments in the past decade. 1993 , 66, 107-15	21
1673	Hypoplastic myelodysplastic syndrome: incidence, morphology, cytogenetics, and prognosis. 1993 , 66, 117-22	75
1672	Serial changes in endogenous erythropoietin levels in patients with myelodysplastic syndromes and aplastic anemia undergoing erythropoietin treatment. 1993 , 66, 175-80	21
1671	Myelodysplastic syndrome associated with relapsing polychondritis: unusual transformation from refractory anemia to chronic myelomonocytic leukemia. 1993 , 67, 45-7	15
1670	Myelodysplastic syndromes: immunohistochemical and morphometric evaluation of proliferative activity in erythropoiesis and endoreduplicative capacity of megakaryocytes. 1993 , 423, 33-8	8
1669	Detection of monosomy 7 by fluorescence in situ hybridization in acute nonlymphocytic leukemia and myelodysplastic syndrome. 1993 , 38, 257-66	2

1668	Myelodysplastic syndrome: diagnostic implications of cytochemical and immunocytochemical studies. 1993 , 68, 47-53	14
1667	Treatment of myelodysplastic syndromes with AML-type chemotherapy. 1993 , 11 Suppl 2, 59-63	17
1666	Clinical and cytogenetic significance of myelodysplastic syndromes with disease evolution. 1993 , 67, 71-8	9
1665	t(5;12)(q31;p12). A clinical entity with features of both myeloid leukemia and chronic myelomonocytic leukemia. 1993 , 65, 7-11	47
1664	Analysis of karyotype, SCE, and point mutation of RAS oncogene in Indian MDS patients. 1993 , 65, 12-20	12
1663	Consistent interstitial chromosomal deletions in myeloid malignancies and their correlation with fragile sites. 1993 , 65, 51-7	11
1662	Translocation (12;14)(q13;q32) in myelodysplastic syndrome. 1993 , 65, 76-8	3
1661	Age- and gender-related heterogeneity of cancer chromosome aberrations. 1993 , 70, 6-11	26
1660	Childhood myelodysplastic syndrome with clonal evolution progressing to acute megakaryoblastic leukemia (ANLL-M7). 1993 , 70, 17-20	4
1659	Cell lineage involvement in four patients with myelodysplastic syndrome and t(1;7) or trisomy 8 studied by simultaneous immunophenotyping and fluorescence in situ hybridization. 1993 , 70, 120-4	31
1658	Expression of the proliferating cell nuclear antigen in bone marrow cells from patients with myelodysplastic syndromes and aplastic anemia. 1993 , 24, 359-63	27
1657	Inflammatory bowel disease and refractory anaemia (myelodysplasia). 1993 , 34, 1630-1	19
1656	Chemotherapy with high-dose cytosine arabinoside and mitoxantrone for poor-prognosis myeloid leukemias. 1993 , 11, 509-16	6
1655	Hematopoietic growth factor therapy of myelodysplastic syndromes. 1993 , 11 Suppl 2, 65-9	3
1654	A combination of granulocyte colony-stimulating factor and erythropoietin may synergistically improve the anaemia in patients with myelodysplastic syndromes. 1993 , 11, 221-8	58
1653	Erythroleukemia and myelodysplastic syndromes: an historical appraisal and a personal view. 1993 , 9, 27-34	9
1652	Megakaryocytic ploidy in myelodysplastic syndromes. 1993 , 9, 55-61	8
1651	Myelodysplasia, vasculitis and anti-neutrophil cytoplasm antibodies. 1993 , 9, 49-54	32

1650	Malignant tumors occurring after treatment of aplastic anemia. European Bone Marrow Transplantation-Severe Aplastic Anaemia Working Party. 1993 , 329, 1152-7	381
1649	The role of interleukin-4 in the negative regulation of leukemia cell growth. 1993 , 9, 205-9	17
1648	Clinical and biological effects of erythropoietin treatment of myelodysplastic syndrome. 1993 , 10, 127-34	4
1647	Common haematological problems in the elderly. 1993 , 3, 335-346	
1646	Sea blue histiocytosis: a common abnormality of the bone marrow in myelodysplastic syndromes. 1993 , 46, 1030-2	24
1645	Chronic myelomonocytic leukaemia (CMML)--a myelodysplastic or myeloproliferative syndrome?. 1993 , 9, 35-41	72
1644	Lymph node disease with lymphocytic abnormal chromatin clumping in a myelodysplastic/myeloproliferative syndrome. 1993 , 46, 177-9	1
1643	General responses of the bone marrow to injury. 1993 , 21, 118-29	16
1642	New uses for old vitamins. The treatment of myelodysplastic disorders. 1993 , 77, 919-29	2
1641	Advances in the Diagnosis of Acute Leukemia. 1993 , 7, 1-46	11
1640	Leukemia Cutis. 1994 , 12, 419-431	91
1639	Clinical Application of Recombinant Erythropoietin in Myelodysplasia. 1994 , 8, 993-1009	8
1638	Bone marrow lymphocyte subsets in myelodysplastic syndromes. 1994 , 47, 505-7	13
1637	Low-dose ara-C in myelodysplastic syndromes (MDS) and acute leukemia following MDS: proposal for a predictive model. 1994 , 12, 343-51	8
1636	Reticulocyte maturity as an indicator for estimating qualitative abnormality of erythropoiesis. 1994 , 47, 736-9	27
1635	Prognostic significance of the surface antigens expressed by leukemic cells. 1994 , 13 Suppl 1, 15-22	1
1634	Myelodysplastic syndromes in childhood--classification, epidemiology, and treatment. 1994 , 13, 11-26	78
1633	Clonality in myelodysplastic syndromes. 1994 , 13, 215-21	40

1632	Extended cytogenetic follow-up and clinical progress in patients with myelodysplastic syndromes (MDS). 1994 , 12, 401-12	21
1631	Hematopoietic malignancies and related disorders among benzene-exposed workers in China. 1994 , 14, 91-102	58
1630	Acute sideroblastic anemia in active systemic lupus erythematosus. 1994 , 3, 157-9	11
1629	The 5q- syndrome: a scientific and clinical update. 1994 , 14, 375-8	16
1628	Differentiation therapy of myelodysplastic syndromes with retinoic acid. 1994 , 14, 401-9	16
1627	Trilineage response to rhG-CSF with subsequent clonal hematopoiesis in a patient with severe bone marrow aplasia. 1994 , 14, 347-51	3
1626	Neutrophils from patients with myelodysplastic syndromes: relationship between impairment of granular contents, complement receptors, functional activities and disease status. 1994 , 13, 471-7	25
1625	CD34 immunophenotyping of blasts in myelodysplasia. 1994 , 15, 65-9	3
1624	Expression and genomic configuration of GM-CSF, IL-3, M-CSF receptor (C-FMS), early growth response gene-1 (EGR-1) and M-CSF genes in primary myelodysplastic syndromes. 1994 , 15, 135-41	4
1623	Efficacy of recombinant human erythropoietin in the treatment of refractory anemias without excess of blasts in myelodysplastic syndromes. 1994 , 12, 307-14	13
1622	Immunological findings in patients with myelodysplastic syndrome. 1994 , 15, 201-8	9
1621	Idarubicin, high-dose cytarabine and etoposide for remission induction in therapy-related acute myeloid leukemia. 1994 , 15, 127-30	8
1620	Myelodysplastic syndrome with bone marrow eosinophilia: clinical and cytogenetic features. 1994 , 15, 491-7	10
1619	Combination of mitoxantrone and etoposide in the treatment of myelodysplastic syndromes transformed into acute myeloid leukemia. 1994 , 12, 421-5	14
1618	Prognostic implications of bone marrow culturing in myelodysplastic syndrome: a retrospective analysis. 1994 , 14, 111-20	13
1617	Impaired proliferation and differentiation of myelodysplastic CD34+ cells. 1994 , 14, 37-47	12
1616	Induction of soluble IL-2 receptor in patients with myelodysplastic syndromes undergoing high-dose interleukin-3 treatment. 1994 , 68, 167-70	4
1615	Cell cycle kinetics of hematopoiesis before and after in vivo administration of GM-CSF in refractory anemia: evidence for a shortening of the granulocyte release time. 1994 , 68, 175-81	2

1614	CD 34 immunotyping of blasts in myelodysplasia. 1994 , 68, 77-80	13
1613	Myelodysplastic syndromes in childhood: description of seven cases. 1994 , 68, 241-5	2
1612	Bone marrow dysplasia in patients with newly diagnosed acute myelogenous leukemia does not correlate with history of myelodysplasia or with remission rate and survival. 1994 , 73, 314-21	14
1611	Serum deoxythymidine kinase in myelodysplastic syndromes. 1994 , 73, 322-7	5
1610	A review of 76 patients with myelodysplastic syndromes treated with danazol. 1994 , 73, 3073-80	40
1609	A knowledge-based system for the interpretation of flow cytometry data in leukemias and lymphomas. 1994 , 17, 266-73	22
1608	Disseminated Mycobacterium avium-intracellulare infection in a patient with myelodysplastic syndrome (refractory anemia). 1994 , 45, 325-9	9
1607	CD34 immunohistochemistry of bone marrow biopsies: prognostic significance in primary myelodysplastic syndromes. 1994 , 46, 9-17	41
1606	Karyotype in myelodysplastic syndromes: relations to morphology, clinical evolution, and survival. 1994 , 46, 270-7	49
1605	Low-dose ARA-C consistently induces hematologic responses in the clinical 5q- syndrome. 1994 , 46, 338-42	15
1604	Trilineage recovery by combination therapy with recombinant human granulocyte colony-stimulating factor and erythropoietin in patients with aplastic anemia and refractory anemia. 1994 , 12, 604-15	12
1603	Hematologic, clinical, and cytogenetic analysis in 109 patients with primary myelodysplastic syndrome. Prognostic significance of morphology and chromosome findings. 1994 , 78, 219-31	62
1602	Immunoglobulin and T-cell receptor delta gene rearrangements are rarely found in myelodysplastic syndromes in chronic phase. 1994 , 18, 365-71	9
1601	Bone marrow cellularity in myeloid stem cell disorders: impact of age correction. 1994 , 18, 559-64	34
1600	Translocation (8;21) in oligoblastic leukemia: is this a true myelodysplastic syndrome?. 1994 , 18, 761-5	22
1599	Pseudo-myelodysplastic syndrome with t(8;21). 1994 , 18, 767-8	6
1598	Therapy with recombinant human erythropoietin in patients with myelodysplastic syndromes. 1994 , 18, 769-76	19
1597	Elevated plasma soluble interleukin 2 receptor level correlates with defective natural killer and CD8+ T-cells in myelodysplastic syndromes. 1994 , 18, 777-82	16

1596	Myelodysplasia and acute megakaryoblastic leukemia in Down's syndrome. 1994 , 18, 163-71		125
1595	Use of cell surface antigen phenotype in guiding therapeutic decisions in chronic myelomonocytic leukemia. 1994 , 18, 173-81		3
1594	The rate of disease progression predicts the quality of remissions following intensive chemotherapy for myelodysplastic syndromes. 1994 , 18, 797-804		7
1593	The morphological studies on M2/t(8; 21) acute nonlymphocytic leukemia. 1994 , 14, 38-41		
1592	Cutaneous involvement in chronic myelomonocytic leukemia. 1994 , 33, 628-31		12
1591	Simultaneous occurrence of two rare cutaneous markers of poor prognosis in myelodysplastic syndrome: erythema elevatum diutinum and specific lesions. 1994 , 131, 112-7		43
1590	Assessment of therapeutic potential of interleukin 2 for myelodysplastic syndromes. <i>British Journal of Haematology</i> , 1994 , 86, 562-7	4.5	9
1589	Identification of a subgroup of myelodysplastic patients with a neutrophil stimulation-signalling defect. <i>British Journal of Haematology</i> , 1994 , 86, 761-6	4.5	10
1588	Long-term follow-up of aplastic anaemia. <i>British Journal of Haematology</i> , 1994 , 86, 837-43	4.5	23
1587	Inactivation of the retinoblastoma gene appears to be very uncommon in myelodysplastic syndromes. <i>British Journal of Haematology</i> , 1994 , 87, 61-7	4.5	32
1586	Non-invasive assessment of tissue iron overload in the liver by magnetic resonance imaging. <i>British Journal of Haematology</i> , 1994 , 87, 171-84	4.5	72
1585	Phenotypic and functional analysis of bone marrow progenitor cell compartment in bone marrow failure. <i>British Journal of Haematology</i> , 1994 , 87, 227-34	4.5	91
1584	Establishment and characterization of a novel myeloid cell line from the bone marrow of a patient with the myelodysplastic syndrome. <i>British Journal of Haematology</i> , 1994 , 87, 235-42	4.5	42
1583	Postnatal changes of CD45 expression in peripheral blood T and B cells. <i>British Journal of Haematology</i> , 1994 , 87, 251-7	4.5	11
1582	Production of fibronectin and adherence to fibronectin by human myeloma cell lines. <i>British Journal of Haematology</i> , 1994 , 87, 258-65	4.5	23
1581	PCR assessment of bone marrow status in 'isolated' extramedullary relapse of childhood B-precursor acute lymphoblastic leukaemia. <i>British Journal of Haematology</i> , 1994 , 87, 282-5	4.5	65
1580	Increased expression of myeloid antigen markers in adult acute lymphoblastic leukaemia patients: diagnostic and prognostic implications. <i>British Journal of Haematology</i> , 1994 , 87, 286-92	4.5	25
1579	Dysplastic haemopoiesis following orthotopic liver transplantation: comparison with similar changes in HIV infection and primary myelodysplasia. <i>British Journal of Haematology</i> , 1994 , 88, 685-92	4.5	17

1578	Metaphase fluorescence in situ hybridization (FISH) in the follow-up of 60 patients with haemopoietic malignancies. <i>British Journal of Haematology</i> , 1994 , 88, 778-83	4.5	18
1577	Establishing the incidence of myelodysplastic syndrome. <i>British Journal of Haematology</i> , 1994 , 87, 743-5	4.5	121
1576	The chronic myeloid leukaemias: guidelines for distinguishing chronic granulocytic, atypical chronic myeloid, and chronic myelomonocytic leukaemia. Proposals by the French-American-British Cooperative Leukaemia Group. <i>British Journal of Haematology</i> , 1994 , 87, 746-54	4.5	369
1575	The proliferative activity of myelopoiesis in myelodysplasia evaluated by multiparameter flow cytometry. <i>British Journal of Haematology</i> , 1994 , 87, 477-82	4.5	14
1574	Cytogenetic studies, ras mutation, and clinical characteristics in primary myelodysplastic syndrome. A study on 68 Chinese patients in Taiwan. 1994 , 74, 40-9		41
1573	Trisomy 19 as the sole chromosomal anomaly in hematologic neoplasms. 1994 , 74, 62-5		21
1572	Involvement of erythrocytic and granulomonocytic lineages by trisomy 11 in two cases of acute myelomonocytic leukemia with trilineage myelodysplasia. An interphase cytogenetic study. 1994 , 77, 33-8		7
1571	Acute myeloblastic leukemia with a pericentric inversion of chromosome 6 in a child with Down syndrome. 1994 , 73, 157-60		2
1570	Gingival and oral mucosal ulceration associated with the myelodysplastic syndrome. 1994 , 30B, 346-50		3
1569	Myelodysplastic syndrome in a quarter horse gelding. 1994 , 26, 83-5		18
1568	HIV-associated bone marrow changes. 1994 , 1, 131-141		5
1567	Cutaneous T-cell lymphoma and myelodysplastic syndrome. 1994 , 31, 1065-7		4
1566	Histological characteristic of bone marrow trephines in myelodysplastic syndromes. 1994 , 1, 189-193		
1565	Isolated bone marrow non-Hodgkin's lymphoma: a clinicopathologic study. 1994 , 69, 37-43		18
1564	Abstracts. 1994 , 12, 1-64		15
1563	New treatment approaches for myelodysplastic syndrome and secondary leukaemias. 1994 , 5, 401-8		10
1562	Myelodysplastic syndromes. 1994 , 39, 5-7		
1561	Myelodysplasia with myelofibrosis--a distinct subgroup within the myelodysplastic syndromes. 1994 , 26, 69-71		5

1560	Pericardial tamponade in chronic myelomonocytic leukemia. 1994 , 106, 967-70		12
1559	Effects of interleukin-12 on natural killer cell cytotoxicity and the production of interferon-gamma and tumour necrosis factor-alpha in patients with myelodysplastic syndromes. <i>British Journal of Haematology</i> , 1995 , 90, 15-21	4.5	22
1558	Prognostic relevance of serum thymidine kinase in primary myelodysplastic syndromes: relationship to development of acute myeloid leukaemia. <i>British Journal of Haematology</i> , 1995 , 90, 125-30	4.5	15
1557	Idiopathic macrocytic anaemia in the aged: molecular and cytogenetic findings. <i>British Journal of Haematology</i> , 1995 , 90, 797-803	4.5	19
1556	Detection of CBFB/MYH11 transcripts in patients with inversion and other abnormalities of chromosome 16 at presentation and remission. <i>British Journal of Haematology</i> , 1995 , 91, 104-8	4.5	73
1555	Increased expression of Fas antigen on bone marrow CD34+ cells of patients with aplastic anaemia. <i>British Journal of Haematology</i> , 1995 , 91, 245-52	4.5	231
1554	Paraneoplastic autoimmune phenomena in patients with myelodysplastic syndromes: response to immunosuppressive therapy. <i>British Journal of Haematology</i> , 1995 , 91, 403-8	4.5	203
1553	t(8;21) myelodysplasia: a further six cases. <i>British Journal of Haematology</i> , 1995 , 91, 515-6	4.5	4
1552	Hypocellular myelodysplastic syndromes (MDS): new proposals. <i>British Journal of Haematology</i> , 1995 , 91, 612-7	4.5	119
1551	Isodicentric (X)(q13) in haematological malignancies: presentation of five new cases, application of fluorescence in situ hybridization (FISH) and review of the literature. <i>British Journal of Haematology</i> , 1995 , 91, 885-91	4.5	27
1550	Chimaeric cultures of human marrow stroma and murine leukaemia cells: evidence for abnormalities in the haemopoietic microenvironment in myeloid malignancies and other infiltrating marrow disorders. <i>British Journal of Haematology</i> , 1995 , 90, 502-11	4.5	11
1549	The myelodysplastic syndromes: an analysis of prognostic factors in 226 cases from a single institution. <i>British Journal of Haematology</i> , 1995 , 90, 602-6	4.5	34
1548	Pathoanatomical aspects of malignant haematological disorders among Danish patients exposed to thorium dioxide. 1995 , 103, 29-36		9
1547	Anerythremic form of acute erythremic myelosis (Di Guglielmo's syndrome) causing hepatosplenomegaly due to the infiltration of hemoglobin-bearing blast cells: an autopsy case. 1995 , 45, 310-4		3
1546	Simultaneous assessment of cell kinetics and programmed cell death in bone marrow biopsies of myelodysplastics reveals extensive apoptosis as the probable basis for ineffective hematopoiesis. 1995 , 48, 143-54		129
1545	Abnormal platelet von Willebrand factor (vWF) as a marker of abnormal function in megakaryocytic dysplasia. 1995 , 48, 155-7		3
1544	Myelodysplastic syndrome treatment with danazol and cis-retinoic acid. 1995 , 48, 233-6		14
1543	Morphologic characteristics of erythroleukemia (acute myeloid leukemia; FAB-M6): a CALGB study. 1995 , 49, 29-38		44

1542	Peripheral blood neutrophil morphology reflects bone marrow dysplasia in myelodysplastic syndromes. 1995 , 49, 115-20	13
1541	Familial myelodysplastic syndrome with onset late in life. 1995 , 49, 153-6	10
1540	Hematological features of patients with myelodysplastic syndromes associated with a chromosome 5q deletion. 1995 , 49, 194-200	32
1539	Late appearance of the Philadelphia chromosome with monosomy 7 in a patient with de novo AML with trilineage myelodysplasia. 1995 , 49, 341-6	16
1538	Steroid-responsive pulmonary disorders associated with myelodysplastic syndromes with der(1q;7p) chromosomal abnormality. 1995 , 50, 110-5	29
1537	Leukemias, myeloma, and other lymphoreticular neoplasms. 1995 , 75, 381-94	72
1536	Myelodysplasia. The clinical spectrum of 51 patients. 1995 , 76, 869-74	5
1535	Juvenile chronic myelocytic leukemia--report of 10 cases. 1995 , 24, 100-3	3
1534	Prognostic factors in myelodysplastic syndromes: analysis of five scoring systems. 1995 , 13, 139-52	7
1533	Comparative genomic hybridization in the investigation of myeloid leukemias. 1995 , 12, 193-200	46
1532	FAB classification of myelodysplastic syndromes: merits and controversies. 1995 , 71, 3-11	32
1531	Comparison of scoring systems in primary myelodysplastic syndromes. 1995 , 70, 301-8	6
1530	Analysis of bone marrow and peripheral blood immunoregulatory lymphocytes in patients with myelodysplastic syndrome. 1995 , 71, 293-9	7
1529	Cytogenetic findings in 179 patients with myelodysplastic syndromes. 1995 , 70, 171-87	74
1528	A megakaryocyte analysis of the bone marrow in patients with myelodysplastic syndrome, myeloproliferative disorder and allied disorders. 1995 , 177, 181-9	15
1527	Myelodysplastic syndrome presenting as cutaneous vasculitis. 1995 , 20, 439-42	9
1526	Karyotype at diagnosis, subsequent leukemic transformation and survival in myelodysplastic syndrome. Czechoslovak MDS Cooperative Group. 1995 , 19, 303-8	8
1525	Morphological comparison of dysplastic changes between de novo acute myeloid leukemia (AML) with trilineage myelodysplasia and AML developed from de novo myelodysplastic syndromes. 1995 , 19, 121-5	13

1524	Clinical characteristics of Japanese patients with primary myelodysplastic syndromes: a co-operative study based on 838 cases. Anemia Study Group of the Ministry of Health and Welfare. 1995 , 19, 219-25	58
1523	Acute leukemic transformation of myelodysplastic syndrome--immunophenotypic, genotypic, and cytogenetic studies. 1995 , 19, 595-603	15
1522	Abnormal regional hypermethylation of the calcitonin gene in myelodysplastic syndromes. 1995 , 19, 719-26	25
1521	Translocation (8;21) in acute myeloid leukemia: when to treat? That is the question!!. 1995 , 19, 357-8	2
1520	Spontaneous cytokine overproduction by peripheral blood mononuclear cells from patients with myelodysplastic syndromes and aplastic anemia. 1995 , 19, 639-44	42
1519	Translocation (8;21)(q22;q22) and the myelodysplastic syndrome. 1995 , 19, 675-7	1
1518	Mutations of the p53 gene in myelodysplastic syndrome and overt leukemia. 1995 , 19, 869-75	15
1517	Apoptosis in myelodysplasia: a paradox or paradigm. 1995 , 19, 887-91	34
1516	An isochromosome of the long arm of chromosome 18 in a patient with myelodysplastic syndrome with myelofibrosis. 1995 , 79, 149-52	3
1515	Prediction of 18-month survival in patients with primary myelodysplastic syndrome. A regression model and scoring system based on the combination of chromosome findings and the Bournemouth score. 1995 , 81, 158-65	23
1514	Heterogeneity of lineage involvement by trisomy 8 in myelodysplastic syndrome. A multiparameter analysis combining conventional cytogenetics, DNA in situ hybridization, and bone marrow culture studies. 1995 , 82, 116-22	21
1513	Characterization by chromosome painting of balanced and unbalanced X chromosome translocations in myelodysplastic syndromes. 1995 , 82, 17-22	11
1512	Chronic myelomonocytic leukemia with a novel t(5;18) translocation. 1995 , 85, 89	3
1511	An unusual cytogenetic abnormality involving chromosomes 1 and 7 in a case of chronic myelomonocytic leukemia. 1995 , 85, 75-7	3
1510	The effect of stem-cell factor, interleukin-3 and erythropoietin on in vitro erythropoiesis in myelodysplastic syndromes. 1995 , 121, 338-42	4
1509	Analysis of mutations of neurofibromatosis type 1 gene and N-ras gene in acute myelogenous leukemia. 1995 , 13, 556-63	18
1508	Granulocyte colony-stimulating factor in acute myeloid leukemia. 1995 , 13, 647-54	9
1507	A hypochlorite-fast metachromatic quick stain for human megakaryocytes. 1995 , 70, 165-8	1

1506	QBEND10 for the diagnosis of myelodysplastic syndromes in routinely processed bone marrow biopsy specimens. 1995 , 48, 291-4	22
1505	Identification of normal and abnormal human megakaryocytes based on acid fast metachromasia after staining with basic black MSP. 1995 , 70, 271-4	2
1504	All-trans retinoic acid in the treatment of myelodysplastic syndromes. 1995 , 19, 277-80	21
1503	Myelopoiesis in myelodysplasia evaluated by multiparameter flow cytometry. 1995 , 20, 17-25	9
1502	De-novo acute myeloid leukemia with trilineage myelodysplasia (AML/TMDS) and myelodysplastic remission marrow (AML/MRM). 1995 , 16, 263-70	8
1501	Chromosomal deletions in myelodysplasia. 1995 , 17, 71-8	32
1500	The contribution of Auer rods to the classification and prognosis of myelodysplastic syndromes. 1995 , 17, 79-85	16
1499	Ultrastructural studies of the megakaryoblastic leukemias of Down syndrome. 1995 , 18, 341-7	21
1498	Recombinant interferon alpha 2a, thymopentin and low doses of cytosine arabinoside for the treatment of myelodysplastic syndromes: a pilot study. 1995 , 16, 335-42	6
1497	The SKM-1 leukemic cell line established from a patient with progression to myelomonocytic leukemia in myelodysplastic syndrome (MDS)-contribution to better understanding of MDS. 1995 , 17, 335-9	24
1496	Epidemiological and etiological aspects of myelodysplastic syndromes. 1995 , 16, 247-62	50
1495	Effects of long-term treatment with recombinant human granulocyte-macrophage colony-stimulating factor in patients with myelodysplastic syndrome. 1995 , 18, 457-63	20
1494	Acquired sideroblastic anaemia associated with penicillamine therapy for rheumatoid arthritis. 1995 , 54, 529-30	5
1493	Glomerular injury in chronic myelomonocytic leukemia. 1995 , 18, 479-83	19
1492	Unusual specific cutaneous lesions in myelodysplastic syndromes. 1995 , 33, 187-91	43
1491	[Systemic diseases in myelodysplastic syndromes]. 1995 , 16, 897-904	7
1490	Myelodysplastic syndromes--a population-based study on transformation and survival. 1995 , 34, 473-8	1
1489	The role of bone marrow transplantation in the treatment of myelodysplastic syndromes. 1995 , 4, 323-34	2

1488	Myelodysplasia and deficiency of uridine diphosphate-galactose 4-epimerase. 1995 , 127, 605-8	9
1487	Myelodysplastic (preleukemia) syndromes: the bone marrow factory failure problem. 1995 , 70, 673-6; quiz 677	7
1486	Bone remodeling alterations in myelodysplastic syndrome. 1996 , 19, 401-5	24
1485	Specific skin infiltration as first sign of chronic myelomonocytic leukemia with an unusual phenotype. 1996 , 35, 804-7	10
1484	Myelodysplastic syndromes. 1996 , 12, 51-8	2
1483	The role of magnetic resonance imaging in the diagnosis and monitoring of myelodysplastic syndromes or leukemia. 1996 , 23, 443-50	11
1482	Clinical features of hematopoietic malignancies and related disorders among benzene-exposed workers in China. Benzene Study Group. 1996 , 104 Suppl 6, 1353-64	27
1481	Interleukin-3 plus low-dose cytosine arabinoside for advanced myelodysplasia: a pilot study. EORTC Leukemia Group. 1996 , 14, 299-306	6
1480	Basazol Black 05L: A New Acid Resistant Metachromatic Stain for Normal and Abnormal Megakaryocytes. 1996 , 19, 317-320	
1479	Haematologic Malignancy Secondary to the Treatment of Lymphoma. 1996 , 1, 117-24	
1478	Dicentric (1;15) in myeloid disorders. 1996 , 88, 86-9	13
1477	Multiple unrelated clones in myelodysplastic syndrome and in acute myeloid leukemia. 1996 , 88, 141-3	13
1476	The relationship between age and karyotypic abnormalities in myelodysplastic syndromes. 1996 , 88, 80-2	2
1475	Partial deletion of the long arm of chromosome 5: a fluorescence in situ hybridization study using band-specific painting probes generated by chromosome microdissection. 1996 , 89, 126-8	4
1474	Trisomy 15 in hematological malignancies: six cases and review of the literature. 1996 , 89, 27-30	18
1473	Activity of Fgr protein-tyrosine kinase is reduced in neutrophils of patients with myelodysplastic syndromes and chronic myelogenous leukemia. 1996 , 20, 221-7	2
1472	Parvovirus B19 infection infrequently involved in children and adults with myelodysplastic syndrome. 1996 , 20, 81-3	8
1471	Study of clonality in myelodysplastic syndromes: detection of trisomy 8 in bone marrow cell smears by fluorescence in situ hybridization. 1996 , 20, 551-7	15

1470	Myelodysplastic syndromes in the elderly: the role of growth factors in management. 1996 , 20, 203-19	30
1469	Combined differentiating therapy for myelodysplastic syndromes: a phase II study. 1996 , 20, 867-76	31
1468	Oligoblastic leukaemia with (8;21) translocation and haemophagocytic syndrome and granulocytic cannibalism. 1996 , 20, 517-21	6
1467	Treatment of high risk myelodysplastic syndromes with idarubicin and cytosine arabinoside supported by granulocyte-macrophage colony-stimulating factor. (GM-CSF). 1996 , 20, 385-90	22
1466	Analysis of the erythropoietin receptor gene in patients with myeloproliferative and myelodysplastic syndromes. 1996 , 20, 459-66	28
1465	Mixed myelodysplastic and myeloproliferative syndromes. 1996 , 20, 717-26	41
1464	A case-control study of myelodysplastic syndromes among Japanese men and women. 1996 , 20, 727-31	47
1463	Successful coronary artery bypass grafting for a patient with myelodysplastic syndrome: report of a case. 1996 , 26, 740-3	6
1462	Myelodysplastic syndromes. 1996 , 23, 57-93	14
1461	Simultaneous development of Crohn's disease and myelodysplastic syndrome progressing to acute myelocytic leukemia in a patient with a normal karyotype. 1996 , 31, 599-602	14
1460	Behcet's disease complicated with myelodysplastic syndrome: a report of two cases and review of the literature. 1996 , 15, 91-3	26
1459	Rheumatic manifestations of the myelodysplastic syndromes: a comparative study. 1996 , 26, 683-8	16
1458	Measurement of apoptosis, proliferation and three cytokines in 46 patients with myelodysplastic syndromes. 1996 , 20, 891-900	171
1457	The myelodysplastic syndromes in 1996: complex stem cell disorders confounded by dual actions of cytokines. 1996 , 20, 881-90	37
1456	Cytogenetic and clinicobiological features of acute leukemia with stem cell phenotype: study of nine cases. 1996 , 92, 31-6	27
1455	Special cytological subtypes of acute myeloid leukaemias and myelodysplastic syndromes. 1996 , 9, 19-33	6
1454	Treatment and prognostic factors in myelodysplastic syndromes. 1996 , 9, 161-83	19
1453	Granulocytic sarcoma of the uterus complicating myelodysplastic syndrome. 1996 , 51, 244-5	2

1452	Lymphoblastic transformation of chronic myelomonocytic leukemia in an infant. 1996 , 52, 212-4	8
1451	Hematologic benefits of 1-hydroxyvitamin D3 in an elderly patient with chronic myelodysplastic syndrome. 1996 , 53, 143-4	4
1450	A combination chemotherapy with low doses of cytarabine and etoposide for high risk myelodysplastic syndromes and their leukemic stage. A pilot study. 1996 , 78, 422-6	12
1449	Diagnosis and treatment of acute myelogenous leukemia in childhood. 1996 , 22, 183-96	1
1448	Diagnostic et classification des syndromes my ^o lodysplasiques. 1996 , 1996, 19-25	
1447	Cytog ^r n ^e tique des syndromes my ^o lodysplasiques. 1996 , 1996, 26-32	
1446	Apport des cultures de moelle dans les syndromes my ^o lodysplasiques. 1996 , 1996, 39-44	
1445	Traitement des syndromes my ^o lodysplasiques. 1996 , 1996, 93-96	
1444	Serum thrombopoietin level in various hematological diseases. 1996 , 14, 558-65	48
1443	Prognostic implications in myelodysplastic syndromes: A review of 62 cases. 1996 , 21, 479-84	1
1442	Myelopoiesis and myeloproliferative disorders. 1996 , 26, 1023-42	36
1441	Determination of interferon-alpha-producing capacity in whole blood cultures from patients with various diseases and from healthy persons. 1996 , 16, 911-8	23
1440	The myeloproliferative disorders. An historical appraisal and personal experiences. 1996 , 22 Suppl 1, 1-14	17
1439	Analytical and clinical implications of soluble transferrin receptors in serum. 1996 , 34, 645-9	4
1438	Incidence and characteristics of lymphoid malignancies in untreated myelodysplastic syndromes. 1996 , 23, 609-12	34
1437	Diagnostic and prognostic significance of cytogenetics in adult primary myelodysplastic syndromes. 1996 , 23, 253-66	37
1436	Proliferation and differentiation of myelodysplastic CD34+ cells. 1996 , 22, 43-51	9
1435	Clonality switch in acute myeloid leukemia. 1996 , 22, 125-30	2

1434	Granulocyte dysplasia and dysfunction, and CD11/CD18 defects in myelodysplastic syndromes. 1996 , 23, 267-75	20
1433	Clinical aspects, cytogenetics and disease evolution in myelodysplastic syndromes. 1996 , 23, 409-15	9
1432	Hematopoietic and lymphatic malignancies in vehicle mechanics. 1997 , 27, 443-94	19
1431	Clinical and biological aspects of Philadelphia-negative/BCR-negative chronic myeloid leukemia. 1997 , 25, 225-32	25
1430	Benzene and the dose-related incidence of hematologic neoplasms in China. Chinese Academy of Preventive Medicine--National Cancer Institute Benzene Study Group. 1997 , 89, 1065-71	262
1429	Clinical use of hematopoietic growth factors in the myelodysplastic syndromes. 1997 , 26 Suppl 1, 13-27	10
1428	Autoimmune phenomena in patients with myelodysplastic syndromes. 1997 , 24, 483-9	85
1427	In vitro culture studies of childhood myelodysplastic syndrome: establishment of the cell line MUTZ-1. 1997 , 25, 345-63	23
1426	The 17p-syndrome: a distinct myelodysplastic syndrome entity?. 1997 , 25, 163-8	32
1425	Hydroxyurea is Worth a Trial in the Treatment of Patients with MDS with Myeloproliferative Features. 1997 , 2, 467-71	
1424	Image bank, diagnostic codification and telediagnosis in hematology. 1997 , 25, 97-104	13
1423	Indications and timing of allogeneic bone marrow transplantation in myelodysplastic syndromes. 1997 , 27, 475-85	3
1422	Effect of GM-CSF, 1, 25-Dihydroxycholecalciferol (Vit.D) and All-Trans-Retinoic Acid (ATRA) on the Proliferation and Differentiation of MDS-Bone Marrow (BM)-Cells In Vitro. 1997 , 2, 11-9	
1421	Chromosome 7 and Haematological Malignancies. 1997 , 2, 359-72	
1420	Pediatric hyperfibrotic myelodysplasia: an unusual clinicopathologic entity. 1997 , 14, 133-9	4
1419	[Myelodysplastic syndromes in children, Groupe d'etude des myelodysplasies de l'enfant de la Societe francaise d'hematologie et d'immunologie pediatrique (SHIP)]. 1997 , 4, 561-7	0
1418	Anaesthetic management of caesarean section in a parturient with acute myelodysplastic syndrome. 1997 , 6, 270-3	2
1417	Myelodysplasia and the leukemias. 1997 , 43, 505-97	4

1416	Excessive proliferation matched by excessive apoptosis in myelodysplastic syndromes: the cause-effect relationship. 1997 , 27, 111-8	45
1415	del 11(q23) as a prognostic factor of iron overload in refractory anemia with ringed sideroblasts. 1997 , 115, 1513-5	1
1414	Cytokine priming of the granulocyte respiratory burst in myelodysplastic syndromes. 1997 , 27, 137-43	11
1413	Combined method for simultaneous morphology, immunophenotype and karyotype (MAC) in leukemias. 1997 , 115, 1336-42	2
1412	Lymphoblastic transformation of myelodysplastic syndrome. 1997 , 115, 1508-12	9
1411	Myelodysplastic syndromes (MDS): prognostic factors and scoring systems. 1997 , 115, 1537-41	
1410	The partial tandem duplication of ALL1 in acute myeloid leukemia with normal cytogenetics or trisomy 11 is restricted to one chromosome. 1997 , 94, 3899-902	45
1409	Impaired Hematopoiesis in Paroxysmal Nocturnal Hemoglobinuria/Aplastic Anemia Is Not Associated With a Selective Proliferative Defect in the Glycosylphosphatidylinositol-Anchored Protein-Deficient Clone. 1997 , 89, 1173-1181	92
1408	Erythropoietin-Induced Activation of STAT5 Is Impaired in the Myelodysplastic Syndrome. 1997 , 89, 1690-1700	80
1407	International Scoring System for Evaluating Prognosis in Myelodysplastic Syndromes. 1997 , 89, 2079-2088	3508
1406	Randomized Comparison of DAT Versus ADE as Induction Chemotherapy in Children and Younger Adults With Acute Myeloid Leukemia. Results of the Medical Research Council's 10th AML Trial (MRC AML10). 1997 , 89, 2311-2318	272
1405	Stem Cell Transplantation for Secondary Acute Myeloid Leukemia: Evaluation of Transplantation as Initial Therapy or Following Induction Chemotherapy. 1997 , 89, 2578-2585	140
1404	International Prognostic Scoring System and Other Prognostic Systems for Myelodysplastic Syndromes. 1997 , 90, 4232-4235	10
1403	Hypermethylation of the p15INK4B Gene in Myelodysplastic Syndromes. 1997 , 90, 1403-1409	222
1402	Effect of Diagnosis (Refractory Anemia With Excess Blasts, Refractory Anemia With Excess Blasts in Transformation, or Acute Myeloid Leukemia [AML]) on Outcome of AML-Type Chemotherapy. 1997 , 90, 2969-2977	189
1401	Serum levels of tumour necrosis factor- β predict response to recombinant human erythropoietin in patients with myelodysplastic syndrome. 1997 , 19, 197-201	27
1400	Cytogenetic abnormalities in pediatric myelodysplastic syndrome: a report of three cases. 1997 , 93, 172-6	8
1399	Pericentric inversion of chromosome 16 and eosinophilia in chronic myelomonocytic leukemia. 1997 , 94, 99-102	4

1398	A novel chromosomal abnormality involving chromosomes 2 and 18 in a patient with myelodysplastic syndrome. 1997 , 96, 7-12	1
1397	Morphological changes and apoptosis in bone marrow from patients with myelodysplastic syndromes treated with granulocyte-CSF and erythropoietin. 1997 , 21, 415-25	104
1396	Intensive chemotherapy of poor prognosis myelodysplastic syndromes (MDS) and acute myeloid leukemia following MDS with idarubicin and cytarabine. 1997 , 21, 133-8	25
1395	Fatal hyperleukocytic syndrome in a patient with chronic myelomonocytic leukemia. 1997 , 21, 249-53	11
1394	Mode of disease progression in primary myelodysplastic syndromes: a Japanese co-operative study. The Refractory Anemia Study Group of The Ministry of Health and Welfare, Japan. 1997 , 21, 241-7	1
1393	Actin polymerization in neutrophils from patients affected by myelodysplastic syndromes--a flow cytometric study. 1997 , 21, 513-8	12
1392	Deficiency of neutrophilic granule membrane glycoproteins in the myelodysplastic syndromes: a common deficiency in 216 patients studied by the Cancer and Leukemia Group B. 1997 , 21, 801-6	21
1391	Ultrastructural observations on bone marrow cells of 26 patients with myelodysplastic syndromes. 1997 , 27, 165-72	16
1390	Neurogenic potential of Ewing's sarcoma cells. 1997 , 430, 41-6	21
1389	Monosomy 7 and 7q--associated with myeloid malignancy. 1997 , 11, 46-55	51
1388	La pathologie maligne du monocyte A. Aspects cliniques et morphologiques. 1997 , 1997, 26-32	
1387	Bullous pemphigoid in association with cutaneous lesions specific to a myelodysplastic syndrome. 1997 , 136, 402-405	0
1386	Systemic vasculitis and myelodysplastic syndromes. A report of two cases. 1997 , 40, 179-82	21
1385	Telomere length in myelodysplastic syndromes. 1997 , 56, 266-71	62
1384	Tumor necrosis factor-alpha suppresses hematopoiesis in children with myelodysplasia. 1997 , 28, 69-74	4
1383	dic(5;17): a recurring abnormality in malignant myeloid disorders associated with mutations of TP53. 1997 , 20, 282-91	51
1382	Behçet's disease associated with myelodysplastic syndromes. A case report and a review of the literature. 1997 , 79, 262-8	36
1381	Immunosuppressive therapy for hypoplastic myelodysplastic syndrome. 1997 , 79, 1548-51	108

1380	Retrospective analysis of clonality and detection of residual disease in myeloid leukemia by FISH on long-term stored bone marrow smears. 1998 , 40, 318-23	1
1379	Increasing incidence of myelodysplastic syndromes: real or fictitious?. 1998 , 22, 93-100	67
1378	Correlation of N-ras point mutations with specific chromosomal abnormalities in primary myelodysplastic syndrome. 1998 , 22, 125-34	28
1377	Treatment with low-dose oral etoposide in patients with myelodysplastic syndromes. 1998 , 22, 7-12	19
1376	Epidemiology of myelodysplastic syndromes in a French general hospital of the Basque country. 1998 , 22, 205-8	15
1375	FISH investigation of 5q and 7q deletions in MDS/AML reveals hidden translocations, insertions and fragmentations of the same chromosomes. 1998 , 22, 303-12	23
1374	Three cases of near-tetraploid acute myeloid leukemias originating in pluripotent myeloid progenitors. 1998 , 22, 581-8	27
1373	GCSF augments post-progenitor proliferation in serum-free cultures of myelodysplastic marrow while ATRA enhances maturation. 1998 , 22, 241-8	3
1372	Problems in the classification of CMML--dysplastic versus proliferative type. 1998 , 22, 871-8	129
1371	Myelodysplastic syndromes in Thailand: a retrospective pathologic and clinical analysis of 117 cases. 1998 , 22, 453-60	38
1370	Analysis of megakaryocyte growth and development factor (thrombopoietin) effects on blast cell and megakaryocyte growth in myelodysplasia. 1998 , 22, 527-35	22
1369	Risk factors and their relationship to prognosis in myelodysplastic syndromes. 1998 , 22 Suppl 1, S3-6	15
1368	Bcl-2 expression by myeloid precursors in myelodysplastic syndromes: relation to disease progression. 1998 , 22, 767-77	53
1367	Significance of chromosomal alterations and mutations of the N-RAS and TP53 genes in relation to leukemogenesis of acute myeloid leukemia. 1998 , 22, 631-7	17
1366	A rare variant translocation t(3;8)(q29;q22) without AML1/ETO fusion transcript in a case of oligoblastic leukemia. 1998 , 22, 1015-9	4
1365	Apoptosis and its role in the myelodysplastic syndromes: implications for disease natural history and treatment. 1998 , 22, 1123-36	102
1364	Fluorescence in situ hybridization on methylcellulose cultured hematopoietic stem cells from myelodysplastic syndromes. 1998 , 101, 12-5	8
1363	Translocation (1;22) in refractory anemia and the prognostic significance of karyotypic abnormalities in refractory anemia. 1998 , 106, 72-5	1

1362	Trisomy 6 is the hallmark of a dysplastic clone in bone marrow aplasia. 1998 , 105, 55-9		14
1361	Complex structural involvement of chromosome 7 in primary myelodysplastic syndromes determined by fluorescence in situ hybridization. 1998 , 106, 110-5		6
1360	Childhood myeloproliferative disorders. 1998 , 11, 875-98		3
1359	Cytogenetic abnormalities and therapy-related myelodysplastic syndromes in rheumatic disease. 1998 , 41, 1493-6		17
1358	Sideroblastic anemias: variations on imprecision in diagnostic criteria, proposal for an extended classification of sideroblastic anemias. 1998 , 57, 1-6		15
1357	Effect of androgen therapy and anemia on serum erythropoietin levels in patients with aplastic anemia and myelodysplastic syndromes. 1998 , 57, 113-8		10
1356	Usefulness of IPSS for the patients with refractory anemia. 1998 , 58, 250-2		10
1355	Progression of a myelodysplastic syndrome with trisomy 8 to acute lymphoblastic leukemia. 1998 , 58, 342		5
1354	Molecular cytogenetic delineation of the critical deleted region in the 5q- syndrome. 1998 , 22, 251-6		61
1353	Cytogenetically unrelated clones in therapy-related myelodysplasia and acute myeloid leukemia: experience from the Copenhagen series updated to 180 consecutive cases. 1998 , 23, 337-49		37
1352	Platelet dysfunction as the presenting feature of atypical myelodysplastic syndrome with monosomy 7, normal blood counts and no bleeding tendency. 1998 , 15, 275-8		2
1351	Early Breast Cancer Following Treatment of Myelodysplastic Syndrome: Report of a Case. 1998 , 5, 183-186		
1350	Cyclosporin A therapy in hypoplastic MDS patients and certain refractory anaemias without hypoplastic bone marrow. <i>British Journal of Haematology</i> , 1998 , 100, 304-9	4.5	157
1349	Vitamin D treatment in myelodysplastic syndromes. <i>British Journal of Haematology</i> , 1998 , 100, 516-20	4.5	38
1348	Association of myelodysplastic changes with purine analogues. <i>British Journal of Haematology</i> , 1998 , 100, 677-9	4.5	32
1347	Variable expression of CD3-zeta and associated protein tyrosine kinases in lymphocytes from patients with myeloid malignancies. <i>British Journal of Haematology</i> , 1998 , 100, 784-92	4.5	48
1346	Paroxysmal nocturnal haemoglobinuria clones in patients with myelodysplastic syndromes. <i>British Journal of Haematology</i> , 1998 , 102, 465-74	4.5	69
1345	Patients with high-risk myelodysplastic syndrome can have polyclonal or clonal haemopoiesis in complete haematological remission. <i>British Journal of Haematology</i> , 1998 , 102, 486-94	4.5	35

1344	Randomized clinical study comparing aggressive chemotherapy with or without G-CSF support for high-risk myelodysplastic syndromes or secondary acute myeloid leukaemia evolving from MDS. <i>British Journal of Haematology</i> , 1998 , 102, 678-83	4.5	30
1343	Exposure to myelotoxic agents and myelodysplasia: case-control study and correlation with clinicobiological findings. <i>British Journal of Haematology</i> , 1998 , 103, 189-97	4.5	60
1342	Plasma thrombopoietin (TPO) levels and expression of TPO receptor on platelets in patients with myelodysplastic syndromes. <i>British Journal of Haematology</i> , 1998 , 103, 778-84	4.5	24
1341	A randomized double-blind placebo-controlled study with subcutaneous recombinant human erythropoietin in patients with low-risk myelodysplastic syndromes. <i>British Journal of Haematology</i> , 1998 , 103, 1070-4	4.5	156
1340	'Low-risk' myelodysplastic syndrome is associated with excessive apoptosis and an increased ratio of pro- versus anti-apoptotic bcl-2-related proteins. <i>British Journal of Haematology</i> , 1998 , 103, 1075-82	4.5	82
1339	The myelodysplastic syndromes: towards a functional classification. 1998 , 12, 73-83		17
1338	Myelodysplasia and the leukemias. 1998 , 22, 384-464		
1337	Myelodysplastic changes in a dog with subsequent acute myeloid leukemia. 1998 , 27, 112-115		15
1336	[Fanconi disease: study of 43 cases in southern Tunisia]. 1998 , 5, 1200-5		2
1335	Acute myeloid leukaemias. 1998 , 34, 862-72; discussion 871-2		14
1334	Immunocytochemistry. 1998 , 1-38		
1333	Growth characteristics of myelodysplastic CD34+ cells. 1998 , 29, 49-60		6
1332	All trans retinoic acid with low dose cytosine arabinoside in the treatment of myelodysplastic syndrome. 1998 , 29, 187-92		6
1331	Bersicht. 1998 , 22, 199-206		2
1330	Pyrexia of unknown origin, the age-old dilemma. 1998 , 74, 761-3		
1329	Fas/APO-1 (CD95) expression in myelodysplastic syndromes. 1998 , 30, 307-12		29
1328	Dyshematopoiesis in de novo acute myeloid leukemia: cell biological features and prognostic significance. 1998 , 29, 523-31		9
1327	Expression of lung resistance protein and correlation with other drug resistance proteins and outcome in myelodysplastic syndromes. 1998 , 29, 547-51		16

1326	Case records of the Massachusetts General Hospital. Weekly clinicopathological exercises. Case 5-1998. A 51-year-old man with myelodysplasia and a pulmonary infiltrate. 1998 , 338, 453-61	8
1325	Case 5-1998: bone marrow blasts in chronic myelomonocytic leukemia. 1998 , 338, 1925-6	
1324	Ultrastructural abnormalities of bone marrow erythroblasts in refractory anemia. 1998 , 22, 173-80	5
1323	Tumor necrosis factor-alpha levels decrease with anticytokine therapy in patients with myelodysplastic syndromes. 1998 , 18, 871-7	19
1322	Obstructive uropathy associated with myelomonocytic infiltration of the prostate. 1998 , 51, 340-2	4
1321	Ploidy Analysis and Ki-67 Expression in Myelodysplastic Syndromes. 1998 , 3, 215-22	0
1320	The association between Crohn disease and the myelodysplastic syndromes. Report of 3 cases and review of the literature. 1998 , 77, 371-7	12
1319	Myelodysplastic syndromes in childhood: is the FAB classification relevant? Report of 81 children from a French multicentre study. French Group of Cellular Hematology. 1998 , 28, 531-40	11
1318	High-risk myelodysplastic syndromes and hypermethylation of the p15Ink4B gene. 1998 , 32, 9-18	23
1317	Pathogenetic Aspects of Myelodysplastic Syndromes. 1998 , 3, 119-42	
1316	Diagnosis and Management of Anemia in Patients With the Myelodysplastic Syndrome. 1998 , 5, 41-45	1
1315	Hematopoietic growth factors for the treatment of myelodysplastic syndromes. 1998 , 28, 491-500	8
1314	17p Deletion in Acute Myeloid Leukemia and Myelodysplastic Syndrome. Analysis of Breakpoints and Deleted Segments by Fluorescence In Situ. 1998 , 91, 1008-1015	108
1313	Fluorescence In Situ Hybridization of Progenitor Cells Obtained by Fluorescence-Activated Cell Sorting for the Detection of Cells Affected by Chromosome Abnormality Trisomy 8 in Patients With Myelodysplastic Syndromes. 1998 , 92, 2886-2892	64
1312	Acute Myeloid Leukemia and Myelodysplastic Syndromes Following Essential Thrombocythemia Treated With Hydroxyurea: High Proportion of Cases With 17p Deletion. 1998 , 91, 616-622	331
1311	Treatment of Anemia in Myelodysplastic Syndromes With Granulocyte Colony-Stimulating Factor Plus Erythropoietin: Results From a Randomized Phase II Study and Long-Term Follow-Up of 71 Patients. 1998 , 92, 68-75	247
1310	Cytogenetic Abnormalities in Primary Myelodysplastic Syndrome Are Highly Predictive of Outcome After Allogeneic Bone Marrow Transplantation. 1998 , 92, 1910-1917	129
1309	Topotecan and cytarabine is an active combination regimen in myelodysplastic syndromes and chronic myelomonocytic leukemia. 1999 , 17, 2819-30	117

1308	Myelofibrosis with myeloid metaplasia: diagnostic definition and prognostic classification for clinical studies and treatment guidelines. 1999 , 17, 2954-70		190
1307	Outcome in patients with myelodysplastic syndrome after autologous bone marrow transplantation for non-Hodgkin's lymphoma. 1999 , 17, 3128-35		159
1306	Prognostic significance of magnetic resonance imaging of femoral marrow in patients with myelodysplastic syndromes. 1999 , 17, 277-83		9
1305	Myelodysplastic and Myeloproliferative Disorders of Childhood: A Study of 167 Patients. 1999 , 93, 459-466		189
1304	Smoldering acute myelogenous leukemia in the elderly. 1999 , 34, 561-7		9
1303	Renal and adrenal gland localization of chronic myelomonocytic leukemia presenting as a kidney tumor. 1999 , 34, 405-8		3
1302	Leukemia arising out of paroxysmal nocturnal hemoglobinuria. 1999 , 32, 401-26		50
1301	Therapy-related leukemia and myelodysplastic syndrome in breast cancer patients treated with cyclophosphamide or anthracyclines. 1999 , 29, 28-32		12
1300	Gingival hemorrhage, myelodysplastic syndromes, and acute myeloid leukemia. A case report. 1999 , 70, 1247-53		8
1299	Myelodysplasia. 1999 , 340, 1649-60		411
1298	Treatment of advanced myelodysplastic syndrome with a regimen including recombinant human granulocyte colony-stimulating factor preceding allogeneic bone marrow transplantation. <i>British Journal of Haematology</i> , 1999 , 104, 569-73	4.5	23
1297	The Italian Consensus Conference on Diagnostic Criteria for Myelofibrosis with Myeloid Metaplasia. <i>British Journal of Haematology</i> , 1999 , 104, 730-7	4.5	151
1296	Dendritic cells in chronic myelomonocytic leukaemia. <i>British Journal of Haematology</i> , 1999 , 105, 974-85	4.5	31
1295	Spontaneous and cytokine-induced thrombocytopenia in myelodysplastic syndromes: serum thrombopoietin levels and bone marrow morphology. Scandinavian MDS Group, Sweden and Norway. <i>British Journal of Haematology</i> , 1999 , 105, 966-73	4.5	11
1294	DNA image cytometry in MDS bone marrow smears. <i>British Journal of Haematology</i> , 1999 , 105, 960-5	4.5	2
1293	Time trends in incidence of haematological malignancies and related conditions. <i>British Journal of Haematology</i> , 1999 , 106, 281-95	4.5	23
1292	Cross-validation of prognostic scores in myelodysplastic syndromes on 386 patients from a single institution confirms importance of cytogenetics. <i>British Journal of Haematology</i> , 1999 , 106, 455-63	4.5	64
1291	A population-based study of childhood myelodysplastic syndrome in British Columbia, Canada. <i>British Journal of Haematology</i> , 1999 , 106, 1027-32	4.5	90

1290	Molecular heterogeneity of the NUP98/HOXA9 fusion transcript in myelodysplastic syndromes associated with t(7;11)(p15;p15). <i>British Journal of Haematology</i> , 1999 , 107, 600-4	4.5	35
1289	Phenotypic and functional characteristics of monocyte-derived dendritic cells from patients with myelodysplastic syndromes. <i>British Journal of Haematology</i> , 1999 , 107, 844-50	4.5	39
1288	'TUNEL' evidence of reduced bone marrow cells apoptosis in a refractory anaemia patient treated with amifostine. <i>British Journal of Haematology</i> , 1999 , 104, 424-5	4.5	6
1287	Paediatric myelodysplastic syndrome (MDS) and juvenile chronic myelogenous leukaemia (JCML) detected by cytogenetic and FISH techniques. 1999 , 21, 403-6		2
1286	Alloimmunization after blood transfusion in patients with hematologic and oncologic diseases. 1999 , 39, 763-71		110
1285	CD56+ blastic transformation of chronic myeloid leukemia involving the skin. 1999 , 26, 497-503		10
1284	Significance of electron-dense deposits in the mitochondrial matrix of erythroid precursors in aplastic anaemia and myelodysplastic syndrome. <i>British Journal of Haematology</i> , 1999 , 105, 149-154	4.5	14
1283	Recombinant human granulocyte-macrophage colony-stimulating factor plus erythropoietin for the treatment of cytopenias in patients with myelodysplastic syndromes. <i>British Journal of Haematology</i> , 1999 , 105, 141-148	4.5	37
1282	Myelodysplasia and myeloproliferative disorders in childhood: an update. <i>British Journal of Haematology</i> , 1999 , 105, 852-863	4.5	62
1281	Apoptosis induced by the myelodysplastic syndrome-associated NPM-MLF1 chimeric protein. 1999 , 18, 3716-24		27
1280	[Clinical course, morphology and prognosis of chronic myelomonocytic leukemia]. 1999 , 94, 467-72		2
1279	Idiopathic myelofibrosis in a cat and in three dogs. 1999 , 9, 17-24		10
1278	Functional activity of hemopoietic and stromal cells in various types of myelodysplastic syndrome. 1999 , 127, 10-13		4
1277	A strategy for erythropoietin treatment in myelodysplastic syndromes. 1999 , 16, 188-90		
1276	Cytogenetic analysis and RAS mutations in primary myelodysplastic syndromes. 1999 , 111, 124-9		7
1275	Biclonal chromosomal aberrations in a child with myelodysplastic syndrome. 1999 , 108, 13-8		9
1274	Elliptocytosis in myelodysplastic syndrome associated with translocation (1;5)(p10;q10) and deletion of 20q. 1999 , 108, 162-5		11
1273	Chromosome 11 abnormalities in myelodysplastic syndromes. 1999 , 114, 58-61		12

1272	Myelodysplastic syndrome with atypical eosinophilia in association with ring chromosome 7. A case report. 1999 , 115, 19-22	4
1271	Role of physiologic concentrations of stem cell factor in leukemic type growth of myelodysplastic CD34+ cells. 1999 , 23, 1-11	8
1270	Hair dye use and occupational exposure to organic solvents as risk factors for myelodysplastic syndrome. 1999 , 23, 57-62	58
1269	Myelodysplastic syndrome: a search for minimal diagnostic criteria. 1999 , 23, 283-90	55
1268	Hematopoietic progenitor cells from patients with myelodysplastic syndromes: in vitro colony growth and long-term proliferation. 1999 , 23, 385-94	31
1267	Enhanced myeloid specificity of CD117 compared with CD13 and CD33. 1999 , 23, 341-7	27
1266	Biologic characteristics of patients with hypocellular myelodysplastic syndromes. 1999 , 23, 357-64	19
1265	Comparisons of prognostic scoring systems for myelodysplastic syndromes: a Korean multicenter study. 1999 , 23, 425-32	21
1264	Unusual clinical presentation in a patient with myelodysplastic syndrome, with subsequent hematological remission and suppression of the malignant clone following treatment with cyclosporine A, erythropoietin and granulocyte colony-stimulating factor. 1999 , 23, 513-7	2
1263	Neutrophil dysplasia is not a specific feature of the abnormal chromosomal clone in myelodysplastic syndromes. 1999 , 23, 579-84	13
1262	Apoptosis and its significance in MDS: controversies revisited. 1999 , 23, 777-85	40
1261	Treatment of unfavorable myelodysplastic syndrome with all-trans-retinoic acid and subcutaneous Ara C. 1999 , 23, 811-5	5
1260	The prognostic value of in vitro cultures of erythroid and megakaryocyte progenitors in myelodysplastic syndromes. 1999 , 23, 889-94	15
1259	Long-term blood product transfusion support for patients with myelodysplastic syndromes (MDS): cost analysis and complications. 1999 , 23, 953-9	46
1258	Genotype of glutathione S-transferase and other genetic configurations in myelodysplasia. 1999 , 23, 975-81	53
1257	Dominant negative effect of a truncated erythropoietin receptor (EPOR-T) on erythropoietin-induced erythroid differentiation: possible involvement of EPOR-T in ineffective erythropoiesis of myelodysplastic syndrome. 1999 , 27, 229-33	22
1256	Myelodysplastic syndrome (MDS), acute myeloid leukaemia (AML) and chronic myeloproliferative disorder (CMPD) in cats. 1999 , 121, 203-16	8
1255	Molecular cytogenetics localizes two new breakpoints on 11q23.3 and 21q11.2 in myelodysplastic syndrome with t(11;21) translocation. 1999 , 24, 199-206	13

1254	Cytogenetic polyclonality in hematologic malignancies. 1999 , 24, 222-229	24
1253	Cytogenetic clonality analysis of megakaryocytes in myelodysplastic syndrome by dual-color fluorescence in situ hybridization and confocal laser scanning microscopy. 1999 , 25, 332-338	15
1252	Combined spectral karyotyping and DAPI banding analysis of chromosome abnormalities in myelodysplastic syndrome. 1999 , 26, 336-345	86
1251	Fludarabine, cytarabine, and granulocyte-colony stimulating factor for the treatment of high risk myelodysplastic syndromes. 1999 , 86, 2006-2013	20
1250	Myelodysplastic syndromes with nephrotic syndrome. 1999 , 60, 200-4	15
1249	Hyperfibrinolysis in a case of myelodysplastic syndrome with leukemic spread of mast cells. 1999 , 61, 66-77	18
1248	Loss of maternal allele in a child with myelodysplastic syndrome and monosomy 7. 1999 , 62, 49-51	5
1247	The relationship between the myelodysplastic syndromes and the myeloproliferative disorders. 1999 , 34, 443-9	30
1246	Childhood myelodysplastic syndromes in a Brazilian population. 1999 , 16, 347-53	11
1245	Critical Commentary. 1999 , 195, 705-706	
1244	Myelodysplastic syndrome with sideroblastic differentiation in a dog. 1999 , 28, 59-63	16
1243	Chronic myelomonocytic leukemia with t(7;11)(p15;p15) and NUP98/HOXA9 fusion. 1999 , 115, 70-2	27
1242	Biologic characteristics of 164 patients with myelodysplastic syndromes. 1999 , 33, 281-7	19
1241	Malignancy: Current Clinical Practice: Current Therapeutic Options in Myelodysplastic Syndromes. 1999 , 4, 91-112	0
1240	Refractory anemia with ringed sideroblasts in children: two diseases with a similar phenotype?. 1999 , 21, 418-23	2
1239	Application of the International Prognostic Scoring System for myelodysplastic syndromes. 1999 , 10, 825-9	26
1238	A Patient with Genetic Deletion of Glutathione-S-Transferase T1 and M1 Who Developed Non-Small-Cell Lung Cancer and Myelodysplastic Syndromes. 1999 , 318, 424-427	
1237	Concurrent inflammatory bowel disease and myelodysplastic syndromes. 1999 , 5, 98-103	29

1236	Clonal evolution of aplastic anaemia to myelodysplasia/acute myeloid leukaemia and paroxysmal nocturnal haemoglobinuria. 1999 , 33, 231-41		20
1235	Chronic myelomonocytic leukemia in a cat. 2000 , 62, 195-7		10
1234	Abnormalities of adherent layers grown from bone marrow of patients with myelodysplasia. <i>British Journal of Haematology</i> , 2000 , 111, 853-862	4.5	47
1233	Clonality analysis of various hematopoietic disorders in cats naturally infected with feline leukemia virus. 2000 , 62, 1059-65		17
1232	A hematological study on thirteen cats with myelodysplastic syndrome. 2000 , 62, 59-64		25
1231	Myelodysplastic syndrome following treatment of malignant melanoma with vincristine, ACNU, and dacarbazine. 2000 , 27, 178-80		2
1230	Chronic Myelomonocytic Leukemia with t(1;3)(p3 6;q2 1) and a Synchronous Gastric Cancer. 2000 , 319, 258-260		
1229	Hemopoietic stem cell transplantation for myelodysplastic syndrome. 2000 , 12, 116-20		10
1228	Myelodysplasia. 2000 , 12, 13-21		21
1227	Immature myeloid precursors in chronic neutrophilic dermatosis associated with myelodysplastic syndrome. 2000 , 22, 429-33		27
1226	Good outcome of children with acute myeloid leukemia and t(8;21)(q22;q22), even when associated with granulocytic sarcoma. 2000 , 88, 1939-1944		36
1225	Utility of blasts with a clear halo around the nucleolus as a predictive indicator for disease progression in patients with myelodysplastic syndromes and aplastic anemia. 2000 , 22, 275-80		
1224	Downregulation of CD43 in RAEB and RAEB-T patients. Report of 3 cases. 2000 , 63, 20-7		5
1223	Myelodysplastic syndromes in children. A critical review of the clinical manifestations and management. 2000 , 63, 212-22		11
1222	5q- syndrome presenting chronic myeloproliferative disorders-like manifestation: a case report. 2000 , 64, 120-3		5
1221	Concurrent Langerhans cell histiocytosis and myelodysplasia in children. 2000 , 35, 421-5		24
1220	Effects of antithymocyte globulin on bone marrow CD34+ cells in aplastic anaemia and myelodysplasia. <i>British Journal of Haematology</i> , 2000 , 108, 582-91	4.5	32
1219	Incidence, characterization and prognostic significance of chromosomal abnormalities in 640 patients with primary myelodysplastic syndromes. Grupo Cooperativo Espa�ol de Citogen�tica Hematol�gica. <i>British Journal of Haematology</i> , 2000 , 108, 346-56	4.5	194

1218	Two types of acquired idiopathic sideroblastic anaemia (AISA): a time-tested distinction. <i>British Journal of Haematology</i> , 2000 , 108, 724-8	4.5	51
1217	Treatment of anaemia in myelodysplastic syndromes with prolonged administration of recombinant human granulocyte colony-stimulating factor and erythropoietin. <i>British Journal of Haematology</i> , 2000 , 109, 367-75	4.5	80
1216	Treatment of chronic myelomonocytic leukaemia by allogeneic marrow transplantation. <i>British Journal of Haematology</i> , 2000 , 110, 217-22	4.5	31
1215	Second malignancies in patients with essential thrombocythaemia treated with busulphan and hydroxyurea: long-term follow-up of a randomized clinical trial. <i>British Journal of Haematology</i> , 2000 , 110, 577-83	4.5	157
1214	Haematopoietic stem cell transplantation for patients with myelo-dysplastic syndromes and secondary acute myeloid leukaemias: a report on behalf of the Chronic Leukaemia Working Party of the European Group for Blood and Marrow Transplantation (EBMT). <i>British Journal of Haematology</i> , 2000 , 110, 620-30	4.5	202
1213	Evaluation of apoptosis as a prognostic factor in myelodysplastic syndromes. <i>British Journal of Haematology</i> , 2000 , 110, 584-90	4.5	32
1212	Cytogenetic and molecular diagnosis of chromosome 5 deletions in myelodysplasia. <i>British Journal of Haematology</i> , 2000 , 110, 847-55	4.5	16
1211	Risk of colorectal cancer in patients with hematologic disease. 2000 , 15, 1272-1276		1
1210	Stem cell transplantation for a myelodysplastic syndrome in children. 2000 , 5, 43-47		
1209	Chromosomal abnormalities in women with breast cancer after autologous stem cell transplantation are infrequent and may not predict development of therapy-related leukemia or myelodysplastic syndrome. 2000 , 25, 1203-8		14
1208	Geographic heterogeneity of cellular characteristics of acute myeloid leukemia: a comparative study of Australian and Japanese adult cases. 2000 , 14, 163-8		42
1207	Cytogenetic analogy between myelodysplastic syndrome and acute myeloid leukemia of elderly patients. 2000 , 14, 636-41		45
1206	Allelotype analysis of the myelodysplastic syndrome. 2000 , 14, 805-10		13
1205	An effective chemotherapeutic regimen for acute myeloid leukemia and myelodysplastic syndrome in children with Down's syndrome. 2000 , 14, 786-91		58
1204	Increase therapy-related leukemia secondary to breast cancer. 2000 , 14, 1014-7		47
1203	Oral 9-cis retinoic acid (Alitretinoin) in the treatment of myelodysplastic syndromes: results from a pilot study. 2000 , 14, 1583-8		6
1202	Elevated MLF1 expression correlates with malignant progression from myelodysplastic syndrome. 2000 , 14, 1757-65		44
1201	Colony-forming unit-megakaryocyte (CFU-meg) numbers and serum thrombopoietin concentrations in thrombocytopenic disorders: an inverse correlation in myelodysplastic syndromes. 2000 , 14, 1751-6		9

1200	Expression and activity of caspases 1 and 3 in myelodysplastic syndromes. 2000 , 14, 2045-51	38
1199	Absence of mutations in the granulocyte colony-stimulating factor (G-CSF) receptor gene in patients with myelodysplastic syndrome/acute myeloblastic leukaemia occurring after treatment of aplastic anaemia with G-CSF. <i>British Journal of Haematology</i> , 2000 , 111, 656-658	4-5
1198	Neutrophil-specific reduction in the expression of granulocyte macrophage colony-stimulating factor receptor subunits in myelodysplastic syndromes. <i>British Journal of Haematology</i> , 2000 , 111, 863-872	4-5
1197	Abnormalities of adherent layers grown from bone marrow of patients with myelodysplasia. <i>British Journal of Haematology</i> , 2000 , 111, 853-862	4-5
1196	Increased apoptosis of bone marrow cells and preserved proliferative capacity of selected progenitors predict for clinical response to anti-inflammatory therapy in myelodysplastic syndromes. 2000 , 28, 941-9	20
1195	Refractory anemia with ringed sideroblasts with a low IPSS score progressed rapidly with de novo appearance of multiple karyotypic abnormalities and into acute erythroleukemia (AML-M6A). 2000 , 24, 597-600	2
1194	Dyshaemopoiesis in adults: a practical classification for diagnosis and management. 2000 , 24, 641-51	3
1193	Hematopoietic stem cell transplantation in patients with myelodysplastic syndrome. 2000 , 24, 653-63	31
1192	Chromosomal alterations associated with evolution from myelodysplastic syndrome to acute myeloid leukemia. 2000 , 24, 839-48	62
1191	P53 overexpression in bone marrow biopsies in refractory anemia and aplastic anemia: impact of antibody selection. 2000 , 24, 975-7	8
1190	Pericardial effusion in chronic myelomonocytic leukemia (CMML): a case report and review of the literature. 2000 , 24, 1059-62	12
1189	Dynamic cell cycle kinetics in vitro and in vivo in myelodysplastic syndromes with special reference to the influence of hematopoietic growth factors. 2000 , 24, 999-1008	1
1188	Validation of the WHO proposals for a new classification of primary myelodysplastic syndromes: a retrospective analysis of 1600 patients. 2000 , 24, 983-92	225
1187	Absolute number of circulating CD34+ cells is abnormally low in refractory anemias and extremely high in RAEB and RAEB-t; novel pathologic features of myelodysplastic syndromes identified by highly sensitive flow cytometry. 2000 , 24, 163-74	18
1186	Erythroblastic and/or megakaryocytic dysplasia in de novo acute myeloid leukemias M0-M5 show relation to myelodysplastic syndromes and delimit two main categories. 2000 , 24, 207-15	9
1185	Comparative multi-color flow cytometric analysis of cell surface antigens in bone marrow hematopoietic progenitors between refractory anemia and aplastic anemia. 2000 , 24, 359-66	17
1184	Myelodysplastic syndrome at a large tertiary care community hospital: analysis according to the international prognostic scoring system. 2000 , 24, 417-26	7
1183	Malignant hematopoietic cell lines: in vitro models for the study of myelodysplastic syndromes. 2000 , 24, 109-15	17

1182	Reciprocal translocation (3;5)(q26;q22) and possible BCHE gene involvement in an unusual myelogenous disorder with both myeloproliferative and dysplastic features. 2000 , 121, 133-8	2
1181	Myelodysplastic syndrome associated with monosomy 7 in a child with Bloom syndrome. 2000 , 116, 44-6	23
1180	Fanconi anemia: myelodysplasia as a predictor of outcome. 2000 , 117, 125-31	84
1179	Secondary myelodysplastic syndrome/acute myeloid leukaemia following mitoxantrone-based therapy for breast carcinoma. 2000 , 83, 91-4	43
1178	Bone marrow transplantation for myelodysplasia. 2000 , 14, 63-77	34
1177	Intensive treatment strategies in patients with high-risk myelodysplastic syndrome and secondary acute myeloid leukemia. 2000 , 14, 182-9	8
1176	Critical evaluation of the World Health Organization classification of myelodysplasia and acute myeloid leukemia. 2000 , 2, 140-3	5
1175	Therapy-related acute myeloid leukemia and myelodysplasia after high-dose chemotherapy and autologous stem cell transplantation. 2000 , 95, 3273-3279	183
1174	The role of apoptosis, proliferation, and the Bcl-2 related proteins in the myelodysplastic syndromes and acute myeloid leukemia secondary to MDS. 2000 , 96, 3932-3938	267
1173	Isolation and characterization of hematopoietic progenitor/stem cells in 5q-deleted myelodysplastic syndromes: evidence for involvement at the hematopoietic stem cell level. 2000 , 96, 2012-2021	193
1172	Defective megakaryocytic development in myelodysplastic syndromes. 2000 , 38, 13-9	23
1171	Therapy-related myelodysplasia and secondary acute myelogenous leukemia after high-dose therapy with autologous hematopoietic progenitor-cell support for lymphoid malignancies. 2000 , 18, 947-55	172
1170	Allogeneic bone marrow transplantation for therapy-related myelodysplastic syndrome and acute myeloid leukemia: a long-term study of 70 patients-report of the French society of bone marrow transplantation. 2000 , 18, 963-71	180
1169	Molecular Mechanisms in Myelodysplastic Syndromes and Implications for Evolution to Acute Leukemias. 2000 , 20, 49-69	4
1168	Problematic WHO reclassification of myelodysplastic syndromes. Members of the International MDS Study Group. 2000 , 18, 3447-52	56
1167	Disease features in acute myeloid leukemia with t(8;21)(q22;q22). Influence of age, secondary karyotype abnormalities, CD19 status, and extramedullary leukemia on survival. 2000 , 40, 67-77	55
1166	A four-parameter index of marrow dysplasia has predictive value for survival in myelodysplastic syndromes. 2000 , 36, 485-96	12
1165	Priming effects of macrophage colony-stimulating factor on monocytic leukemia cells in combination with chemotherapy: induction of programmed cell death in vivo. 2000 , 36, 589-93	

1164	Negative regulators of hemopoiesis and stroma function in patients with myelodysplastic syndrome. 2000 , 37, 405-14	111
1163	Myelodysplasia or myeloneoplasia: thoughts on the nosology of clonal myeloid diseases. 2000 , 26, 572-81	25
1162	Increased HbF levels in dyserythropoiesis. 2000 , 291, 83-7	7
1161	Myelodysplastic syndrome and aplastic anemia: distinct entities or diseases linked by a common pathophysiology?. 2000 , 37, 15-29	133
1160	Platelet glycoprotein expression in patients with myelodysplastic syndrome. 2000 , 100, 27-34	10
1159	Red cells II: acquired anaemias and polycythaemia. 2000 , 355, 1260-8	26
1158	White blood cells 1: non-malignant disorders. 2000 , 355, 1351-7	44
1157	Primary Myelodysplastic Syndromes of Dogs: A Report of 12 Cases. 2000 , 14, 491-494	20
1156	Alteration of c-mpl-mediated signal transduction in CD34(+) cells from patients with myelodysplastic syndromes. 2000 , 28, 1158-63	26
1155	Combination of granulocyte colony-stimulating factor and low-dose cytosine arabinoside further enhances myeloid differentiation in leukemia cells in vitro. 2000 , 39, 173-84	9
1154	Effect of thrombopoietin on proliferation of blasts from patients with myelodysplastic syndromes. 2000 , 18, 112-9	18
1153	In vitro proliferation and differentiation of megakaryocytic progenitors in patients with aplastic anemia, paroxysmal nocturnal hemoglobinuria, and the myelodysplastic syndromes. 2000 , 18, 428-34	13
1152	The cytogenetics of myelodysplastic syndromes. 2001 , 14, 479-95	59
1151	Vascular endothelial cell growth factor is an autocrine promoter of abnormal localized immature myeloid precursors and leukemia progenitor formation in myelodysplastic syndromes. 2001 , 97, 1427-34	292
1150	Cytologic evaluation of primary and secondary myelodysplastic syndromes in the dog. 2001 , 30, 67-75	32
1149	Hematologic Abnormalities and Outcome of 16 Cats with Myelodysplastic Syndromes. 2001 , 15, 471-477	38
1148	[Iron overload and myelodysplastic syndromes]. 2001 , 8, 422-32	12
1147	Síndromes mielodisplásicos. 2001 , 8, 2749-2754	

1146	[Incidence and survival of leukemias according to the different histologic subsets, in Tarragona, Spain, between 1980-1994]. 2001 , 116, 174-8	3
1145	Telomere dynamics in myelodysplastic syndromes and acute leukemic transformation. 2001 , 42, 291-9	41
1144	Trisomy 8 involved in myelodysplastic syndromes as a risk factor for intestinal ulcers and thrombosis--Behçet's syndrome. 2001 , 42, 115-21	62
1143	Myelodysplastic syndromes in the elderly. 2001 , 8, 79-102	12
1142	Detection of chromosome abnormalities pre-high-dose treatment in patients developing therapy-related myelodysplasia and secondary acute myelogenous leukemia after treatment for non-Hodgkin's lymphoma. 2001 , 19, 2472-81	46
1141	Response to recombinant human erythropoietin (rHu-Epo) in a patient with chronic renal failure and myelomonocytic leukaemia. 2001 , 16, 191-2	0
1140	Myelodysplastic syndromes, from French-American-British to World Health Organization: comparison of classifications on 431 unselected patients from a single institution. 2001 , 98, 2935-41	101
1139	Expression, epitope analysis, and functional role of the LFA-2 antigen detectable on neoplastic mast cells. 2001 , 98, 3784-92	46
1138	Identification of myelodysplastic syndrome-specific genes by DNA microarray analysis with purified hematopoietic stem cell fraction. 2001 , 98, 422-7	129
1137	Expression of p15(ink4b) gene during megakaryocytic differentiation of normal and myelodysplastic hematopoietic progenitors. 2001 , 98, 495-7	37
1136	Thalidomide produces transfusion independence in long-standing refractory anemias of patients with myelodysplastic syndromes. 2001 , 98, 958-65	272
1135	Diagnostic utility of flow cytometric immunophenotyping in myelodysplastic syndrome. 2001 , 98, 979-87	238
1134	Transcription patterning of uncoupled proliferation and differentiation in myelodysplastic bone marrow with erythroid-focused arrays. 2001 , 98, 1914-21	31
1133	Classifying chronic myelomonocytic leukemia. 2001 , 19, 3790-2	3
1132	Treatment of myelodysplastic syndrome with low-dose human granulocyte colony-stimulating factor: a multicenter study. 2001 , 74, 144-6	6
1131	Proliferative capacity of single isolated CD34+ hematopoietic stem/progenitor cells in paroxysmal nocturnal hemoglobinuria. 2001 , 74, 42-52	1
1130	Epidemiological features of myelodysplastic syndromes: results from regional cancer surveys and hospital-based statistics. 2001 , 73, 405-410	67
1129	Bone marrow colony-forming unit assay in cats with naturally occurring myelodysplastic syndromes. 2001 , 73, 453-456	5

1128	Reduced CD43 expression on the neutrophils of MDS patients correlates with an activated phenotype of these cells. 2001 , 73, 483-491		5
1127	Methylation of the p15(INK4B) gene in myelodysplastic syndrome: it can be detected early at diagnosis or during disease progression and is highly associated with leukaemic transformation. <i>British Journal of Haematology</i> , 2001 , 112, 148-54	4.5	128
1126	Apoptosis in refractory anaemia with ringed sideroblasts is initiated at the stem cell level and associated with increased activation of caspases. <i>British Journal of Haematology</i> , 2001 , 112, 714-26	4.5	47
1125	Haemopoietic stem cell transplantation for advanced polycythaemia vera or essential thrombocythaemia. <i>British Journal of Haematology</i> , 2001 , 112, 392-6	4.5	28
1124	Occupational and environmental risk factors of the myelodysplastic syndromes in the North of France. <i>British Journal of Haematology</i> , 2001 , 112, 927-35	4.5	61
1123	The prognostic impact of karyotypic subgroups in myelodysplastic syndromes is strongly modified by sex. <i>British Journal of Haematology</i> , 2001 , 113, 347-56	4.5	22
1122	Prognostic significance of risk group stratification in elderly patients with acute myeloid leukaemia. <i>British Journal of Haematology</i> , 2001 , 115, 25-33	4.5	63
1121	International prognostic scoring system and TP53 mutations are independent prognostic indicators for patients with myelodysplastic syndrome. <i>British Journal of Haematology</i> , 2001 , 115, 309-12	4.5	72
1120	Cytogenetic and morphological abnormalities in paroxysmal nocturnal haemoglobinuria. <i>British Journal of Haematology</i> , 2001 , 115, 360-8	4.5	36
1119	Multilineage glycosylphosphatidylinositol anchor-deficient haematopoiesis in untreated aplastic anaemia. <i>British Journal of Haematology</i> , 2001 , 115, 476-82	4.5	74
1118	The clinical and biological effects of thalidomide in patients with myelodysplastic syndromes. <i>British Journal of Haematology</i> , 2001 , 115, 881-94	4.5	84
1117	Effect of cytokines on growth and differentiation of leukaemic cells with translocation t(6;9)(p23;q34). <i>British Journal of Haematology</i> , 2001 , 115, 812-6	4.5	3
1116	Spherocytosis preceding the development of myelodysplasia. 2001 , 23, 249-51		3
1115	Hyperdiploid karyotype in a childhood MDS patient. 2001 , 23, 255-8		3
1114	Quantitative, phenotypic, and functional evaluation of basophils in myelodysplastic syndromes. 2001 , 31, 894-901		9
1113	Primary myelodysplasia: management and outcome at 3 years in 45 patients age 65 and older. 2001 , 49, 1358-60		2
1112	Myelodysplastic and myeloproliferative type of chronic myelomonocytic leukemia--distinct subgroups or two stages of the same disease?. 2001 , 25, 493-9		42
1111	Re-evaluation of refractory anemia with excess blasts in transformation. 2001 , 25, 933-9		13

1110	Successful establishment of long-term bone marrow cultures in 103 patients with myelodysplastic syndromes. 2001 , 25, 941-54	24
1109	Increased peripheral stem cell pool in MDS: an indication of disease progression?. 2001 , 25, 955-9	12
1108	Management of high-risk myelodysplastic syndromes. 2001 , 40, 215-28	6
1107	Myelodysplastic syndrome: review of the cytogenetic and molecular data. 2001 , 40, 229-38	42
1106	The spleen as a diagnostic specimen: a review of 10 years' experience at two tertiary care institutions. 2001 , 91, 2001-9	93
1105	High-dose chemotherapy in high-risk myelodysplastic syndrome: covariate-adjusted comparison of five regimens. 2001 , 92, 1999-2015	70
1104	Apoptotic index by Annexin V flow cytometry: adjunct to morphologic and cytogenetic diagnosis of myelodysplastic syndromes. 2001 , 46, 28-32	36
1103	Phase II study of combination human recombinant GM-CSF with intermediate-dose cytarabine and mitoxantrone chemotherapy in patients with high-risk myelodysplastic syndromes (RAEB, RAEBT, and CMML): an Eastern Cooperative Oncology Group Study. 2001 , 66, 23-7	8
1102	Monocytic leukemia cutis diagnosed simultaneously with refractory anemia with monocytosis: a case report. 2001 , 66, 120-2	2
1101	Successful treatment of refractory anemia by high-dose methylprednisolone associated with an increment in CD68-positive cells in bone marrow. 2001 , 66, 80-4	2
1100	DNA content of granulocytes, monocytes, and lymphocytes in the bone marrow smears of patients with myelodysplastic syndromes. 2001 , 67, 112-8	
1099	Benzene and lymphohematopoietic malignancies in humans. 2001 , 40, 117-26	89
1098	Morphological diagnoses of the Japan adult leukemia study group acute myeloid leukemia protocols: central review. 2001 , 73, 93-9	15
1097	Tyrosine phosphorylation of proteins in primary human myeloid leukemic cells stimulated by macrophage colony-stimulating factor: analysis by disease type and comparison with normal human hematopoietic cells. 2001 , 73, 100-7	1
1096	A fludarabine-based dose-reduced conditioning regimen followed by allogeneic stem cell transplantation from related or unrelated donors in patients with myelodysplastic syndrome. 2001 , 28, 643-7	42
1095	Incidence of hematological malignancies in Martinique, French West Indies, overrepresentation of multiple myeloma and adult T cell leukemia/lymphoma. 2001 , 15, 828-31	16
1094	Role of splenectomy in the treatment of myelodysplastic syndromes with peripheral thrombocytopenia: a report on six cases. 2001 , 15, 950-3	38
1093	Apoptosis/differentiation-inducing effects of vitamin K2 on HL-60 cells: dichotomous nature of vitamin K2 in leukemia cells. 2001 , 15, 1111-7	50

1092	Myelodysplastic syndrome in childhood: a retrospective study of 189 patients in Japan. 2001 , 15, 1713-20	80
1091	Predicting the presence or absence of ringed sideroblasts in patients suspected of having a myelodysplastic syndrome and increased iron stores: a simple observation. 2001 , 15, 1793-5	1
1090	Clinical importance of interphase cytogenetics detecting occult chromosome lesions in myelodysplastic syndromes with normal karyotype. 2001 , 15, 1841-7	77
1089	Genotypically nonidentical related donors for transplantation of patients with myelodysplastic syndromes: comparison with unrelated donor transplantation and autologous stem cell transplantation. 2001 , 15, 1878-84	28
1088	Cytogenetic responses in high-risk myelodysplastic syndrome following low-dose treatment with the DNA methylation inhibitor 5-aza-2'-deoxycytidine. <i>British Journal of Haematology</i> , 2001 , 114, 349-354 ⁵	2
1087	Myelodysplastic features in patients with long-term HIV infection and haemophilia. 2001 , 7, 47-52	1
1086	Trisomy 8 and monosomy 7 detected in bone marrow using primed in situ labeling, fluorescence in situ hybridization, and conventional cytogenetic analyses. A study of 54 cases with hematological disorders. 2001 , 125, 30-40	20
1085	Acute myeloid leukemia with concomitant trisomies 4 and 10: a distinctive form of myeloid leukemia?. 2001 , 127, 74-6	5
1084	Therapy-related refractory anemia with ringed sideroblasts in chronic lymphocytic leukemia. involvement of 3q21 region. 2001 , 129, 43-6	4
1083	The incidence of trisomy 8 as a sole chromosomal aberration in myeloid malignancies varies in relation to gender, age, prior iatrogenic genotoxic exposure, and morphology. 2001 , 130, 160-5	48
1082	Masked monosomy 7 in myelodysplastic syndromes is uncommon and of undetermined clinical significance. 2001 , 25, 197-203	14
1081	Mutation analysis of the DNA-damage checkpoint gene CHK2 in myelodysplastic syndromes and acute myeloid leukemias. 2001 , 25, 333-8	54
1080	Prognostic value of lactate dehydrogenase activity in myelodysplastic syndromes. 2001 , 25, 287-94	30
1079	Mitochondrial disruption and limited apoptosis of erythroblasts are associated with high risk myelodysplasia. An ultrastructural analysis. 2001 , 25, 385-93	33
1078	Dysplastic versus proliferative CMML—a retrospective analysis of 91 patients from a single institution. 2001 , 25, 741-7	46
1077	Diagnostic criteria and classification of mastocytosis: a consensus proposal. 2001 , 25, 603-25	871
1076	Myelomastocytic overlap syndromes: biology, criteria, and relationship to mastocytosis. 2001 , 25, 595-602	57
1075	Morphologic properties of neoplastic mast cells: delineation of stages of maturation and implication for cytological grading of mastocytosis. 2001 , 25, 529-36	184

1074	Myelodysplasia with fibrosis: a distinct entity?. 2001 , 25, 829-38	44
1073	Refractory anemia with excess of blasts in transformation: a dying category?. 2001 , 25, 1095-6	2
1072	Systemic medium-sized vessel vasculitis associated with chronic myelomonocytic leukemia. 2001 , 31, 119-26	59
1071	Increased cytotoxic T cells with effector phenotype in aplastic anemia and myelodysplasia. 2001 , 29, 1270-7	85
1070	Investigation for the presence of anti-erythropoietin antibodies in patients with myelodysplastic syndromes. 2001 , 66, 31-6	7
1069	Decreased amount of mpl and reduced expression of glycoprotein IIb/IIIa and glycoprotein Ib on platelets from patients with refractory anemia: analysis by a non-isotopic quantitative ligand binding assay and immunofluorescence. 2001 , 66, 245-52	4
1068	Cytogenetic responses in high-risk myelodysplastic syndrome following low-dose treatment with the DNA methylation inhibitor 5-aza-2'-deoxycytidine. <i>British Journal of Haematology</i> , 2001 , 114, 349-57 ⁴⁻⁵	207
1067	Evaluation of children with myelodysplastic syndrome: importance of extramedullary disease as a presenting symptom. 2001 , 42, 665-74	28
1066	Immunophenotyping of Acute Leukaemias. Immunophänotypisierung akuter Leukämien. 2001 , 25, 512-532	
1065	Guillain-Barré syndrome following herpes zoster in a patient with systemic sclerosis. 2001 , 11, 251-4	3
1064	Targeting hypomethylation of DNA to achieve cellular differentiation in myelodysplastic syndromes (MDS). 2001 , 6 Suppl 5, 8-14	86
1063	Successful unrelated donor bone marrow transplantation for paroxysmal nocturnal hemoglobinuria. 2001 , 27, 589-92	25
1062	Blood levels of angiogenin and vascular endothelial growth factor are elevated in myelodysplastic syndromes and in acute myeloid leukemia. 2002 , 11, 119-25	60
1061	The World Health Organization (WHO) classification of the myeloid neoplasms. 2002 , 100, 2292-302	1637
1060	Conditioning with targeted busulfan and cyclophosphamide for hemopoietic stem cell transplantation from related and unrelated donors in patients with myelodysplastic syndrome. 2002 , 100, 1201-7	253
1059	Genetic susceptibility to Hodgkin's disease and secondary neoplasias: FISH analysis reveals patients at high risk of developing secondary neoplasia. 2002 , 13 Suppl 1, 40-3	4
1058	A practical, comprehensive classification for pediatric myelodysplastic syndromes: the CCC system. 2002 , 24, 596-605	42
1057	Spurious dyserythropoiesis. 2002 , 117, 57-9	14

1056	Myeloid disorders with deletion of 5q as the sole karyotypic abnormality: the clinical and pathologic spectrum. 2002 , 43, 761-5	10
1055	High incidence of point mutations of p53 suppressor oncogene in patients with myelodysplastic syndrome among atomic-bomb survivors: a 10-year follow-up. 2002 , 16, 154-6	10
1054	Primary myelodysplasia occurring in adults under 50 years old: a clinicopathologic study of 52 patients. 2002 , 16, 623-31	18
1053	Myelodysplastic syndromes. 2002 , 2002, 136-61	107
1052	Thalidomide for the treatment of patients with myelodysplastic syndromes. 2002 , 16, 1-6	125
1051	Soluble TNF receptor fusion protein (etanercept) for the treatment of myelodysplastic syndrome: a pilot study. 2002 , 16, 162-4	83
1050	Elevated plasma level of differentiation inhibitory factor nm23-H1 protein correlates with risk factors for myelodysplastic syndrome. 2002 , 16, 165-9	3
1049	Die neue WHO-Klassifikation zur Einteilung der akuten myeloischen Leukamien (AML): Vorteile und Probleme im Vergleich zur FAB (French-American-British)-Klassifikation/The New WHO Classification for Acute Myeloid Leukemias: Comparison to the FAB Classification. 2002 , 26, 19-22	
1048	Risk of therapy-related myelodysplastic syndrome/acute leukemia following high-dose therapy and autologous bone marrow transplantation for non-Hodgkin's lymphoma. 2002 , 13, 450-9	51
1047	New approaches to the treatment of myelodysplasia. 2002 , 7 Suppl 1, 39-49	48
1046	Myelodysplastic syndrome following therapy for brain tumor--two case reports. 2002 , 42, 170-4	3
1045	Atypical cellular disorders. 2002 , 2002, 297-314	23
1044	A practical, comprehensive classification for pediatric myelodysplastic syndromes: the CCC system. 2002 , 24, 343-52	15
1043	Proposed changes in the definitions of acute myeloid leukemia and myelodysplastic syndrome: are they helpful?. 2002 , 14, 19-23	17
1042	Myelodysplasia and the acute myeloid leukaemias. 2002 , 7, 325-38	1
1041	Bethesda proposals for classification of nonlymphoid hematopoietic neoplasms in mice. 2002 , 100, 238-45	355
1040	Acute myeloid leukemia and myelodysplastic syndrome in children treated for cancer: comparison with primary presentation. 2002 , 100, 427-34	63
1039	Myelodysplastic syndrome is not merely "preleukemia". 2002 , 100, 791-8	109

1038	Therapy-related myelodysplastic syndrome-acute myelogenous leukemia in patients treated for acute promyelocytic leukemia: an emerging problem. 2002 , 99, 822-4	110
1037	Prognostic factors and scoring systems in chronic myelomonocytic leukemia: a retrospective analysis of 213 patients. 2002 , 99, 840-9	304
1036	Sustained response to recombinant human erythropoietin and intermittent all-trans retinoic acid in patients with myelodysplastic syndromes. 2002 , 99, 1578-84	41
1035	Unrelated donor marrow transplantation for myelodysplastic syndromes: outcome analysis in 510 transplants facilitated by the National Marrow Donor Program. 2002 , 99, 1943-51	190
1034	Myelodysplastic syndromes: from French-American-British to World Health Organization: a commentary. 2002 , 99, 3074-5	21
1033	Narrowing and genomic annotation of the commonly deleted region of the 5q- syndrome. 2002 , 99, 4638-41	213
1032	Outcome after induction chemotherapy for older patients with acute myeloid leukemia is not improved with mitoxantrone and etoposide compared to cytarabine and daunorubicin: a Southwest Oncology Group study. 2002 , 100, 3869-76	153
1031	Clinical significance of a minor population of paroxysmal nocturnal hemoglobinuria-type cells in bone marrow failure syndrome. 2002 , 100, 3897-902	168
1030	Monocytic Cell Lines. 2002 , 237-257	1
1029	Effect of azacytidine in the release of leukemia inhibitory factor, oncostatin m, interleukin (IL)-6, and IL-11 by mononuclear cells of patients with refractory anemia. 2002 , 20, 154-62	8
1028	Tuberculosis in patients with myelodysplastic syndromes. 2002 , 57, 408-14	6
1027	Risk factors for evolution of acquired aplastic anemia into myelodysplastic syndrome and acute myeloid leukemia after immunosuppressive therapy in children. 2002 , 100, 786-90	150
1026	Myelodysplastic Syndrome. 2002 , 1, 301-311	1
1025	Apoptosis and prognostic factors in myelodysplastic syndromes. 2002 , 43, 257-60	12
1024	Autoimmune phenomena in patients with myelodysplastic syndromes and chronic myelomonocytic leukemia. 2002 , 43, 2083-92	120
1023	Therapy-related acute myeloid leukemia and myelodysplasia after successful treatment of acute promyelocytic leukemia. 2002 , 43, 275-80	24
1022	Curative therapy of advanced essential thrombocythemia or polycythemia vera by hemopoietic stem cell transplantation. 2002 , 43, 1409-14	16
1021	Myelodysplastic syndrome overview. 2002 , 39, 18-25	42

1020	Thalidomide in myelodysplastic syndromes. 2002 , 56, 20-30	7
1019	[New WHO classification of myelodysplastic syndromes. The consequences]. 2002 , 50, 278-82	3
1018	Acute myeloid leukemia and related conditions. 2002 , 16, 301-19	7
1017	Systemic mast cell disease without associated hematologic disorder: a combined retrospective and prospective study. 2002 , 77, 1169-75	30
1016	Randomized controlled trial of azacitidine in patients with the myelodysplastic syndrome: a study of the cancer and leukemia group B. 2002 , 20, 2429-40	1478
1015	Prospective study of 90 children requiring treatment for juvenile myelomonocytic leukemia or myelodysplastic syndrome: a report from the Children's Cancer Group. 2002 , 20, 434-40	79
1014	Predominance of trisomy 1q in myelodysplastic syndromes in Korea: is there an ethnic difference? A 3-year multi-center study. 2002 , 132, 97-101	38
1013	Refractory anemia with ring sideroblasts associated with i(17q) and mutation of the TP53 gene. 2002 , 136, 86-9	5
1012	Aplastic anemia evolving into overt myelodysplastic syndrome/acute myeloid leukemia with t(3;5)(p25;q31). 2002 , 137, 91-4	4
1011	Cytogenetic survey of 117 Tunisian patients with de novo myelodysplastic syndrome. 2002 , 45, 131-5	1
1010	Improved outcome in adult acute myeloid leukemia is almost entirely restricted to young patients and associated with stem cell transplantation. 2002 , 68, 54-63	15
1009	Serum erythropoietin (EPO) levels correlate with survival and independently predict response to EPO treatment in patients with myelodysplastic syndromes. 2002 , 68, 180-5	37
1008	Stem cell transplantation for leukemias following myelodysplastic syndromes or secondary to cytotoxic therapy. 2002 , 6, 72-85; discussion 86-7	9
1007	Loss of genomic imprinting of insulin-like growth factor 2 is strongly associated with cellular proliferation in normal hematopoietic cells. 2002 , 30, 318-23	29
1006	Clonal evolution in marrows of patients with Shwachman-Diamond syndrome: a prospective 5-year follow-up study. 2002 , 30, 659-69	74
1005	Expression and prognostic significance of Bcl-2 family proteins in myelodysplastic syndromes. 2002 , 70, 115-25	46
1004	Danazol for the treatment of thrombocytopenia in patients with myelodysplastic syndrome. 2002 , 71, 166-71	40
1003	Comparison in treatments of nonleukemic granulocytic sarcoma: report of two cases and a review of 72 cases in the literature. 2002 , 94, 1739-46	283

1002	Characteristics and outcome of patients with Philadelphia chromosome negative, bcr/abl negative chronic myelogenous leukemia. 2002 , 95, 1673-84	63
1001	Immunophenotypic characterization of myelopoiesis in early and late myelodysplastic syndromes: use of CD44 as an aid in early diagnosis. 2002 , 50, 225-30	11
1000	New human myelodysplastic cell line, TER-3: G-CSF specific downregulation of Ca ²⁺ /calmodulin-dependent protein kinase IV. 2002 , 191, 183-90	3
999	Double minute chromosomes in acute myeloid leukemia and myelodysplastic syndrome: identification of new amplification regions by fluorescence in situ hybridization and spectral karyotyping. 2002 , 34, 42-7	53
998	Identification of cytogenetic subclasses and recurring chromosomal aberrations in AML and MDS with complex karyotypes using M-FISH. 2002 , 33, 60-72	88
997	Two independent clones in myelodysplastic syndrome following treatment of acute myeloid leukemia. 2002 , 75, 182-6	7
996	Biological significance of proliferation, apoptosis, cytokines, and monocyte/macrophage cells in bone marrow biopsies of 145 patients with myelodysplastic syndrome. 2002 , 75, 289-97	68
995	Reversible acceleration of disease progression following cyclosporin A treatment in a patient with myelodysplastic syndrome. 2002 , 75, 302-4	5
994	Pure red cell aplasia developing into myeloproliferation with myelodysplasia and subsequent leukemia after cyclosporin A therapy. 2002 , 75, 514-8	5
993	Histologic verification of leukemia, myelodysplasia, and multiple myeloma diagnoses in patients in Ukraine, 1987-1998. 2002 , 76, 55-60	12
992	Platelet dysfunction in myelodysplastic syndromes: a clinicopathological study. 2002 , 76, 272-8	31
991	Allogeneic hemopoietic stem cell transplantation in patients with myelodysplastic syndrome or myelofibrosis. 2002 , 76 Suppl 2, 29-34	13
990	Important features of myelodysplastic syndrome. 2002 , 76 Suppl 2, 222-7	10
989	The myelodysplastic syndromes: morphology, risk assessment, and clinical management (2002). 2002 , 76 Suppl 2, 228-38	27
988	Chronic myelomonocytic leukemia. 2002 , 3, 221-3	10
987	Early diagnosis of myelodysplastic syndromes using clonal analyses. 2002 , 14, 225-229	1
986	Unrelated donor bone marrow transplantation for children with juvenile myelomonocytic leukaemia. <i>British Journal of Haematology</i> , 2002 , 116, 716-24	4.5 63
985	Excessive apoptosis, increased phagocytosis, nuclear inclusion bodies and cylindrical confronting cisternae in bone marrow biopsies of myelodysplastic syndrome patients. <i>British Journal of Haematology</i> , 2002 , 116, 817-25	4.5 18

984	A case of S ^c zary's syndrome associated with granulomatous lesions, myelodysplastic syndrome and transformation into CD30-positive large-cell pleomorphic lymphoma. 2002 , 147, 582-6		23
983	Evolution of myelodysplastic syndrome and acute myelogenous leukaemia in children with hepatitis-associated aplastic anaemia. <i>British Journal of Haematology</i> , 2002 , 116, 151-4	4.5	16
982	Results of treatment of children with refractory anaemia with excess blasts (RAEB) and RAEB in transformation (RAEBt) in Great Britain 1990-99. <i>British Journal of Haematology</i> , 2002 , 117, 33-9	4.5	39
981	Prolonged administration of erythropoietin increases erythroid response rate in myelodysplastic syndromes: a phase II trial in 281 patients. <i>British Journal of Haematology</i> , 2002 , 118, 174-80	4.5	90
980	Hypoplastic myelodysplastic syndromes can be distinguished from acquired aplastic anaemia by bone marrow stem cell expression of the tumour necrosis factor receptor. <i>British Journal of Haematology</i> , 2002 , 118, 181-8	4.5	18
979	Sex ratios and the risks of haematological malignancies. <i>British Journal of Haematology</i> , 2002 , 118, 1071-7	4.5	84
978	Prognosis of myelodysplastic patients: non-parametric multiple regression analysis of populations stratified by mean corpuscular volume and marrow myeloblast number. <i>British Journal of Haematology</i> , 2002 , 119, 87-96	4.5	11
977	rHuEpo administration in patients with low-risk myelodysplastic syndromes: evaluation of erythroid precursors' response by fluorescence in situ hybridization on May-Grunwald-Giemsa-stained bone marrow samples. <i>British Journal of Haematology</i> , 2002 , 119, 652-9	4.5	28
976	Does isochromosome 7q mandate bone marrow transplant in children with Shwachman-Diamond syndrome?. <i>British Journal of Haematology</i> , 2002 , 119, 1062-9	4.5	38
975	Detection of small numbers of cells characteristic for haematological disorders in peripheral blood (the deep diff). 2002 , 24, 73-80		2
974	Megakaryoblastic transformation of chronic myelomonocytic leukemia presenting with severe bone pain. 2002 , 2, 105-109		
973	Classification des leuc ^m mies aigu ^s : nouvelles propositions de l'oms (Organisation Mondiale de la Sant ^e). 2002 , 2002, 19-24		4
972	Increased risk for therapy-associated hematologic malignancies in patients with carcinoma of the breast and combined homozygous gene deletions of glutathione transferases M1 and T1. 2002 , 26, 249-54		43
971	Pilot study of recombinant human soluble tumor necrosis factor receptor (TNFR:Fc) in patients with low risk myelodysplastic syndrome. 2002 , 26, 721-4		38
970	Two groups of chronic myelomonocytic leukaemia: myelodysplastic and myeloproliferative. Prognostic implications in a series of a single center. 2002 , 26, 821-4		46
969	Comparative analysis of the in vitro proliferation and expansion of hematopoietic progenitors from patients with aplastic anemia and myelodysplasia. 2002 , 26, 955-63		17
968	Bone marrow transplantation for myelodysplastic syndrome--who? when? and which?. 2002 , 30, 199-206		15
967	Chemotherapy only compared to chemotherapy followed by transplantation in high risk myelodysplastic syndrome and secondary acute myeloid leukemia; two parallel studies adjusted for various prognostic factors. 2002 , 16, 1615-21		52

966	More cell death in refractory anemia with excess blasts in transformation than in acute myeloid leukemia. 2002 , 16, 2249-52	19
965	Successful management and perinatal outcome of pregnancy complicated with myelodysplastic syndrome. 2002 , 26, 255-60	13
964	Bone marrow lymphoid aggregates in myelodysplastic syndromes: incidence, immunomorphological characteristics and correlation with clinical features and survival. 2002 , 26, 525-30; discussion 531	12
963	In vitro characterization of hematopoietic microenvironment cells from patients with myelodysplastic syndrome. 2002 , 26, 677-86	111
962	Monoclonal constitution of neutrophils detected by PCR-based human androgen receptor gene assay in a subset of idiopathic thrombocytopenic purpura patients. 2002 , 26, 825-30	9
961	Comparison of cytogenetics with FISH in 40 myelodysplastic syndrome patients. 2002 , 26, 993-6	53
960	Oxidative stress and the myelodysplastic syndromes. 2003 , 77, 342-50	80
959	Successful aortic valve replacement in severe pancytopenia related to myelodysplastic syndrome. 2003 , 51, 77-80	6
958	Successful replacement of aortic root with valve-sparing technique and proximal arch in a patient with myelodysplastic syndrome. 2003 , 51, 322-5	5
957	Pathogenesis, classification, and treatment of myelodysplastic syndromes (MDS). 2003 , 115, 515-36	4
956	Diagnostic and prognostic value of colony formation of hematopoietic progenitor cells in myeloid malignancies. 2003 , 115, 537-46	12
955	Circulating myeloid colony-forming cells predict survival in myelodysplastic syndromes. 2003 , 82, 271-7	11
954	Uneventful outcome of unrelated hematopoietic stem cell transplantation in a patient with leukemic transformation of Kostmann syndrome and long-lasting invasive pulmonary mycosis. 2003 , 70, 322-5	12
953	Long-term marrow reconstitutive ability of autologous grafts in lymphoma patients using peripheral blood mobilized with granulocyte colony-stimulating factor or granulocyte-macrophage colony-stimulating factor compared to bone marrow. 2003 , 31, 89-97	7
952	Reduced expression of flavocytochrome b558, a component of the NADPH oxidase complex, in neutrophils from patients with myelodysplasia. 2003 , 31, 752-9	10
951	A unique clone involving multiple structural chromosome rearrangements in a myelodysplastic syndrome case. 2003 , 140, 138-44	5
950	Apoptotic rate in patients with myelodysplastic syndrome treated with modulatory compounds of pro-apoptotic cytokines. 2003 , 7, 313-21	3
949	Evidence for expression of early myeloid antigens in mature, non-blast myeloid cells in myelodysplasia. 2003 , 74, 9-16	15

948	A prognostic impact of separation of refractory cytopenia with multilineage dysplasia and 5q-syndrome from refractory anemia in primary myelodysplastic syndrome. 2003 , 27, 221-9		43
947	The myelodysplastic syndrome(s): a perspective and review highlighting current controversies. 2003 , 27, 95-120		125
946	Clonal cytogenetic abnormalities in bone marrow specimens without clear morphologic evidence of dysplasia: a form fruste of myelodysplasia?. 2003 , 27, 235-42		54
945	Is it still possible to ameliorate the diagnosis of refractory anemia?. 2003 , 27, 201-3		1
944	Splenic histopathological patterns in chronic myelomonocytic leukemia with clinical correlations: reinforcement of the heterogeneity of the syndrome. 2003 , 27, 775-82		25
943	Disordered hematopoiesis and myelodysplasia in the elderly. 2003 , 51, S22-6		34
942	Guidelines for the diagnosis and therapy of adult myelodysplastic syndromes. <i>British Journal of Haematology</i> , 2003 , 120, 187-200	4.5	211
941	A pilot study of antithymocyte globulin (ATG) in the treatment of patients with 'low-risk' myelodysplasia. <i>British Journal of Haematology</i> , 2003 , 120, 679-84	4.5	108
940	A validated decision model for treating the anaemia of myelodysplastic syndromes with erythropoietin + granulocyte colony-stimulating factor: significant effects on quality of life. <i>British Journal of Haematology</i> , 2003 , 120, 1037-46	4.5	322
939	Paediatric myelodysplastic syndromes and juvenile myelomonocytic leukaemia in the UK: a population-based study of incidence and survival. <i>British Journal of Haematology</i> , 2003 , 121, 758-67	4.5	103
938	Progression of myelodysplastic syndrome: allelic loss on chromosomal arm 1p. <i>British Journal of Haematology</i> , 2003 , 122, 226-30	4.5	31
937	The impact of intensive antileukaemic treatment strategies on prognosis of myelodysplastic syndrome patients aged less than 61 years according to International Prognostic Scoring System risk groups. <i>British Journal of Haematology</i> , 2003 , 123, 81-9	4.5	15
936	Lack of cytoprotective effect of amifostine following HLA-identical sibling transplantation for advanced myelodysplastic syndrome (MDS): a pilot study. 2003 , 32, 1071-5		11
935	A pediatric approach to the WHO classification of myelodysplastic and myeloproliferative diseases. 2003 , 17, 277-82		346
934	Application of different prognostic scoring systems and comparison of the FAB and WHO classifications in Korean patients with myelodysplastic syndrome. 2003 , 17, 305-13		87
933	The emergence of a C/EBPalpha mutation in the clonal evolution of MDS towards secondary AML. 2003 , 17, 343-9		35
932	Aberrant methylation and impaired expression of the p15(INK4b) cell cycle regulatory gene in chronic myelomonocytic leukemia (CMML). 2003 , 17, 910-8		53
931	Cytogenetic response to thalidomide treatment in three patients with myelodysplastic syndrome. 2003 , 17, 1200-2		23

930	The presence of an HLA-identical sibling donor has no impact on outcome of patients with high-risk MDS or secondary AML (sAML) treated with intensive chemotherapy followed by transplantation: results of a prospective study of the EORTC, EBMT, SAKK and GIMEMA Leukemia Groups (EORTC study 06921). 2003 , 17, 859-68	34
929	Myelodysplastic syndrome after acute promyelocytic leukemia: the European APL group experience. 2003 , 17, 1600-4	62
928	No benefit from adding GM-CSF to induction chemotherapy in transforming myelodysplastic syndromes: better outcome in patients with less proliferative disease. 2003 , 17, 1827-33	30
927	DNA microarray analysis of hematopoietic stem cell-like fractions from individuals with the M2 subtype of acute myeloid leukemia. 2003 , 17, 1990-7	20
926	Antithymocyte globulin (ATG)-based therapy in patients with myelodysplastic syndromes. 2003 , 17, 2101-6	67
925	Determination of T-cell receptors of clonal CD8-positive T-cells in myelodysplastic syndrome with erythroid hypoplasia. 2003 , 27, 305-12	32
924	Refractory anemia with excess of blasts in transformation: analysis of reclassification according to the WHO proposals. 2003 , 27, 397-404	32
923	NOD/SCID mice transplanted with marrow from patients with myelodysplastic syndrome (MDS) show long-term propagation of normal but not clonal human precursors. 2003 , 27, 425-36	49
922	MDS--new classification, new problem?. 2003 , 27, 567-9	4
921	Hematopoietic cell transplantation for adult patients with myelodysplastic syndromes and myeloproliferative disorders. 2003 , 78, 981-90	2
920	Reduced-intensity transplantation for patients with myelodysplastic syndrome achieves durable remission with less graft-versus-host disease. 2003 , 9, 753-9	29
919	Overexpression of the dual-specificity MAPK phosphatase PYST2 in acute leukemia. 2003 , 199, 185-92	27
918	New insights into the physiology and treatment of acquired myelodysplastic syndromes and aplastic pancytopenia. 2003 , 33, 1317-34	13
917	[Biologic and clinical relevance of cytogenetic analysis in primary myelodysplastic syndromes]. 2003 , 51, 346-55	2
916	Myelodysplastic syndromes, chronic myeloproliferative diseases, and myelodysplastic/myeloproliferative diseases. 2003 , 20, 154-79	15
915	Epidemiology and clinical burden of acute myeloid leukemia. 2003 , 3, 695-710	23
914	Chronic myelomonocytic leukemia coexisting with B-cell chronic lymphocytic leukemia. 2003 , 44, 2001-8	8
913	Configuration of the TP53 gene as an independent prognostic parameter of myelodysplastic syndrome. 2003 , 44, 915-22	41

912	Evaluation for the development of 11q23 rearrangements in lymphoma patients treated with a high dose VP-16 and cyclophosphamide salvage regimen. 2003 , 44, 1001-9	0
911	Acute myeloid leukemia and myelodysplastic syndrome after doxorubicin-cyclophosphamide adjuvant therapy for operable breast cancer: the National Surgical Adjuvant Breast and Bowel Project Experience. 2003 , 21, 1195-204	258
910	Significant correlation between the degree of WT1 expression and the International Prognostic Scoring System Score in patients with myelodysplastic syndromes. 2003 , 21, 1988-95	125
909	Imbalance between apoptosis and telomerase activity in myelodysplastic syndromes: possible role in ineffective hemopoiesis. 2003 , 44, 1339-46	25
908	Additional prognostic value of bone marrow histology in patients subclassified according to the International Prognostic Scoring System for myelodysplastic syndromes. 2003 , 21, 273-82	48
907	Morphologic dysplasia in de novo acute myeloid leukemia (AML) is related to unfavorable cytogenetics but has no independent prognostic relevance under the conditions of intensive induction therapy: results of a multiparameter analysis from the German AML Cooperative Group 2003 , 21, 257-65	139
906	Increased age at diagnosis has a significantly negative effect on outcome in children with Down syndrome and acute myeloid leukemia: a report from the Children's Cancer Group Study 2891. 2003 , 21, 3415-22	135
905	Assessment of differences in patient populations selected for excluded from participation in clinical phase III acute myelogenous leukemia trials. 2003 , 21, 3933-9	92
904	Immunosuppressive treatments for myelodysplastic syndromes. 2003 , 44, 593-604	17
903	Myelodysplasia: differentiating neoplastic from nonneoplastic syndromes of ineffective hematopoiesis in dogs. 2003 , 31 Suppl, 44-8	10
902	Clinico-hematologic features of myelodysplastic syndrome presenting as isolated thrombocytopenia: an entity with a relatively favorable prognosis. 2003 , 44, 653-8	24
901	Behçet's disease accompanied by myelodysplastic syndrome with trisomy 8: two case reports and a review of 15 Japanese cases. 2003 , 13, 90-4	8
900	The evolution of juvenile myelomonocytic leukemia in a female patient with paternally inherited neurofibromatosis type 1. 2003 , 25, 145-7	4
899	Diagnostic significance of detecting dysgranulopoiesis in chronic myeloid leukemia. 2003 , 120, 778-84	2
898	Hematopoietic Cell Transplantation for Adult Patients With Myelodysplastic Syndromes and Myeloproliferative Disorders. 2003 , 78, 981-990	15
897	Recent progress in the treatment of myelodysplastic syndrome in adult patients. 2003 , 15, 1-9	6
896	Current challenges in therapy of myelodysplastic syndromes. 2003 , 10, 60-7	4
895	cDNA microarray analysis reveals an overexpression of the dual-specificity MAPK phosphatase PYST2 in acute leukemia. 2003 , 366, 103-13	17

894	Granulocyte colony-stimulating factor inhibits spontaneous cytochrome c release and mitochondria-dependent apoptosis of myelodysplastic syndrome hematopoietic progenitors. 2003 , 101, 1080-6	106
893	Mitochondrial DNA mutations in patients with myelodysplastic syndromes. 2003 , 101, 3118-25	68
892	Myeloid and monocytic dyspoiesis as determined by flow cytometric scoring in myelodysplastic syndrome correlates with the IPSS and with outcome after hematopoietic stem cell transplantation. 2003 , 102, 394-403	269
891	Contribution of beta-2 microglobulin levels to the prognostic stratification of survival in patients with myelodysplastic syndrome (MDS). 2003 , 102, 1622-5	25
890	Farnesyltransferase inhibitor R115777 in myelodysplastic syndrome: clinical and biologic activities in the phase 1 setting. 2003 , 102, 4527-34	117
889	Unrelated cord blood transplantation for adult patients with advanced myelodysplastic syndrome. 2003 , 101, 4711-3	69
888	Increased apoptosis in bone marrow B lymphocytes but not T lymphocytes in myelodysplastic syndrome. 2003 , 102, 1866-8	31
887	Decreased phosphorylation of protein kinase B and extracellular signal-regulated kinase in neutrophils from patients with myelodysplasia. 2003 , 101, 1172-80	47
886	Prevalence and clinical characteristics of myelodysplastic syndrome with bone marrow eosinophilia or basophilia. 2003 , 101, 3386-90	73
885	Unusual skin lesions in chronic myelomonocytic leukemia. 2003 , 96, 681-4	6
884	Classification, treatment goals, and management principles for myelodysplastic syndromes. 2004 , 11, 3-6	3
883	Multiple drug resistance protein (MDR-1), multidrug resistance-related protein (MRP) and lung resistance protein (LRP) gene expression in childhood acute lymphoblastic leukemia. 2004 , 122, 166-71	47
882	Therapeutic spectrum in the treatment of myelodysplastic syndromes. 2004 , 5, 2451-8	1
881	Arsenic trioxide for the treatment of myelodysplastic syndromes. 2004 , 5, 613-21	8
880	Low dose Ara-C for myelodysplastic syndromes: is it still a current therapy?. 2004 , 45, 1531-8	16
879	Myelodysplastic syndromes. 2004 , 2004, 297-317	93
878	Granulocytic sarcoma of the ovotestis: an association of myelodysplastic syndrome and hermaphroditism. 2004 , 45, 1285-7	7
877	The 5q- syndrome. 2004 , 9, 271-7	60

876	CD34+ cells from acute myeloid leukemia, myelodysplastic syndromes, and normal bone marrow display different apoptosis and drug resistance-associated phenotypes. 2004 , 10, 7599-606		27
875	Models of granulocyte DNA structure are highly predictive of myelodysplastic syndrome. 2004 , 101, 5008-11		14
874	Molecular analysis of TCR clonotypes in LGL: a clonal model for polyclonal responses. 2004 , 172, 1960-9		57
873	Phase II study of R115777, a farnesyl transferase inhibitor, in myelodysplastic syndrome. 2004 , 22, 1287-92		124
872	Differentiation of acute myeloid leukemia from B- and T-lineage acute lymphoid leukemias by real-time quantitative reverse transcription-PCR of lineage marker mRNAs. 2004 , 50, 1165-73		9
871	Disturbed granulocyte macrophage-colony stimulating factor priming of phosphatidylinositol 3,4,5-trisphosphate accumulation and Rac activation in fMLP-stimulated neutrophils from patients with myelodysplasia. 2004 , 76, 254-62		11
870	Comparison of the outcomes of allogeneic bone marrow transplantation from partially mismatched related donors, matched sibling donors, and matched unrelated donors in Japanese pediatric patients: a single center result. 2004 , 8, 260-6		7
869	CD90/Thy-1 is preferentially expressed on blast cells of high risk acute myeloid leukaemias. <i>British Journal of Haematology</i> , 2004 , 125, 203-12	4.5	22
868	Gene expression profiling in the myelodysplastic syndromes using cDNA microarray technology. <i>British Journal of Haematology</i> , 2004 , 125, 576-83	4.5	65
867	Natural history of paroxysmal nocturnal haemoglobinuria using modern diagnostic assays. <i>British Journal of Haematology</i> , 2004 , 126, 133-8	4.5	177
866	In patients with myelodysplastic syndromes response to rHuEPO and G-CSF treatment is related to an increase of cytogenetically normal CD34 cells. <i>British Journal of Haematology</i> , 2004 , 126, 501-7	4.5	20
865	Levels of soluble forms of ICAM and VCAM in patients with myelodysplastic syndromes and their prognostic significance. 2004 , 26, 391-5		7
864	Myelodysplasia-associated autoimmunity: clinical and pathophysiologic concepts. 2004 , 34, 690-700		71
863	Isolated PACNS-like presentation of a systemic vasculitis complicating a myelodysplastic syndrome. 2004 , 255, 674-9		7
862	Monitoring treatment efficiency in MDS at the molecular level; possibilities now and in the future. 2004 , 28, 101-8		8
861	Allogeneic stem cell transplantation in patients with Fanconi's anemia and myelodysplasia or leukemia utilizing low-dose cyclophosphamide and total body irradiation. 2004 , 33, 15-7		8
860	Donor lymphocyte infusion to treat relapse after allogeneic bone marrow transplantation for myelodysplastic syndrome. 2004 , 33, 531-4		45
859	Allogeneic bone marrow transplantation in children with myelodysplastic syndrome or juvenile myelomonocytic leukemia: the Seattle experience. 2004 , 33, 805-14		58

858	Clinical, morphological, cytogenetic, and prognostic features of patients with myelodysplastic syndromes and del(5q) including band q31. 2004 , 18, 113-9	163
857	A prospective, randomised, phase II study of horse antithymocyte globulin vs rabbit antithymocyte globulin as immune-modulating therapy in patients with low-risk myelodysplastic syndromes. 2004 , 18, 460-5	116
856	Acquisition of FLT3 or N-ras mutations is frequently associated with progression of myelodysplastic syndrome to acute myeloid leukemia. 2004 , 18, 466-75	126
855	Translocation t(2;3)(p15-23;q26-27) in myeloid malignancies: report of 21 new cases, clinical, cytogenetic and molecular genetic features. 2004 , 18, 1108-14	28
854	Circulating myeloid and lymphoid precursor dendritic cells are clonally involved in myelodysplastic syndromes. 2004 , 18, 1451-6	43
853	Cytogenetic patterns in 384 northern-Spanish patients with haematological disorders. 1993 , 118, 79-85	1
852	Clinical and morphological features of paediatric myelodysplastic syndromes: a review of 34 cases. 2004 , 93, 1015-23	15
851	Matrix metalloproteinase inhibitor reduces apoptosis induction of bone marrow cells in MDS-RA. 2004 , 73, 17-24	9
850	Clinical, haematological and histomorphological profile of adult myelodysplastic syndrome. Study of 96 cases in a single institute. 2004 , 73, 93-7	15
849	Flow cytometric detection of accelerated telomere shortening in myelodysplastic syndromes: correlations with aetiological and clinical-biological findings. 2004 , 73, 351-8	27
848	Targeted therapies in myeloid leukemia. 2004 , 14, 41-62	39
847	Update on myelodysplastic syndromes: new approaches to classification and therapy. 2004 , 31, 72-9	6
846	High-dose cyclophosphamide as salvage therapy for severe aplastic anemia. 2004 , 32, 435-40	30
845	Systematic screening at diagnosis of -5/del(5)(q31), -7, or chromosome 8 aneuploidy by interphase fluorescence in situ hybridization in 110 acute myelocytic leukemia and high-risk myelodysplastic syndrome patients: concordances and discrepancies with conventional cytogenetics. 2004 , 152, 29-41	35
844	Novel loss-of-function mutations of the haematopoiesis-related transcription factor, acute myeloid leukaemia 1/runt-related transcription factor 1, detected in acute myeloblastic leukaemia and myelodysplastic syndrome. <i>British Journal of Haematology</i> , 2004 , 125, 709-19	4-5 26
843	Possibility of the diagnosis of subacute myeloid leukemia for a group of patients with trisomy 8: a report of 34 cases. 2004 , 80, 159-63	
842	Simultaneous demonstration of clonal chromosome abnormalities and apoptosis in individual marrow cells in myelodysplastic syndrome. 2004 , 80, 140-5	35
841	Expression of the proliferation-associated nuclear protein MIB-1 and its relationship with microvascular density in bone marrow biopsies of patients with myelodysplastic syndromes. 2004 , 35, 857-63	12

840	Classification of refractory anemia. 2004 , 28, 213; discussion 215	
839	Genomic instability in bone marrow failure syndromes. 2004 , 76, 220-4	16
838	Centrosome amplification and aneuploidy in bone marrow failure patients. 2004 , 40, 329-33	13
837	Novel therapies for myelodysplastic syndromes. 2004 , 101, 226-41	41
836	Hematological malignancies in the island of Sardinia, 1974-1993: age and sex distributions and temporal changes in incidence. 2004 , 22, 91-109	10
835	Imatinib therapy for hypereosinophilic syndrome and eosinophilia-associated myeloproliferative disorders. 2004 , 28 Suppl 1, S47-52	22
834	Combined stratification of refractory anemia according to both WHO and IPSS criteria has a prognostic impact and improves identification of patients who may benefit from stem cell transplantation. 2004 , 28, 551-7	16
833	Normal bone marrow function over 6 years in a patient with dysplastic hematopoiesis and a complex karyotype. 2004 , 28, 651-5	6
832	Philadelphia chromosome positive myelodysplastic syndrome and acute myeloid leukemia-retrospective study and review of literature. 2004 , 28, 579-86	87
831	Factors influencing survival in myelodysplastic syndromes in a Brazilian population: comparison of FAB and WHO classifications. 2004 , 28, 587-94	51
830	What is in a name? Refined diagnostic criteria for prognostic assessment in myelodysplastic syndrome (MDS). 2004 , 28, 543-4	5
829	Bone marrow stroma in childhood myelodysplastic syndrome: composition, ability to sustain hematopoiesis in vitro, and altered gene expression. 2004 , 28, 831-44	32
828	Dynamics of telomere erosion and its association with genome instability in myelodysplastic syndromes (MDS) and acute myelogenous leukemia arising from MDS: a marker of disease prognosis?. 2004 , 28, 1013-21	59
827	Limited numbers of apoptotic cells in fresh paraffin embedded bone marrow samples of patients with myelodysplastic syndrome. 2004 , 28, 921-5	9
826	Overexpression of delta-like (Dlk) in a subset of myelodysplastic syndrome bone marrow trephines. 2004 , 28, 1081-3	18
825	Association between phenotypic features of blasts and the blast percentage in bone marrow of patients with myelodysplastic syndromes. 2004 , 28, 1171-5	13
824	Evaluation of temozolomide in patients with myelodysplastic syndrome. 2004 , 45, 1209-14	3
823	Serum levels of CD137 ligand and CD178 are prognostic factors for progression of myelodysplastic syndrome. 2004 , 45, 301-8	14

822	Severe gingival bleeding in a myelodysplastic patient: management and outcome. 2004 , 75, 483-6	5
821	[Applications of molecular biology to care of patients with malignant hematological disease]. 2004 , 62, 401-20	1
820	Systemic mastocytosis associated with acute myeloid leukemia: case report and implications for disease pathogenesis. 2004 , 114, 28-33	18
819	Risk assessment in chronic myelomonocytic leukemia (CMML). 2004 , 45, 1311-8	106
818	The World Health Organization classification of myeloproliferative and myelodysplastic syndromes. 2004 , 10, 394-403	3
817	Accumulation of homoplasmic mtDNA point mutations in erythroblasts isolated from the bone marrow of patients with refractory anemia with ring sideroblasts (RARS). 2004 , 4, 321-9	2
816	[Disease associations in 250 patients with temporal (giant cell) arteritis]. 2004 , 33, 1304-12	11
815	Impact of TET2 mutations on response rate to azacitidine in myelodysplastic syndromes and low blast count acute myeloid leukemias. 2011 , 25, 1147-52	369
814	Draft consensus guidelines for diagnosis and treatment of Shwachman-Diamond syndrome. 2011 , 1242, 40-55	146
813	Lack of efficacy of pyridoxine (vitamin B6) treatment in acquired idiopathic sideroblastic anaemia, including refractory anaemia with ring sideroblasts. 2011 , 86, 512-6	2
812	Quality of life, physical function and MRI T2* in elderly low-risk MDS patients treated to a haemoglobin level of ≥ 120 g/L with darbepoetin alfa + filgrastim or erythrocyte transfusions. 2011 , 87, 244-52	47
811	Incidence and prevalence of myelodysplastic syndromes: data from the Düsseldorf MDS-registry. 2011 , 35, 1591-6	136
810	Idiopathic cytopenia of undetermined significance (ICUS) and idiopathic dysplasia of uncertain significance (IDUS), and their distinction from low risk MDS. 2012 , 36, 1-5	68
809	Classification and prognostic evaluation of myelodysplastic syndromes. 2011 , 38, 627-34	55
808	Computerized texture analysis of atypical immature myeloid precursors in patients with myelodysplastic syndromes: an entity between blasts and promyelocytes. 2011 , 6, 93	10
807	Mutational spectrum analysis of chronic myelomonocytic leukemia includes genes associated with epigenetic regulation: UTX, EZH2, and DNMT3A. 2011 , 118, 3932-41	265
806	Cigarette smoking shortens the survival of patients with low-risk myelodysplastic syndromes. 2011 , 22, 623-9	9
805	Iron status and treatment modalities in transfusion-dependent patients with myelodysplastic syndromes. 2011 , 90, 655-66	10

804	Clinical utility of the neutrophil distribution pattern obtained using the CELL-DYN SAPPHERE hematology analyzer for the diagnosis of myelodysplastic syndrome. 2011 , 94, 169-177	13
803	Azacitidine for the treatment of myelodysplastic syndromes in the elderly. 2011 , 28 Suppl 2, 10-5	1
802	Treatment of myelodysplastic syndromes in elderly patients. 2011 , 28 Suppl 2, 1-9	1
801	Azacitidine for the treatment of patients with acute myeloid leukemia with 20%-30% blasts and multilineage dysplasia. 2011 , 28 Suppl 3, 1-9	5
800	Treatment of poor-risk myelodysplastic syndromes and acute myeloid leukemia with a combination of 5-azacytidine and valproic acid. 2011 , 2, 389-99	36
799	Clinical observation of the treatment of myelodysplastic syndrome mainly with Qinghuang Powder. 2011 , 17, 834-9	17
798	The search for better prognostic models in myelodysplastic syndromes. 2011 , 6, 13-21	9
797	Therapeutic modalities for patients with lower-risk myelodysplastic syndromes: current options and future directions. 2011 , 6, 5-12	3
796	Management of lower-risk myelodysplastic syndromes: the art and evidence. 2011 , 6, 145-53	22
795	Integrative analysis of next generation sequencing for small non-coding RNAs and transcriptional regulation in Myelodysplastic Syndromes. 2011 , 4, 19	34
794	The physiology and pathology of inositide signaling in the nucleus. 2011 , 226, 14-20	26
793	Case-control study of risk factors of myelodysplastic syndromes according to World Health Organization classification in a Chinese population. 2011 , 86, 163-9	31
792	Partial and total monosomal karyotypes in myelodysplastic syndromes: comparative prognostic relevance among 421 patients. 2011 , 86, 540-5	26
791	Systemic and immune manifestations in myelodysplasia: a multicenter retrospective study. 2011 , 63, 1188-94	61
790	A Phase 2 study of combination therapy with arsenic trioxide and gemtuzumab ozogamicin in patients with myelodysplastic syndromes or secondary acute myeloid leukemia. 2011 , 117, 1253-61	26
789	Activity of azacitidine in chronic myelomonocytic leukemia. 2011 , 117, 2690-6	108
788	Continued azacitidine therapy beyond time of first response improves quality of response in patients with higher-risk myelodysplastic syndromes. 2011 , 117, 2697-702	139
787	Prognostic impact of severe thrombocytopenia in low-risk myelodysplastic syndrome. 2011 , 117, 5529-37	41

786	Serum CD44 levels predict survival in patients with low-risk myelodysplastic syndromes. 2011 , 78, 150-61	9
785	Evaluation of comorbidities at diagnosis predicts outcome in myelodysplastic syndrome patients. 2011 , 35, 159-62	33
784	Aberrant methylation of the RIZ1 gene in myelodysplastic syndrome and acute myeloid leukemia. 2011 , 35, 516-21	12
783	Aberrant methylation of tumor suppressor genes in patients with refractory anemia with ring sideroblasts. 2011 , 35, 479-83	7
782	The Myelodysplastic Syndromes (MDS) Foundation: a retrospective analysis of a nonprofit foundation. 2011 , 35, 283-5	1
781	Characteristics and outcome of myelodysplastic syndromes (MDS) with isolated 20q deletion: a report on 62 cases. 2011 , 35, 863-7	34
780	Flow cytometric scoring system as a diagnostic and prognostic tool in myelodysplastic syndromes. 2011 , 35, 868-73	49
779	Epigenetic regulation in myelodysplastic syndromes: implications for therapy. 2011 , 20, 465-93	16
778	Risk of myelodysplastic syndromes in people exposed to ionizing radiation: a retrospective cohort study of Nagasaki atomic bomb survivors. 2011 , 29, 428-34	82
777	Coalesced multicentric analysis of 2,351 patients with myelodysplastic syndromes indicates an underestimation of poor-risk cytogenetics of myelodysplastic syndromes in the international prognostic scoring system. 2011 , 29, 1963-70	121
776	Unusually long survival of a 67-year-old patient with near-tetraploid acute myeloid leukemia m0 without erythroblastic and megakaryocytic dysplasia. 2011 , 126, 129-34	4
775	Myelodysplastic/myeloproliferative neoplasms. 2011 , 391-406	
774	Cytogenetic abnormalities in myelodysplastic syndrome: an overview. 2011 , 16, 131-8	22
773	Retrospective epidemiological study of Latin American patients with transfusional hemosiderosis: the first Latin American epidemiological study in iron overload--the RELATH study. 2011 , 16, 265-73	9
772	Association of comorbidities with overall survival in myelodysplastic syndrome: development of a prognostic model. 2011 , 29, 2240-6	110
771	Myelodysplastic syndrome and histone deacetylase inhibitors: "to be or not to be acetylated"?. 2011 , 2011, 214143	16
770	Review of stem-cell transplantation for myelodysplastic syndromes in older patients in the context of the Decision Memo for Allogeneic Hematopoietic Stem Cell Transplantation for Myelodysplastic Syndrome emanating from the Centers for Medicare and Medicaid Services. 2011 , 29, 566-72	21
769	Prognostic relevance of cytogenetic systems in myelodysplastic syndromes. 2012 , 53, 1640-2	1

768	Myelodysplastic syndrome and benzene exposure among petroleum workers: an international pooled analysis. 2012 , 104, 1724-37	123
767	Impacts of cytogenetic categories in the Revised International Prognostic Scoring System on the prognosis of primary myelodysplastic syndromes: results of a single-center study. 2012 , 53, 940-6	13
766	How to manage lower-risk myelodysplastic syndromes. 2012 , 26, 390-4	5
765	Activation of nuclear inositide signalling pathways during erythropoietin therapy in low-risk MDS patients. 2012 , 26, 2474-82	29
764	C-terminal mutation of RUNX1 attenuates the DNA-damage repair response in hematopoietic stem cells. 2012 , 26, 303-11	32
763	Specific skin lesions in chronic myelomonocytic leukemia: a spectrum of myelomonocytic and dendritic cell proliferations: a study of 42 cases. 2012 , 36, 1302-16	68
762	Diagnosis and classification. 21-48	1
761	Myelodysplastic syndrome. 429-443	
760	Chronic myeloproliferative disorders. 444-502	3
759	[Bone marrow failure syndrome (idiopathic hematopoietic disorders): progress in diagnosis and treatment. Topics: III. Diagnosis and treatments; 3. Myelodysplastic syndrome]. 2012 , 101, 1945-52	
758	[Pharmacological profiles and clinical roles of 5-azacitidine (Vidaza(®)) for injection 100 mg) for the treatment of myelodysplastic syndrome (MDS)]. 2012 , 140, 235-43	1
757	Myelodysplasia presenting as thoracic spinal epidural extramedullary hematopoiesis: a rare treatable cause of spinal cord myelopathy. 2012 , 41, 611-4	7
756	Recurrent acute lower-limb ischemia with multiple organ infarctions secondary to acute myeloid leukaemia M1. 2012 , 26, 1128.e1-5	3
755	New comprehensive cytogenetic scoring system for primary myelodysplastic syndromes (MDS) and oligoblastic acute myeloid leukemia after MDS derived from an international database merge. 2012 , 30, 820-9	466
754	Emerging roles of the spliceosomal machinery in myelodysplastic syndromes and other hematological disorders. 2012 , 26, 2447-54	82
753	Revised international prognostic scoring system for myelodysplastic syndromes. 2012 , 120, 2454-65	1799
752	Clinical presentation, diagnosis, and prognosis of myelodysplastic syndromes. 2012 , 125, S6-13	38
751	Myelodysplastic syndromes: challenges to improving patient and caregiver satisfaction. 2012 , 125, S26-30	7

750	Erythroid proliferations in myeloid neoplasms. 2012 , 43, 153-64	23
749	Myelodysplastic syndrome in New Zealand and Australia. 2012 , 42, 1235-42	12
748	Azacitidine: a review of its use in the management of myelodysplastic syndromes/acute myeloid leukaemia. 2012 , 72, 1111-36	29
747	Allogeneic hematopoietic cell transplantation for myelodysplastic syndrome: the past decade. 2012 , 8, 373-81	5
746	Amonafide: a future in treatment of resistant and secondary acute myeloid leukemia?. 2012 , 5, 17-26	13
745	Targeting acute myeloid leukemia cells with cytokines. 2012 , 92, 567-75	9
744	Overview of myelodysplastic syndromes. 2012 , 49, 287-94	6
743	Clinical results with the DNA hypomethylating agent 5-aza-2'-deoxycytidine (decitabine) in patients with myelodysplastic syndromes: an update. 2012 , 49, 330-41	31
742	Introduction: application of new therapies to myelodysplastic syndrome. 2012 , 49, 285-6	
741	Comparison of autologous hematopoietic cell transplantation and chemotherapy as postremission treatment in non-M3 acute myeloid leukemia in first complete remission. 2012 , 12, 444-51	7
740	Efficacy of hypomethylating agents in therapy-related myelodysplastic syndromes. 2012 , 36, 1093-7	21
739	Improved survival with iron chelation therapy for red blood cell transfusion dependent lower IPSS risk MDS may be more significant in patients with a non-RARS diagnosis. 2012 , 36, 1380-6	30
738	Clinical and cytogenetic characteristics of myelodysplastic syndrome in patients with HIV infection. 2012 , 36, 1376-9	11
737	Prognostic scoring systems in MDS. 2012 , 36, 1463-9	19
736	Historical perspectives on myelodysplastic syndromes. 2012 , 36, 1441-52	8
735	The classification of MDS: from FAB to WHO and beyond. 2012 , 36, 1453-8	35
734	Molecular genetics in myelodysplastic syndromes. 2012 , 36, 1459-62	22
733	[Myelodysplastic syndrome in the elderly: comprehensive geriatric assessment and therapeutic recommendations]. 2012 , 138, 119.e1-9	1

732	Update on the science of myelodysplastic syndromes. 2012 , 16 Suppl, 9-22	2
731	Myelodysplastic Disorders. 2012 , 331-344	
730	Dysplasia has A differential diagnosis: distinguishing genuine myelodysplastic syndromes (MDS) from mimics, imitators, copycats and impostors. 2012 , 7, 310-20	63
729	Prognostic features of patients with myelodysplastic syndromes aged 2012, 53, 2439-43	6
728	The challenge of individualised risk assessment and therapy planning in elderly high-risk myelodysplastic syndromes (MDS) patients. 2012 , 91, 1333-43	33
727	Pregnancy complicated with myelodysplastic syndrome and severe preeclampsia: A case report. 2012 , 55, 745	
726	Azacitidine has limited activity in 'real life' patients with MDS and AML: a single centre experience. 2012 , 30, 76-81	20
725	Chronic myelomonocytic leukemia: 2012 update on diagnosis, risk stratification, and management. 2012 , 87, 610-9	37
724	Predicting survival of patients with hypocellular myelodysplastic syndrome: development of a disease-specific prognostic score system. 2012 , 118, 4462-70	35
723	Favorable survival maintained in children who have myeloid leukemia associated with Down syndrome using reduced-dose chemotherapy on Children's Oncology Group trial A2971: a report from the Children's Oncology Group. 2012 , 118, 4806-14	54
722	Evaluation of flow cytometric assessment of myeloid nuclear differentiation antigen expression as a diagnostic marker for myelodysplastic syndromes in a series of 269 patients. 2012 , 82, 295-304	12
721	Late effect of atomic bomb radiation on myeloid disorders: leukemia and myelodysplastic syndromes. 2012 , 95, 232-8	26
720	Features of Japanese patients with myelodysplastic syndrome in an aging population of Sado Island. 2012 , 95, 420-7	1
719	Angiogenesis and survival in patients with myelodysplastic syndrome. 2012 , 18, 681-90	15
718	Characteristics of MDS patients seen at private practices differ significantly from those treated at university hospitals in Germany. 2012 , 138, 953-7	2
717	Time changes in predictive power of established and recently proposed clinical, cytogenetical and comorbidity scores for Myelodysplastic Syndromes. 2012 , 36, 132-9	13
716	The utility of fluorescence in situ hybridization analysis in diagnosing myelodysplastic syndromes is limited to cases with karyotype failure. 2012 , 36, 448-52	22
715	The degree of neutropenia has a prognostic impact in low risk myelodysplastic syndrome. 2012 , 36, 287-92	16

714	The quest for the perfect MDS scoring system. 2012 , 36, 125-6		1
713	Morphologic analysis in myelodysplastic syndromes with del(5q) treated with lenalidomide. A Japanese multiinstitutional study. 2012 , 36, 575-80		1
712	Evaluation of dysplasia through detailed cytomorphology in 3156 patients from the Düsseldorf Registry on myelodysplastic syndromes. 2012 , 36, 727-34		53
711	Bortezomib combined with low-dose cytarabine in Intermediate-2 and high risk myelodysplastic syndromes. A phase I/II Study by the GFM. <i>British Journal of Haematology</i> , 2012 , 158, 232-237	4-5	11
710	Better prognosis for patients with del(7q) than for patients with monosomy 7 in myelodysplastic syndrome. 2012 , 118, 127-33		36
709	Treatment of myelodysplastic syndromes with excess of blasts by bevacizumab is well tolerated and is associated with a decrease of VEGF plasma level. 2012 , 91, 39-46		8
708	Microscopic examination of bone marrow aspirates in malignant disorders of haematopoiesis--a comparison of two slide preparation techniques. 2012 , 91, 497-505		4
707	Azacitidine might be beneficial in a subgroup of older AML patients compared to intensive chemotherapy: a single centre retrospective study of 227 consecutive patients. 2013 , 6, 29		45
706	Inter-observer variance with the diagnosis of myelodysplastic syndromes (MDS) following the 2008 WHO classification. 2013 , 92, 19-24		46
705	Development and validation of QOL-E [®] instrument for the assessment of health-related quality of life in myelodysplastic syndromes. 2013 , 8, 835-844		2
704	Border between aplastic anemia and myelodysplastic syndrome. 2013 , 97, 558-63		8
703	Effects of DNA methyltransferase inhibitors (DNMTi) on MDS-derived cell lines. 2013 , 41, 189-97		21
702	The myelodysplastic syndromes: a personal recollection of four decades of classification and prognostic scoring systems. 2013 , 54, 2588-91		2
701	Clinical prognostic factors for survival and risk of progression to acute myeloid leukemia in patients with myelodysplastic syndromes with 2013, 13, 144-52		15
700	High response rate and improved exercise capacity and quality of life with a new regimen of darbepoetin alfa with or without filgrastim in lower-risk myelodysplastic syndromes: a phase II study by the GFM. 2013 , 92, 621-31		34
699	Therapeutic effects of thalidomide in hematologic disorders: a review. 2013 , 7, 290-300		9
698	Myelodysplastic syndromes: toward a risk-adapted treatment approach. 2013 , 6, 611-24		21
697	Current therapy of myelodysplastic syndromes. 2013 , 27, 243-59		69

696	Monosomal karyotype in MDS: explaining the poor prognosis?. 2013 , 27, 1988-95	38
695	Monosomal karyotype predicts poor survival after allogeneic stem cell transplantation in chromosome 7 abnormal myelodysplastic syndrome and secondary acute myeloid leukemia. 2013 , 27, 879-88	39
694	Identification of gene expression-based prognostic markers in the hematopoietic stem cells of patients with myelodysplastic syndromes. 2013 , 31, 3557-64	39
693	Standardizing the initial evaluation for myelodysplastic syndromes. 2013 , 8, 361-9	4
692	Higher fetuin-A, lower adiponectin and free leptin levels mediate effects of excess body weight on insulin resistance and risk for myelodysplastic syndrome. 2013 , 62, 1830-9	28
691	Morphology, cytogenetics and classification of MDS. 2013 , 26, 337-53	31
690	Myelodysplastic syndromes should be renamed as myelodysplastic neoplasms. 2013 , 37, 463-4	1
689	Chronic myelomonocytic leukemia: 2013 update on diagnosis, risk stratification, and management. 2013 , 88, 967-74	22
688	Clinical evaluation of WT1 mRNA expression levels in peripheral blood and bone marrow in patients with myelodysplastic syndromes. 2013 , 54, 1450-8	20
687	Long-term outcome of immunosuppressive therapy for Japanese patients with lower-risk myelodysplastic syndromes. 2013 , 98, 687-93	4
686	There's risk, and then there's risk: The latest clinical prognostic risk stratification models in myelodysplastic syndromes. 2013 , 8, 351-60	31
685	Azacitidine in the treatment of therapy related myelodysplastic syndrome and acute myeloid leukemia (tMDS/AML): a report on 54 patients by the Groupe Francophone Des Myelodysplasies (GFM). 2013 , 37, 637-40	40
684	Diagnosis and treatment of primary myelodysplastic syndromes in adults: recommendations from the European LeukemiaNet. 2013 , 122, 2943-64	437
683	Prognostic factors and risk models in myelodysplastic syndromes. 2013 , 13 Suppl 2, S295-9	12
682	Current pathology practices in and barriers to MDS diagnosis. 2013 , 37, 1656-61	10
681	The immunomodulatory agents lenalidomide and thalidomide for treatment of the myelodysplastic syndromes: a clinical practice guideline. 2013 , 85, 162-92	8
680	Application of FISH 7q in MDS patients without monosomy 7 or 7q deletion by conventional G-banding cytogenetics: does -7/7q- detection by FISH have prognostic value?. 2013 , 37, 416-21	13
679	High frequency of NAD(P)H:quinone oxidoreductase 1 (NQO1) C(609)T germline polymorphism in MDS/AML with trisomy 8. 2013 , 37, 742-6	5

678	Update on Myelodysplastic Syndromes Classification and Prognosis. 2013 , 6, 693-728		1
677	Prognosis of acute myeloid leukemia transformed from myelodysplastic syndromes: a multicenter retrospective study. 2013 , 37, 862-7		10
676	The need for additional genetic markers for myelodysplastic syndrome stratification: what does the future hold for prognostication?. 2013 , 6, 59-68		13
675	Clinicopathologic analysis of acute myeloid leukemia arising from chronic myelomonocytic leukemia. 2013 , 26, 751-61		32
674	Classification of the Acute Leukemias: Cytochemical and Morphologic Considerations. 2013 , 213-239		
673	The Myelodysplastic Syndromes. 2013 , 487-518		1
672	Myelodysplasia: new approaches. 2013 , 14, 156-69		4
671	Pathology of the Chronic Myeloid Leukemias. 2013 , 19-28		
670	Comparative analysis between azacitidine and decitabine for the treatment of myelodysplastic syndromes. <i>British Journal of Haematology</i> , 2013 , 161, 339-47	4-5	67
669	[Myelodysplastic syndromes]. 2013 , 54, 699-708		
668	Aberrant hypomethylation of SALL4 gene in patients with myelodysplastic syndrome. 2013 , 37, 71-5		17
667	Response to lenalidomide in myelodysplastic syndromes with del(5q): influence of cytogenetics and mutations. <i>British Journal of Haematology</i> , 2013 , 162, 74-86	4-5	59
666	Refractory anemia with ring sideroblasts. 2013 , 26, 377-85		30
665	Surgical treatment for esophageal cancer patients with myelodysplastic syndrome. 2013 , 10, 149-152		1
664	Histopathological and immunohistochemical evaluation of bone marrow biopsy in myelodysplastic syndromes. 2013 , 2, 219-228		
663	Chronic myelomonocytic leukemia: a review of the molecular biology, prognostic models and treatment. 2013 , 2, 151-162		
662	Correlation between dysplastic lineage and type of cytopenia in myelodysplastic syndromes patients with refractory anemia according to the FAB classification. 2013 , 140, 253-7		
661	Role of reduced-intensity conditioning allogeneic hematopoietic stem-cell transplantation in older patients with de novo myelodysplastic syndromes: an international collaborative decision analysis. 2013 , 31, 2662-70		203

660	Epidemiology and risk factors for infections in myelodysplastic syndromes. 2013 , 15, 652-7	13
659	Efficacy of oral cytarabine ocfosfate and etoposide in the treatment of elderly patients with higher-risk myelodysplastic syndromes compared to that in elderly acute myeloid leukemia patients. 2013 , 59, 152-8	4
658	Single nucleotide polymorphism array karyotyping: a diagnostic and prognostic tool in myelodysplastic syndromes with unsuccessful conventional cytogenetic testing. 2013 , 52, 1167-77	28
657	Association of A(313)G glutathione S-transferase P1 germline polymorphism with susceptibility to de novo myelodysplastic syndrome. 2013 , 54, 1756-61	6
656	The impact of age on the diagnosis and therapy of myelodysplastic syndromes: results from a retrospective multicenter analysis in Germany. 2013 , 91, 473-82	15
655	Prognostic impact of RAS mutations in patients with myelodysplastic syndrome. 2013 , 88, 365-9	22
654	Proposed score for survival of patients with myelodysplastic syndromes. 2013 , 43, 1120-8	10
653	Long-term outcome of anemic lower-risk myelodysplastic syndromes without 5q deletion refractory to or relapsing after erythropoiesis-stimulating agents. 2013 , 27, 1283-90	54
652	Risk of therapy-related secondary leukemia in Hodgkin lymphoma: the Stanford University experience over three generations of clinical trials. 2013 , 31, 592-8	72
651	Revised International Prognostic Scoring System (IPSS) predicts survival and leukemic evolution of myelodysplastic syndromes significantly better than IPSS and WHO Prognostic Scoring System: validation by the Gruppo Romano Mielodisplasie Italian Regional Database. 2013 , 31, 2671-7	97
650	Impact of donor source on hematopoietic cell transplantation outcomes for patients with myelodysplastic syndromes (MDS). 2013 , 122, 1974-82	69
649	Development and validation of a prognostic scoring system for patients with chronic myelomonocytic leukemia. 2013 , 121, 3005-15	197
648	Allogeneic hematopoietic stem cell transplantation in Fanconi anemia: the European Group for Blood and Marrow Transplantation experience. 2013 , 122, 4279-86	142
647	[Leukemia: recent progress in diagnosis and treatment topics: II. Approach to diagnosis; 1. FAB classification and WHO classification of leukemias]. 2013 , 102, 1667-75	
646	A case of myelodysplastic syndrome with marked eosinophilia showing favorable prognosis. 2013 , 48, 222-5	1
645	Platelet apoptosis and agonist-mediated activation in myelodysplastic syndromes. 2013 , 109, 909-19	11
644	Distinct clinical and experimental characteristics in the patients younger than 60 years old with myelodysplastic syndromes. 2013 , 8, e57392	7
643	A Meta-Analysis of the Relationship between Cigarette Smoking and Incidence of Myelodysplastic Syndromes. 2013 , 8, e67537	24

642	Immunophenotyping in myelodysplastic syndromes can add prognostic information to well-established and new clinical scores. 2013 , 8, e81048	20
641	Acute myelogenous leukemia at Baylor Charles A. Sammons Cancer Center, 2010 to 2012: retrospective analysis of molecular genetic evaluation. 2014 , 27, 299-304	1
640	Stopping higher-risk myelodysplastic syndrome in its tracks. 2014 , 9, 421-31	2
639	Translational hematology. 2014 , 164, 487-96	
638	Cytogenetics and clinical features of pediatric myelodysplastic syndrome in Japan. 2014 , 100, 478-84	6
637	Myelodysplastic syndromes (MDS). 2014 , 7, 134-137	0
636	Identification of campath-1 (CD52) as novel drug target in neoplastic stem cells in 5q-patients with MDS and AML. 2014 , 20, 3589-602	19
635	Clinical features of de novo acute myeloid leukemia with concurrent DNMT3A, FLT3 and NPM1 mutations. 2014 , 7, 74	60
634	Expression of nucleoside-metabolizing enzymes in myelodysplastic syndromes and modulation of response to azacitidine. 2014 , 28, 621-8	68
633	Validation of the IPSS-R in lenalidomide-treated, lower-risk myelodysplastic syndrome patients with del(5q). 2014 , 4, e242	19
632	The Porphyrias and Sideroblastic Anemias. 2014 , 1488-1498	
631	Cytogenetic as an important tool for diagnosis and prognosis for patients with hypocellular primary myelodysplastic syndrome. 2014 , 2014, 542395	7
630	+ 252A/G polymorphism in lymphotoxin- β gene influences long-term survival in patients with myelodysplastic syndrome with excess blasts. 2014 , 55, 1406-7	1
629	Eltrombopag can overcome the anti-megakaryopoietic effects of lenalidomide without increasing proliferation of the malignant myelodysplastic syndrome/acute myelogenous leukemia clone. 2014 , 55, 2901-6	8
628	Prognostic assessment in myelodysplastic syndromes. 2014 , 70-84	
627	Peroxiredoxin 2 expression is increased in neutrophils of patients with refractory cytopenia with multilineage dysplasia. <i>British Journal of Haematology</i> , 2014 , 166, 720-8	4.5 6
626	De novo acute myeloid leukemia with 20-29% blasts is less aggressive than acute myeloid leukemia with \geq 30% blasts in older adults: a Bone Marrow Pathology Group study. 2014 , 89, E193-9	17
625	IPSS-R in 555 Taiwanese patients with primary MDS: Integration of monosomal karyotype can better risk-stratify the patients. 2014 , 89, E142-9	14

624	Refined medullary blast and white blood cell count based classification of chronic myelomonocytic leukemias. 2014 , 38, 1413-9	60
623	BRAF kinase domain mutations are present in a subset of chronic myelomonocytic leukemia with wild-type RAS. 2014 , 89, 499-504	28
622	IDH mutations are closely associated with mutations of DNMT3A, ASXL1 and SRSF2 in patients with myelodysplastic syndromes and are stable during disease evolution. 2014 , 89, 137-44	68
621	Positive impact of chronic graft-versus-host disease on the outcome of patients with de novo myelodysplastic syndrome after allogeneic hematopoietic cell transplantation: a single-center analysis of 115 patients. 2014 , 92, 137-46	10
620	Impact of comorbidities by ACE-27 in the revised-IPSS for patients with myelodysplastic syndromes. 2014 , 89, 509-16	22
619	Clinical implications of the SETBP1 mutation in patients with primary myelodysplastic syndrome and its stability during disease progression. 2014 , 89, 181-6	49
618	Lessons from the atomic bomb about secondary MDS. 2014 , 9, 407-11	1
617	Results of treatment with azacitidine in patients aged \geq 75 years included in the Spanish Registry of Myelodysplastic Syndromes. 2014 , 55, 1300-3	15
616	Myelodysplastic syndromes in the United States: an update for clinicians. 2014 , 46, 283-9	19
615	The Myelodysplastic Syndromes. 2014 , 42-48	
614	Dysplasia features of myelodysplastic syndrome in ethnically Chinese people. 2014 , 131, 126-32	4
613	Risk for developing myelodysplastic syndromes in prostate cancer patients definitively treated with radiation. 2014 , 106, djt462	17
612	Initially lymphocytic Sweet's syndrome in male patients with myelodysplasia: a distinguished clinicopathological entity? Case report and systematic review of the literature. 2014 , 132, 220-5	9
611	Disseminated noninterstitial granulomatous dermatitis as a cutaneous manifestation of the preleukemic state in a patient with myelodysplasia and ulcerative colitis--apropos a case and review of the literature. 2014 , 36, e117-20	6
610	Validation of the revised international prognostic scoring system (IPSS-R) in patients with myelodysplastic syndrome: a multicenter study. 2014 , 38, 57-64	50
609	Receptors, cells and circuits involved in pruritus of systemic disorders. 2014 , 1842, 869-92	62
608	Application of the revised International Prognostic Scoring System for myelodysplastic syndromes in Argentinean patients. 2014 , 93, 705-7	2
607	Gene mutations differently impact the prognosis of the myelodysplastic and myeloproliferative classes of chronic myelomonocytic leukemia. 2014 , 89, 604-9	32

606	Treatment of older patients with high-risk myelodysplastic syndromes (MDS): the emerging role of allogeneic hematopoietic stem cell transplantation (Allo HSCT). 2014 , 9, 57-65		11
605	Guidelines for the diagnosis and management of adult myelodysplastic syndromes. <i>British Journal of Haematology</i> , 2014 , 164, 503-25	4.5	69
604	Proposal for refining the definition of dysgranulopoiesis in acute myeloid leukemia and myelodysplastic syndromes. 2014 , 38, 447-53		34
603	Bone marrow hypocellularity does not affect tolerance or efficacy of azacitidine in patients with higher-risk myelodysplastic syndromes. <i>British Journal of Haematology</i> , 2014 , 165, 49-56	4.5	7
602	Prognostic impact of blast cell counts in dysplastic bone marrow disorders (MDS and CMML I) with concomitant fibrosis. 2014 , 93, 57-64		13
601	Trends in incidence, initial treatment and survival of myelodysplastic syndromes: a population-based study of 5144 patients diagnosed in the Netherlands from 2001 to 2010. 2014 , 50, 1004-12		39
600	Improved risk stratification by the integration of the revised international prognostic scoring system with the myelodysplastic syndromes comorbidity index. 2014 , 50, 3198-205		24
599	Myelodysplastic/Myeloproliferative Neoplasms. 2014 , 511-552		
598	Myelodysplastic Syndromes. 2014 , 181-284		
597	Acute Myeloid Leukaemia. 2014 , 285-421		1
596	High flow cytometric scores identify adverse prognostic subgroups within the revised international prognostic scoring system for myelodysplastic syndromes. <i>British Journal of Haematology</i> , 2014 , 167, 100-9	4.5	21
595	Specific abnormalities versus number of abnormalities and cytogenetic scoring systems for outcome prediction after allogeneic hematopoietic SCT for myelodysplastic syndromes. 2014 , 49, 1022-8		6
594	Chronic myelomonocytic leukemia prognostic classification and management: evidence base and current practice. 2014 , 9, 301-10		2
593	Significance of telomere capture in myelodysplastic syndromes. 2014 , 31, 216		
592	The role of telomeres and telomerase in hematologic malignancies and hematopoietic stem cell transplantation. 2014 , 7, 61		27
591	Multivariate time-dependent comparison of the impact of lenalidomide in lower-risk myelodysplastic syndromes with chromosome 5q deletion. <i>British Journal of Haematology</i> , 2014 , 166, 189-201	4.5	12
590	Hematopoietic stem cell transplantation in children and young adults with secondary myelodysplastic syndrome and acute myelogenous leukemia after aplastic anemia. 2014 , 20, 425-9		12
589	Isolated clonal cytogenetic abnormalities after high-dose therapy. 2014 , 20, 1130-8		6

588	A prognostic model of therapy-related myelodysplastic syndrome for predicting survival and transformation to acute myeloid leukemia. 2014 , 14, 401-10		41
587	Challenges of phase III trial design for novel treatments in diseases with no standard treatment: the AZA-001 myelodysplasia study model. 2014 , 38, 258-62		5
586	Predicting response to epigenetic therapy. 2014 , 124, 47-55		56
585	Morphology of Blood Cells. 2014 , 67-185		1
584	Two splice-factor mutant leukemia subgroups uncovered at the boundaries of MDS and AML using combined gene expression and DNA-methylation profiling. 2014 , 123, 3327-35		45
583	Predictive factors for the outcome of allogeneic transplantation in patients with MDS stratified according to the revised IPSS-R. 2014 , 123, 2333-42		119
582	Five-aza-2'-deoxycytidine-induced hypomethylation of cholesterol 25-hydroxylase gene is responsible for cell death of myelodysplasia/leukemia cells. 2015 , 5, 16709		15
581	Genes break barrier between MDS and AML. 2015 , 125, 9-10		4
580	The level of bone marrow WT1 message is a useful marker to differentiate myelodysplastic syndromes with low blast percentage from cytopenia due to other reasons. 2015 , 54, 445-51		5
579	Myelodysplastic syndromes in South America: a multinational study of 1080 patients. 2015 , 90, 851-8		7
578	Validation of the revised international prognostic scoring system (IPSS-R) in patients with lower-risk myelodysplastic syndromes: a report from the prospective European LeukaemiaNet MDS (EUMDS) registry. <i>British Journal of Haematology</i> , 2015 , 170, 372-83	4-5	47
577	Myelodysplastic syndromes and myelodysplastic/myeloproliferative neoplasms: an update on risk stratification, molecular genetics, and therapeutic approaches including allogeneic hematopoietic stem cell transplantation. 2015 , e398-412		8
576	Hematopoietic cell transplantation for myelodysplastic syndrome. 2015 , e375-80		6
575	Radiotherapy- and chemotherapy-induced myelodysplasia syndrome: a nationwide population-based nested case-control study. 2015 , 94, e737		15
574	Treatment of Patients With Myelodysplastic Syndrome With Lenalidomide in Clinical Routine in Austria. 2015 , 15, e143-9		1
573	Hematopoietic stem cell transplantation in children with refractory cytopenia of childhood: single-center experience using high-dose cytarabine containing myeloablative and aplastic anemia oriented reduced-intensity conditioning regimens. 2015 , 21, 565-9		14
572	Immunophenotyping for diagnosis and prognosis in MDS: ready for general application?. 2015 , 28, 14-21		6
571	Wilms tumor gene 1 expression as a predictive marker for relapse and survival after hematopoietic stem cell transplantation for myelodysplastic syndromes. 2015 , 21, 460-7		11

570	Specific scoring systems to predict survival of patients with high-risk myelodysplastic syndrome (MDS) and de novo acute myeloid leukemia (AML) after intensive antileukemic treatment based on results of the EORTC-GIMEMA AML-10 and intergroup CRIANT studies. 2015 , 94, 23-34	10
569	Multiparameter flow cytometry provides independent prognostic information in patients with suspected myelodysplastic syndromes: A study on 804 patients. 2015 , 88, 154-64	17
568	Clonal origin and evolution of myelodysplastic syndrome analyzed by dysplastic morphology and fluorescence in situ hybridization. 2015 , 101, 58-66	1
567	Interobserver variance in myelodysplastic syndromes with less than 5 % bone marrow blasts: unilineage vs. multilineage dysplasia and reproducibility of the threshold of 2 % blasts. 2015 , 94, 565-73	38
566	Acute Myeloid Leukemia With Myelodysplasia-Related Changes. 2015 , 144, 29-43	37
565	Myelodysplastic syndromes in Chernobyl clean-up workers. 2015 , 94, 1639-43	2
564	10th anniversary of the Austrian MDS Platform: aims and ongoing projects. 2015 , 127, 12-5	1
563	SF3B1 mutation identifies a distinct subset of myelodysplastic syndrome with ring sideroblasts. 2015 , 126, 233-41	269
562	Chronic myelomonocytic leukemia: Forefront of the field in 2015. 2015 , 95, 222-42	19
561	Clonal hematopoiesis of indeterminate potential and its distinction from myelodysplastic syndromes. 2015 , 126, 9-16	1005
560	RETRACTED ARTICLE: 5-Azacididine for treating acute myelogenous leukemia. 2015 , 3, 1197-1207	1
559	Decitabine versus best supportive care in older patients with refractory anemia with excess blasts in transformation (RAEBt) - results of a subgroup analysis of the randomized phase III study 06011 of the EORTC Leukemia Cooperative Group and German MDS Study Group (GMDSSG). 2015 , 94, 2003-13	19
558	Impact of TET2, SRSF2, ASXL1 and SETBP1 mutations on survival of patients with chronic myelomonocytic leukemia. 2015 , 4, 14	26
557	Whole-exome sequencing enhances prognostic classification of myeloid malignancies. 2015 , 58, 104-113	9
556	Anemia as the Main Manifestation of Myelodysplastic Syndromes. 2015 , 52, 348-56	25
555	The role of magnetic resonance imaging in the evaluation of transfusional iron overload in myelodysplastic syndromes. 2015 , 37, 252-8	3
554	Flow cytometry immunophenotypic findings in chronic myelomonocytic leukemia and its utility in monitoring treatment response. 2015 , 95, 168-76	26
553	Evolution of iron overload in patients with low-risk myelodysplastic syndrome: iron chelation therapy and organ complications. 2015 , 94, 779-87	47

552	Prognostic relevance of the flow cytometric count of medullar blasts in myelodysplastic syndromes. 2015 , 94, 519-25		1
551	The myelodysplastic syndromes: the era of understanding. 2015 , 94, 379-90		7
550	Prognostic Impact of IPSS-R and Chromosomal Translocations in 751 Korean Patients with Primary Myelodysplastic Syndrome. 2016 , 11, e0166245		5
549	Mutational spectrum and risk stratification of intermediate-risk acute myeloid leukemia patients based on next-generation sequencing. 2016 , 7, 32065-78		24
548	Allogeneic stem cell transplantation in myelodysplastic syndromes: does pretransplant clonal burden matter?. 2016 , 23, 167-74		13
547	Standard dose and prolonged administration of azacitidine are associated with improved efficacy in a real-world group of patients with myelodysplastic syndrome or low blast count acute myeloid leukemia. 2016 , 96, 344-51		24
546	Impact of socioeconomic status on disease phenotype, genomic landscape and outcomes in myelodysplastic syndromes. <i>British Journal of Haematology</i> , 2016 , 174, 227-34	4-5	4
545	Response to erythropoietic-stimulating agents in patients with chronic myelomonocytic leukemia. 2016 , 97, 33-8		21
544	Chronic myelomonocytic leukemia (myelodysplastic type) in transformation to acute myeloid leukemia (diagnostic and therapeutic options: case report and literature review / Leucemie mielomonocitar (cronic) forma mielodisplazic in transformare spre leucemie acut (mieloid) diagnostic si optiuni terapeutice: prezentare de caz si revizuirea literaturii. 2016 , 24, 263-277		
543	Role of microRNA-29b in myelodysplastic syndromes during transformation to overt leukaemia. 2016 , 48, 233-41		5
542	Quality control initiative on the evaluation of the dysmegakaryopoiesis in myeloid neoplasms: Difficulties in the assessment of dysplasia. 2016 , 45, 75-81		21
541	Azacitidine versus decitabine in patients with refractory anemia with excess blast-Results of multicenter study. 2016 , 45, 82-9		9
540	Scoring System Prognostic of Outcome in Patients Undergoing Allogeneic Hematopoietic Cell Transplantation for Myelodysplastic Syndrome. 2016 , 34, 1864-71		46
539	Haploidentical transplant for myelodysplastic syndrome: registry-based comparison with identical sibling transplant. 2016 , 30, 2055-2063		63
538	β-Hemoglobin-stabilizing Protein: An Effective Marker for Erythroid Precursors in Bone Marrow Biopsy Specimens. 2016 , 24, 51-6		6
537	Palbociclib treatment of FLT3-ITD+ AML cells uncovers a kinase-dependent transcriptional regulation of FLT3 and PIM1 by CDK6. 2016 , 127, 2890-902		69
536	PDE4 Differential Expression Is a Potential Prognostic Factor and Therapeutic Target in Patients With Myelodysplastic Syndrome and Chronic Myelomonocytic Leukemia. 2016 , 16 Suppl, S67-73		3
535	Mammalian-target of rapamycin inhibition with temsirolimus in myelodysplastic syndromes (MDS) patients is associated with considerable toxicity: results of the temsirolimus pilot trial by the German MDS Study Group (D-MDS). <i>British Journal of Haematology</i> , 2016 , 175, 917-924	4-5	6

534	Hematopoietic Cell Transplantation for Juvenile Myelomonocytic Leukemia. 2016 , 554-565		
533	Hematopoietic Cell Transplantation for Myelodysplastic Syndromes and Myeloproliferative Neoplasms. 2016 , 613-627		
532	Effect of granulocyte colony-stimulating factor priming combined with low-dose cytarabine and homoharringtonine in higher risk myelodysplastic syndrome patients. 2016 , 48, 57-61		5
531	Chronic myelomonocytic leukemia: 2016 update on diagnosis, risk stratification, and management. 2016 , 91, 631-42		47
530	Myelodysplastic syndromes: Contemporary review and how we treat. 2016 , 91, 76-89		119
529	Abnormal neutrophil scattergram obtained using Pentra MS CRP in the patients with myelodysplastic syndrome showing dysgranulopoiesis. 2016 , 38, 27-33		7
528	Erythroleukemia shares biological features and outcome with myelodysplastic syndromes with excess blasts: a rationale for its inclusion into future classifications of myelodysplastic syndromes. 2016 , 29, 1541-1551		11
527	Changes in the Updated 2016: WHO Classification of the Myelodysplastic Syndromes and Related Myeloid Neoplasms. 2016 , 16, 607-609		26
526	Considering Bone Marrow Blasts From Nonerythroid Cellularity Improves the Prognostic Evaluation of Myelodysplastic Syndromes. 2016 , 34, 3284-92		18
525	Unravelling the relevance of CLEC12A as a cancer stem cell marker in myelodysplastic syndrome. <i>British Journal of Haematology</i> , 2016 , 175, 393-401	4.5	16
524	Up-regulation of ribosomal genes is associated with a poor response to azacitidine in myelodysplasia and related neoplasms. 2016 , 104, 566-573		7
523	Recent advances in the understanding of myelodysplastic syndromes with ring sideroblasts. <i>British Journal of Haematology</i> , 2016 , 174, 847-58	4.5	20
522	Good riddance to the term "refractory anemia" in myelodysplastic syndromes. 2016 , 51, 22-26		3
521	Analysis of hematopathology and alteration of JAK1/STAT3/STAT5 signaling axis in experimental myelodysplastic syndrome. 2016 , 260, 176-185		10
520	Azacitidine front-line in 339 patients with myelodysplastic syndromes and acute myeloid leukaemia: comparison of French-American-British and World Health Organization classifications. 2016 , 9, 39		28
519	Could the mosaic pattern of chromosomal abnormality predict overall survival of patients with myelodysplastic syndrome?. 2016 , 9, 41-7		1
518	Unraveling Myelodysplastic Syndromes: Current Knowledge and Future Directions. 2016 , 18, 4		14
517	Multiparameter flow cytometry is instrumental to distinguish myelodysplastic syndromes from non-neoplastic cytopenias. 2016 , 54, 49-56		25

516	Pre- and post-treatment serum ferritin levels in patients with higher risk myelodysplastic syndromes receiving azacitidine. 2016 , 57, 2709-11	2
515	Allogeneic hematopoietic stem cell transplantation for myelofibrosis and chronic myelomonocytic leukemia. 2016 , 91, 123-30	6
514	Proposal of criteria for dyserythropoiesis in the diagnosis of myelodysplastic syndromes. 2016 , 103, 227-33	3
513	SF3B1-mutated myelodysplastic syndrome with ring sideroblasts harbors more severe iron overload and corresponding over-erythropoiesis. 2016 , 44, 8-16	12
512	Rigosertib versus best supportive care for patients with high-risk myelodysplastic syndromes after failure of hypomethylating drugs (ONTIME): a randomised, controlled, phase 3 trial. 2016 , 17, 496-508	112
511	Sensitivity, Specificity, and Posttest Probability of Parotid Fine-Needle Aspiration: A Systematic Review and Meta-analysis. 2016 , 154, 9-23	89
510	A method for determining both multiple refractive indices and 3D substructure of a binucleate cell. 2016 , 365, 113-119	3
509	The myelodysplastic syndromes flow cytometric score: a three-parameter prognostic flow cytometric scoring system. 2016 , 30, 658-65	32
508	Hypermethylation of DLX4 predicts poor clinical outcome in patients with myelodysplastic syndrome. 2016 , 54, 865-71	8
507	Results of a phase II study of thalidomide and azacitidine in patients with clinically advanced myelodysplastic syndromes (MDS), chronic myelomonocytic leukemia (CMML) and low blast count acute myeloid leukemia (AML). 2017 , 58, 298-307	9
506	Occupational, dietary, and other risk factors for myelodysplastic syndromes in Western Greece. 2017 , 22, 419-429	13
505	New proposals of the WHO working group (2016) for the diagnosis of myelodysplastic syndromes (MDS): Characteristics of refined MDS types. 2017 , 57, 78-84	18
504	Efficacy, safety, and pharmacokinetics of subcutaneous azacitidine in Taiwanese patients with higher-risk myelodysplastic syndromes. 2017 , 13, e430-e439	2
503	An exploratory clinical trial of bortezomib in patients with lower risk myelodysplastic syndromes. 2017 , 92, 674-682	17
502	Validation of the revised International Prognostic Scoring System in patients with myelodysplastic syndrome in Japan: results from a prospective multicenter registry. 2017 , 106, 375-384	15
501	GPX3 methylation in bone marrow predicts adverse prognosis and leukemia transformation in myelodysplastic syndrome. 2017 , 6, 267-274	20
500	Diagnostic value of platelet indices and bone marrow megakaryocytic parameters in immune thrombocytopenic purpura. 2017 , 28, 83-90	19
499	Oligomonocytic chronic myelomonocytic leukemia (chronic myelomonocytic leukemia without absolute monocytosis) displays a similar clinicopathologic and mutational profile to classical chronic myelomonocytic leukemia. 2017 , 30, 1213-1222	36

498	Influence of TNF and IL6 gene polymorphisms on the severity of cytopenias in Argentine patients with myelodysplastic syndromes. 2017 , 96, 1287-1295		2
497	Accumulation of classical monocytes defines a subgroup of MDS that frequently evolves into CMML. 2017 , 130, 832-835		39
496	The Nature of Leukaemia, Cytology, Cytochemistry and the Morphological Classification of Acute Leukaemia. 2017 , 1-68		
495	The Myelodysplastic Syndromes and the Myelodysplastic/Myeloproliferative Neoplasms. 2017 , 295-370		
494	Natural history of chronic myelomonocytic leukemia treated with hypomethylating agents. 2017 , 92, 599-606		32
493	Cytogenetics and comorbidity predict outcomes in older myelodysplastic syndrome patients after allogeneic stem cell transplantation using reduced intensity conditioning. 2017 , 123, 2661-2670		8
492	Infectious complications in patients with myelodysplastic syndromes: A review of the literature with emphasis on patients treated with 5-azacitidine. 2017 , 99, 112-118		11
491	Enumerating bone marrow blasts from nonerythroid cellularity improves outcome prediction in myelodysplastic syndromes and permits a better definition of the intermediate risk category of the Revised International Prognostic Scoring System (IPSS-R). 2017 , 92, 614-621		8
490	The only thing that is constant is change: The 2016 revision to the World Health Organisation classification of myelodysplastic syndrome. 2017 , 57, 102-103		
489	The incorporation of comorbidities in the prognostication of patients with lower-risk myelodysplastic syndrome. 2017 , 58, 1893-1902		6
488	TP53 mutations predict decitabine-induced complete responses in patients with myelodysplastic syndromes. <i>British Journal of Haematology</i> , 2017 , 176, 600-608	4.5	45
487	Models of Prognostication in Chronic Myelomonocytic Leukemia. 2017 , 12, 513-521		6
486	Individual risk assessment in MDS in the era of genomic medicine. 2017 , 54, 133-140		2
485	Novel treatment opportunities for sulfur mustard-related cancers: genetic and epigenetic perspectives. 2017 , 91, 3717-3735		8
484	Nuances of Morphology in Myelodysplastic Diseases in the Age of Molecular Diagnostics. 2017 , 12, 448-454		3
483	Smoking and alcohol and subsequent risk of myelodysplastic syndromes in Japan: the Japan Public Health Centre-based Prospective Study. <i>British Journal of Haematology</i> , 2017 , 178, 747-755	4.5	11
482	DICER1 gene and miRNA dysregulation in mesenchymal stem cells of patients with myelodysplastic syndrome and acute myeloblastic leukemia. 2017 , 63, 62-71		19
481	Azacitidine in adult patients with acute myeloid leukemia. 2017 , 116, 159-177		31

480	Clinical characteristics and outcomes according to age in lenalidomide-treated patients with RBC transfusion-dependent lower-risk MDS and del(5q). 2017 , 10, 131	4
479	Outcomes of Allogeneic Hematopoietic Stem Cell Transplantation in Adult Patients with Myelodysplastic Syndrome Harboring Trisomy 8. 2017 , 23, 75-80	2
478	Negative impact on clinical outcome of the mutational co-occurrence of SF3B1 and DNMT3A in refractory anemia with ring sideroblasts (RARS). 2017 , 58, 1686-1693	12
477	Cytogenetic profiling by FISH microscopy and comparison with light microscopy and complete blood count findings in myelodysplastic syndrome. 2017 , 265, 94-100	1
476	An miRNA-DNMT1 Axis Is Involved in Azacitidine Resistance and Predicts Survival in Higher-Risk Myelodysplastic Syndrome and Low Blast Count Acute Myeloid Leukemia. 2017 , 23, 3025-3034	17
475	Diagnostics and Prognostication of Myelodysplastic Syndromes. 2017 , 37, 465-474	13
474	Erythrocyte and Leucocyte Cytochemistry. 2017 , 312-329	2
473	Proposed minimal diagnostic criteria for myelodysplastic syndromes (MDS) and potential pre-MDS conditions. 2017 , 8, 73483-73500	99
472	Azacitidine Use for Myeloid Neoplasms. 2018 , 18, e147-e155	3
471	The prognostic value of monosomal karyotype (MK) in higher-risk patients with myelodysplastic syndromes treated with 5-Azacitidine: A retrospective analysis of the Hellenic (Greek) Myelodysplastic syndromes Study Group. 2018 , 93, 895-901	8
470	Inter-observer variance and the need for standardization in the morphological classification of myelodysplastic syndrome. 2018 , 69, 54-59	13
469	Incorporation of mutations in five genes in the revised International Prognostic Scoring System can improve risk stratification in the patients with myelodysplastic syndrome. 2018 , 8, 39	43
468	Changing role of bone marrow examination in the diagnosis of hematological malignancies. 2018 , 59, 2018-2020	1
467	Iron overload in lower international prognostic scoring system risk patients with myelodysplastic syndrome receiving red blood cell transfusions: Relation to infections and possible benefit of iron chelation therapy. 2018 , 67, 75-81	13
466	Association of red cell distribution width with clinical outcomes in myelodysplastic syndrome. 2018 , 67, 56-59	10
465	Chromosomal analysis of myelodysplastic syndromes among atomic bomb survivors in Nagasaki. <i>British Journal of Haematology</i> , 2018 , 180, 381-390	4.5 3
464	Efficacy, safety and pharmacokinetics of subcutaneous azacitidine in Chinese patients with higher risk myelodysplastic syndromes: Results from a multicenter, single-arm, open-label phase 2 study. 2018 , 14, 270-278	4
463	Is bone marrow examination always necessary to establish the diagnosis of myelodysplastic syndromes? A proposed non-invasive diagnostic model. 2018 , 59, 2227-2232	2

462	Diagnosis, management and response criteria of iron overload in myelodysplastic syndromes (MDS): updated recommendations of the Austrian MDS platform. 2018 , 11, 109-116	3
461	Dynamics of mutation and prognostic relevance in patients with primary myelodysplastic syndrome. 2018 , 10, 42	22
460	Maternal Exposure to Pesticides, Paternal Occupation in the Army/Police Force, and CYP2D6*4 Polymorphism in the Etiology of Childhood Acute Leukemia. 2018 , 40, e207-e214	6
459	Classification of the Acute Leukemias: Cytochemical and Morphologic Considerations. 2018 , 197-236	
458	Association of bone marrow fibrosis with inferior survival outcomes in chronic myelomonocytic leukemia. 2018 , 97, 1183-1191	11
457	Verification of Survival Predictors in Elderly Patients with Myelodysplastic Syndrome from Outpatient Clinical Practice. 2018 , 12, 27-31	0
456	Effects of vascular endothelial growth factors and their receptors on megakaryocytes and platelets and related diseases. <i>British Journal of Haematology</i> , 2018 , 180, 321-334	4-5 23
455	NY-ESO-1 Vaccination in Combination with Decitabine Induces Antigen-Specific T-lymphocyte Responses in Patients with Myelodysplastic Syndrome. 2018 , 24, 1019-1029	55
454	Intragenic hypomethylation of DNMT3A in patients with myelodysplastic syndrome. 2018 , 56, 485-491	2
453	A phase I study of lenalidomide in patients with chronic myelomonocytic leukemia (CMML) - AGMT_CMML-1. 2018 , 59, 1121-1126	1
452	Validation of Immunohistochemical Assays for Integral Biomarkers in the NCI-MATCH EAY131 Clinical Trial. 2018 , 24, 521-531	44
451	Myelodysplastic syndromes without peripheral monocytosis but with evidence of marrow monocytosis share clinical and molecular characteristics with CMML. 2018 , 65, 1-4	13
450	Shanghai Health Study (2001-2009): What was learned about benzene health effects?. 2018 , 48, 217-251	20
449	Iron chelation therapy in lower IPSS risk myelodysplastic syndromes; which subtypes benefit?. 2018 , 64, 24-29	8
448	DNA methylation profile in chronic myelomonocytic leukemia associates with distinct clinical, biological and genetic features. 2018 , 13, 8-18	8
447	Azacitidine in Lower-Risk Myelodysplastic Syndromes: A Meta-Analysis of Data from Prospective Studies. 2018 , 23, 159-170	16
446	Therapeutic Vulnerabilities in -Mutant AML Unmasked by Palbociclib. 2018 , 19,	7
445	Clonal architecture in patients with myelodysplastic syndromes and double or minor complex abnormalities: Detailed analysis of clonal composition, involved abnormalities, and prognostic significance. 2018 , 57, 547-556	0

444	Azacitidine with or without eltrombopag for first-line treatment of intermediate- or high-risk MDS with thrombocytopenia. 2018 , 132, 2629-2638		50
443	Myelodysplastic Syndromes: Laboratory Workup in the Context of New Concepts and Classification Criteria. 2018 , 13, 467-476		4
442	Incidence of Myelodysplastic Syndromes in a Major Canadian Metropolitan Area. 2018 , 3, 378-383		1
441	Differing clinical features between Japanese and Caucasian patients with myelodysplastic syndromes: Analysis from the International Working Group for Prognosis of MDS. 2018 , 73, 51-57		13
440	How I use molecular genetic tests to evaluate patients who have or may have myelodysplastic syndromes. 2018 , 132, 1657-1663		28
439	Myelodysplastic Syndromes. 2018 , 539-563.e2		1
438	Five-day regimen of azacitidine for lower-risk myelodysplastic syndromes (refractory anemia or refractory anemia with ringed sideroblasts): A prospective single-arm phase 2 trial. 2018 , 109, 3209-3215		9
437	Evaluation of Parameters Related to the Probability of Leukemic Progression in Patients With Lower-Risk Myelodysplastic Syndrome. 2018 , 18, 469-474.e1		0
436	Hypomethylating Agents-associated Infections-Systematic Review and Meta-analysis of Randomized Controlled Trials. 2018 , 18, 603-610.e1		2
435	Gene mutations and clonal architecture in myelodysplastic syndromes and changes upon progression to acute myeloid leukaemia and under treatment. <i>British Journal of Haematology</i> , 2018 , 182, 830-842	4.5	12
434	Can bone marrow cellularity help in predicting prognosis in myelodysplastic syndromes?. 2018 , 101, 502-507		4
433	Heme Biosynthesis and Its Disorders. 2018 , 497-513.e6		1
432	Progress in the Classification of Hematopoietic and Lymphoid Neoplasms. 2018 , 763-773		
431	Myelodysplastic Syndromes. 2018 , 944-969.e13		0
430	Myelodysplastic Syndromes and Myeloproliferative Neoplasms in Children. 2018 , 994-1004.e7		
429	Regulation of Malignant Hematopoiesis by Bone Marrow Microenvironment. 2018 , 8, 119		9
428	Minimally invasive mitral valve repair via right mini-thoracotomy in patient with myelodysplastic syndrome. 2018 , 13, 45		
427	More is less, less is more, or does it really matter? The curious case of impact of azacitidine administration schedules on outcomes in patients with myelodysplastic syndromes. 2018 , 18, 4		5

426	Part 2: Myelodysplastic syndromes - classification systems. 2018 , 40, 262-266	0
425	Molecular Basis of Lymphoid and Myeloid Diseases. 2018 , 299-328	1
424	Interobserver concordance of assessments of dysplasia and blast counts for the diagnosis of patients with cytopenia: From the Japanese central review study. 2018 , 74, 137-143	5
423	The current approach to the diagnosis of myelodysplastic syndromes. 2019 , 56, 15-21	9
422	The Austrian biodatabase for chronic myelomonocytic leukemia (ABCMML) : A representative and useful real-life data source for further biomedical research. 2019 , 131, 410-418	9
421	Immune Dysregulation in MDS: The Role of Cytokines and Immune Cells. 2019 ,	0
420	Serum ferritin levels at diagnosis predict prognosis in patients with low blast count myelodysplastic syndromes. 2019 , 110, 533-542	4
419	Myelodysplastic Syndromes: An Update on Pathophysiology and Management. 2019 ,	
418	Decitabine promotes apoptosis in mesenchymal stromal cells isolated from patients with myelodysplastic syndromes by inducing reactive oxygen species generation. 2019 , 863, 172676	4
417	Outcome of Myelodysplastic Syndromes Over Time in the United States: A National Cancer Data Base Study From 2004-2013. 2019 , 94, 1467-1474	8
416	A novel automated image analysis system using deep convolutional neural networks can assist to differentiate MDS and AA. 2019 , 9, 13385	26
415	Therapeutic Modulation of Autophagy in Leukaemia and Lymphoma. 2019 , 8,	23
414	Medical Conditions and Modifiable Risk Factors for Myelodysplastic Syndrome: A Systematic Review. 2019 , 28, 1502-1517	8
413	Delayed time from RBC transfusion dependence to first cardiac event in lower IPSS risk MDS patients receiving iron chelation therapy. 2019 , 83, 106170	7
412	Hematologic improvement with iron chelation therapy in myelodysplastic syndromes: Clinical data, potential mechanisms, and outstanding questions. 2019 , 141, 54-72	12
411	EPO-R+ myelodysplastic cells with ring sideroblasts produce high erythroferrone levels to reduce hepcidin expression in hepatic cells. 2019 , 78, 1-8	4
410	Favorable Outcomes With Tumor Burden Reduction Following Administration of Hypomethylating Agents Before Allogeneic Hematopoietic Cell Transplantation in Patients With Higher Risk Myelodysplastic Syndrome. 2019 , 19, e367-e373	0
409	ACUTE MYELOID LEUKAEMIA, MIXED PHENOTYPE ACUTE LEUKAEMIA, THE MYELODYSPLASTIC SYNDROMES AND HISTIOCYTIC NEOPLASMS. 2019 , 185-266	

408	MYELOPROLIFERATIVE AND MYELOYDYSPLASTIC/MYELOPROLIFERATIVE NEOPLASMS AND RELATED CONDITIONS. 2019 , 267-345	
407	Increased opportunity for prolonged survival after allogeneic hematopoietic stem cell transplantation in patients aged 60-69 years with myelodysplastic syndrome. 2019 , 98, 1367-1381	6
406	Clinical impact of the loss of chromosome 7q on outcomes of patients with myelodysplastic syndromes treated with allogeneic hematopoietic stem cell transplantation. 2019 , 54, 1471-1481	2
405	Molecular Genetics in Myelodysplasia Outcomes Prognostication. 2019 , 2, 35-43	
404	Treatment of MDS/MPN and the MDS/MPN IWG International Trial: ABNL MARRO. 2019 , 14, 543-549	1
403	Myelodysplastic Syndromes (MDS). 2019 , 333-341	
402	Clinical and biological characteristics of acute myeloid leukemia with 20-29% blasts: a retrospective single-center study. 2019 , 60, 1136-1145	0
401	Epidemiology of myelodysplastic syndromes: Why characterizing the beast is a prerequisite to taming it. 2019 , 34, 1-15	60
400	Myelodysplastic syndromes. 2020 , 589-602	
399	Gaucher disease, myelodysplastic syndrome and ICUS. 2020 , 80, 102373	3
398	Myelodysplastic Syndromes. 2020 , 1798-1820.e11	
397	Myelodysplastic/myeloproliferative neoplasm, unclassifiable (MDS/MPN-U): More than just a "catch-all" term?. 2020 , 33, 101132	3
396	Myelodysplastic/myeloproliferative neoplasms: are morphology and immunophenotyping still relevant?. 2020 , 33, 101139	1
395	Hypomethylation of MIR-378 5'-flanking region predicts poor survival in young patients with myelodysplastic syndrome. 2020 , 8, e1067	2
394	Serum Inflammation-miR Signature: A Biomarker of Myelodysplastic Syndrome?. 2020 , 10, 595838	1
393	Vitamin B deficiency influences increased formation of ring sideroblasts in pre-myelodysplastic syndromes. 2020 , 20, 1092-1093	
392	Identification of latent core genes and pathways associated with myelodysplastic syndromes based on integrated bioinformatics analysis. 2020 , 25, 299-308	4
391	Prognostic Markers of Myelodysplastic Syndromes. 2020 , 56,	4

390	Effects of Acute and Chronic Graft-versus-myelodysplastic Syndrome on Long-term Outcomes Following Allogeneic Hematopoietic Cell Transplantation. 2020 , 26, 6483-6493	3
389	Outcome of allogeneic hematopoietic stem cell transplantation for hypoplastic myelodysplastic syndrome. 2020 , 112, 825-834	1
388	How I Diagnose Low-Grade Myelodysplastic Syndromes. 2020 , 154, 5-14	3
387	Nationwide epidemiological survey of familial myelodysplastic syndromes/acute myeloid leukemia in Japan: a multicenter retrospective study. 2020 , 61, 1688-1694	1
386	TIFAB Regulates USP15-Mediated p53 Signaling during Stressed and Malignant Hematopoiesis. 2020 , 30, 2776-2790.e6	11
385	Genetic Factors in Acute Myeloid Leukemia With Myelodysplasia-Related Changes. 2020 , 153, 656-663	6
384	Correlation of RAS-Pathway Mutations and Spontaneous Myeloid Colony Growth with Progression and Transformation in Chronic Myelomonocytic Leukemia-A Retrospective Analysis in 337 Patients. 2020 , 21,	8
383	The Effects of Human BDH2 on the Cell Cycle, Differentiation, and Apoptosis and Associations with Leukemia Transformation in Myelodysplastic Syndrome. 2020 , 21,	3
382	Clinicopathologic characterisation of myeloid neoplasms with concurrent spliceosome mutations and myeloproliferative-neoplasm-associated mutations. 2020 , 73, 728-736	3
381	The Blood Circulating Rare Cell Population. What is it and What is it Good For?. 2020 , 9,	13
380	Characterization of myelodysplastic syndromes progressing to acute lymphoblastic leukemia. 2021 , 100, 63-78	1
379	Autophagy in Hematological Malignancies: Molecular Aspects in Leukemia and Lymphoma. 2021 , 52, 16-23	0
378	Therapy-related myelodysplastic syndromes deserve specific diagnostic sub-classification and risk-stratification-an approach to classification of patients with t-MDS. 2021 , 35, 835-849	20
377	Hypomethylating agents in the treatment of chronic myelomonocytic leukemia: a meta-analysis and systematic review. 2021 , 26, 312-320	0
376	Pre-transplantation cytoreduction does not benefit advanced myelodysplastic syndrome patients after myeloablative transplantation with grafts from family donors. 2021 , 41, 333-344	3
375	DNA methylation epitypes highlight underlying developmental and disease pathways in acute myeloid leukemia. 2021 , 31, 747-761	4
374	Phenotypic characterization of leukemia-initiating stem cells in chronic myelomonocytic leukemia. 2021 , 35, 3176-3187	4
373	Clinical effectiveness of DNA methyltransferase inhibitors and lenalidomide in older patients with refractory anemia with ring sideroblasts: a population-based study in the United States. 2021 , 62, 2438-2447	

372	In vitro induction of neoantigen-specific T cells in myelodysplastic syndrome, a disease with low mutational burden. 2021 , 23, 320-328	1
371	Multiplex ligation-dependent probe amplification and fluorescence in situ hybridization for detecting chromosome abnormalities in myelodysplastic syndromes: A retrospective study. 2021 , 100, e25768	0
370	Somatic mutations of activated signaling genes, transcription factors, or tumor suppressors are a precondition for leukemic transformation from myelodysplastic syndromes: a sequencing analysis of 64 paired samples.	
369	Elevated mature monocytes in bone marrow accompanied with a higher IPSS-R score predicts a poor prognosis in myelodysplastic syndromes. 2021 , 21, 546	3
368	High PRAME expression is associated with poor survival and early disease progression in myelodysplastic syndromes with a low bone marrow blast percentage. 2021 , 62, 2448-2456	1
367	Micromegakaryocytes in peripheral blood in a case of AML, t(6;11)(q27;23). 2021 , 14,	1
366	Role of cedazuridine/decitabine in the management of myelodysplastic syndrome and chronic myelomonocytic leukemia. 2021 , 17, 2077-2087	5
365	A phase I clinical trial to study the safety of treatment with tipifarnib combined with bortezomib in patients with advanced stages of myelodysplastic syndrome and oligoblastic acute myeloid leukemia. 2021 , 105, 106573	1
364	Distinguishing AML from MDS: a fixed blast percentage may no longer be optimal. 2021 ,	14
363	Chronic Myelomonocytic Leukemia Gold Jubilee. 2021 , 2, 403-428	
362	SCOPUS VERİTABANINA DAYALI BBLİYOMETRİK DEĞERLENDİRME: MYELODİSPLASTİK SENDROM KONULU YAYINLARIN GLOBAL ANALİZİ VE TÜRKİYE KAYNAKLI YAYINLARIN DEĞERLENDİRİMESİ	4
361	Prognostic value of the revised International Prognostic Scoring System five-group cytogenetic abnormality classification for the outcome prediction of hematopoietic stem cell transplantation in pediatric myelodysplastic syndrome. 2021 , 56, 3016-3023	0
360	Programmed necroptosis is upregulated in low-grade myelodysplastic syndromes and may play a role in the pathogenesis. 2021 , 103, 60-72.e5	
359	Comparison of Upfront Transplantation and Pretransplant Cyto-reductive Therapy for Advanced Myelodysplastic Syndrome. 2021 , 21, 631-640	0
358	Molecular Pathogenesis of Chronic Myelomonocytic Leukemia and Potential Molecular Targets for Treatment Approaches. 2021 , 11, 751668	0
357	Smoking, alcohol consumption, body fatness, and risk of myelodysplastic syndromes: A prospective study. 2021 , 109, 106593	
356	Leukemias, myeloma, and other lymphoreticular neoplasms. 1995 , 75, 381-394	46
355	Concurrent inflammatory bowel disease and myelodysplastic syndromes. 5, 98-103	10

354	Classification and Staging of Myelodysplastic Syndromes. 2006 , 39-53	1
353	Role of hematopoietic stem cell transplantation in acute myelogenous leukemia and myelodysplastic syndrome. 2009 , 144, 415-39	1
352	Advances in the therapy of the myelodysplastic syndromes. 1999 , 99, 335-62	1
351	Classification of 358 Cases of Acute Myeloid Leukemia by FAB Criteria: Analysis of Clinical and Morphologic Features. 1985 , 147-174	7
350	Evolving concepts in myelodysplastic syndromes. 2001 , 108, 1-24	3
349	Myelodysplastic syndromes complicating hematopoietic stem cell transplantation. 2001 , 108, 169-84	3
348	Novel in vitro culture and ultrastructural techniques to study the biology of myelodysplastic syndromes (MDS). 2001 , 108, 65-79	2
347	The monocytic component in myelodysplastic syndromes. 2001 , 108, 81-92	2
346	Biological Response Modifiers and Differentiating Agents in Myelodysplastic Syndromes. 1993 , 171-177	1
345	Cancer Cytogenetics. 1999 , 345-420	2
344	Allogeneic Hematopoietic Cell Transplantation for Patients with Myelodysplastic Syndrome and Myeloproliferative Disorders. 2008 , 167-182	2
343	Prognostic Models in Myelodysplastic Syndromes. 2020 , 109-127	2
342	Neoplastische Bildungsstufen der Hämatoopoiese mit erhaltener Ausreifung. 2019 , 47-87	2
341	RT-PCR in Diagnostics and Monitoring of Acute Myeloid. 2001 , 44-48	2
340	5-Azacytidine/5-Azacitidine. 2014 , 201, 299-324	6
339	Hautveränderungen bei Leukämien. 1997 , 469-472	1
338	Differentiation in myelodysplastic, myeloid leukaemic and normal haemopoietic cells: a new approach exploiting the synergistic interaction between differentiation inducers and DNA synthesis inhibitors. 1985 , 29, 402-8	4
337	Pilot Study of Pentoxifylline and Ciprofloxacin with or without Dexamethasone Produces Encouraging Results in Myelodysplastic Syndromes. 1998 , 42-51	12

336	AML in the Elderly: a Biologically Distinct Disease in which MDR1 Expression and Unfavorable Cytogenetics Contribute to Poor Clinical Response. Studies of the Southwest Oncology Group. 1998 , 413-421	2
335	Effect of treatment with rhGM-CSF and low-dose cytosine arabinoside on leukemic blast cells in patients with myelodysplastic syndromes. 1990 , 33, 763-9	4
334	In vitro growth kinetics of myeloid progenitor cells of myelodysplastic patients in response to granulocyte-macrophage colony-stimulating factor and interleukin-3. 1990 , 33, 98-102	2
333	High-dose Ara-C as a single-agent consolidation therapy in childhood acute myelogenous leukemia. 1990 , 33, 215-21	7
332	Oral idarubicin in elderly acute leukemia and refractory anemia with excess of blasts. 1990 , 33, 342-5	4
331	Treatment of advanced myelodysplastic syndromes: trend toward more aggressive chemotherapy?. 1990 , 33, 382-6	4
330	Chronic myelomonocytic leukemia: clinical data, morphological features, and outcome in 56 patients. 1990 , 33, 387-91	1
329	Chemotherapy of the Leukaemias. 1990 , 5-77	2
328	Bone Marrow Transplantation. 1990 , 117-171	1
327	Patterns of Chromosome Variation in Neoplasia. 1990 , 86-100	4
326	Bone Marrow Biopsy in RAEB and RAEB-t Myelodysplastic Syndromes. 1992 , 67-73	1
325	Bone Marrow Histology in Myelodysplastic Syndromes: An Update. 1992 , 103-106	1
324	Chronic Myelomonocytic Leukaemia and Atypical Chronic Myeloid Leukaemia. 1992 , 131-139	1
323	Myelodysplastic Syndromes in Childhood: Description of 11 Cases. 1992 , 38-43	1
322	Thymidine Kinase Activity in Bone Marrow Cells as Basis for Rational Treatment of Myelodysplastic Syndromes. 1994 , 623-627	1
321	Childrens Cancer Group Transplant Trials for Acute Myeloid Leukemia in Children: A Cross-Study Analysis of CCG-251, CCG-213, CCG-2861, and CCG-2891. 1994 , 476-485	1
320	Morphology, cytochemistry, and ultrastructure of leukemic cells with regard to the classification of leukemias. 1984 , 93, 51-68	4
319	"Atypical" leukemias: preleukemia, smoldering leukemia and hypoplastic leukemia. 1984 , 93, 69-101	31

318	Preleukemia: bone marrow histopathology in myelodysplasia and preleukemic syndrome. 1988 , 106, 159-71	7
317	Multiparameter analysis of blast cells in patients with acute leukemia following a primary myelodysplastic syndrome. 1993 , 131, 393-400	1
316	Prognostic Scoring in MDS. 2011 , 103-120	2
315	Nuclear phosphoinositides: location, regulation and function. 2012 , 59, 335-61	27
314	Nuclear PI-PLC β and Myelodysplastic syndromes: from bench to clinics. 2012 , 362, 235-45	7
313	New Possibilities for Cytogenetic Analysis of Leukemic Cells. 1986 , 1-11	2
312	Myelodysplastic Syndromes. 2008 , 2235-2259	1
311	Erythrocyte and leucocyte cytochemistry. 2012 , 333-352	3
310	Myeloid Leukemia, Myelodysplasia, and Myeloproliferative Disease in Children. 2009 , 331-402	1
309	Leukocytic Disorders. 2011 , 601-655	2
308	Childhood Leukemia. 2014 , 1849-1872.e11	4
307	3 Prognostic Significance of Chromosomal Abnormalities in Acute Leukaemias and Myelodysplastic Syndromes. 1986 , 15, 597-620	63
306	5 Biology of Acute Myeloid Leukaemia. 1986 , 15, 641-667	17
305	12 Preleukaemia. 1986 , 15, 829-850	16
304	Cytogenetics. 1992 , 6, 523-541	37
303	Morphologic and Cytochemical Characteristics of Childhood Lymphoblastic Leukemia. 1990 , 4, 715-741	6
302	Cytochemistry and Immunocytochemistry in Bone Marrow Examination: Contemporary Techniques for the Diagnosis of Acute Leukemia and Myelodysplastic Syndromes: A Combined Approach. 1988 , 2, 537-555	2
301	Myelodysplastic syndrome. 548-570	1

300	Chronic myeloproliferative disorders. 571-598		8
299	Primary myelodysplasia occurring in adults under 50 years old: a clinicopathologic study of 52 patients.		1
298	Absence of mutations in the granulocyte colony-stimulating factor (G-CSF) receptor gene in patients with myelodysplastic syndrome/acute myeloblastic leukaemia occurring after treatment of aplastic anaemia with G-CSF. <i>British Journal of Haematology</i> , 2000 , 111, 656-8	4.5	3
297	Neutrophil-specific reduction in the expression of granulocyte-macrophage colony-stimulating factor receptor subunits in myelodysplastic syndromes. <i>British Journal of Haematology</i> , 2000 , 111, 863-872	4.5	1
296	Myelodysplastic features in patients with long-term HIV infection and haemophilia. 2001 , 7, 47-52		13
295	Myelodysplastic Syndromes. 2020 , 383, 1358-1374		94
294	A patient with genetic deletion of glutathione-S-transferase T1 and M1 who developed non-small-cell lung cancer and myelodysplastic syndromes. 1999 , 318, 424-7		2
293	Splenic pathology in myelodysplasia: a report of 13 cases with clinical correlation. 1998 , 22, 1255-66		37
292	Smoking and myelodysplastic syndromes. 2000 , 11, 285-91		60
291	Crohn's disease and the myelodysplastic syndrome. 1997 , 24, 286-7		9
290	Medical surveillance for hematological disorders among active and retired oil refinery workers. 1998 , 40, 475-80		3
289	Bullous pemphigoid in association with cutaneous lesions specific to a myelodysplastic syndrome. 1997 , 136, 402-405		8
288	Decreased T helper cells in the myelodysplastic syndromes. <i>British Journal of Haematology</i> , 1983 , 54, 97-102	4.5	71
287	The 5q--syndrome: an underdiagnosed form of macrocytic anaemia. <i>British Journal of Haematology</i> , 1983 , 54, 103-10	4.5	19
286	Myelodysplastic syndromes: evolution of overt leukaemia by one or several steps of transformation. <i>British Journal of Haematology</i> , 1987 , 67, 141-6	4.5	8
285	A multivariate analysis of prognostic factors in chronic myelomonocytic leukaemia according to the FAB criteria. <i>British Journal of Haematology</i> , 1987 , 65, 307-11	4.5	31
284	Specific molecular signatures predict decitabine response in chronic myelomonocytic leukemia. 2015 , 125, 1857-72		129
283	Achievements in Understanding and Treatment of Myelodysplastic Syndromes. 2000 , 2000, 110-132		2

282	Achievements in Understanding and Treatment of Myelodysplastic Syndromes. 2000 , 2000, 110-132	3
281	Hypermethylation of the p15INK4B Gene in Myelodysplastic Syndromes. 1997 , 90, 1403-1409	13
280	Acute Myeloid Leukemia and Myelodysplastic Syndromes Following Essential Thrombocythemia Treated With Hydroxyurea: High Proportion of Cases With 17p Deletion. 1998 , 91, 616-622	2
279	17p Deletion in Acute Myeloid Leukemia and Myelodysplastic Syndrome. Analysis of Breakpoints and Deleted Segments by Fluorescence In Situ. 1998 , 91, 1008-1015	4
278	Cytogenetic Abnormalities in Primary Myelodysplastic Syndrome Are Highly Predictive of Outcome After Allogeneic Bone Marrow Transplantation. 1998 , 92, 1910-1917	3
277	Fluorescence In Situ Hybridization of Progenitor Cells Obtained by Fluorescence-Activated Cell Sorting for the Detection of Cells Affected by Chromosome Abnormality Trisomy 8 in Patients With Myelodysplastic Syndromes. 1998 , 92, 2886-2892	3
276	Myelodysplastic and Myeloproliferative Disorders of Childhood: A Study of 167 Patients. 1999 , 93, 459-466	5
275	The role of apoptosis, proliferation, and the Bcl-2-related proteins in the myelodysplastic syndromes and acute myeloid leukemia secondary to MDS. 2000 , 96, 3932-3938	5
274	Isolation and characterization of hematopoietic progenitor/stem cells in 5q-deleted myelodysplastic syndromes: evidence for involvement at the hematopoietic stem cell level. 2000 , 96, 2012-2021	8
273	Real-World Costs of Azacitidine Treatment in Patients With Higher-Risk Myelodysplastic Syndromes/Low Blast-Count Acute Myeloid Leukemia. 2021 , 17, e517-e525	2
272	Myelodysplastic syndromes: recent progress in diagnosis and understanding of their pathophysiology. 2006 , 73, 300-7	10
271	The role of the iron transporter ABCB7 in refractory anemia with ring sideroblasts. 2008 , 3, e1970	98
270	EZH2 mutations are related to low blast percentage in bone marrow and -7/del(7q) in de novo acute myeloid leukemia. 2013 , 8, e61341	46
269	Prognostic value of isocitrate dehydrogenase mutations in myelodysplastic syndromes: a retrospective cohort study and meta-analysis. 2014 , 9, e100206	35
268	Karyotypic identification of abnormal clones preceding morphological changes or occurring with no definite morphological features of myelodysplastic syndrome: a preliminary study. 2007 , 13, 17-21	7
267	Automated neutrophil morphology and its utility in the assessment of neutrophil dysplasia. 2007 , 13, 98-102	27
266	Cytogenetic study of 50 Brazilian patients with primary myelodysplastic syndrome. 1997 , 20, 87-91	1
265	Physician Education. 1996 , 1, 284-287	9

264	The Myelodysplastic Syndromes. 1997 , 2, 28-39	3
263	Understanding the Myelodysplastic Syndromes. 1997 , 2, 389-401	32
262	Standards and Impact of Hematopathology in Myelodysplastic Syndromes (MDS). 2010 , 1, 483-496	42
261	Bone marrow fibrosis in chronic myelomonocytic leukemia is associated with increased megakaryopoiesis, splenomegaly and with a shorter median time to disease progression. 2017 , 8, 103274-103282	12
260	Heat Shock Protein 90 is overexpressed in high-risk myelodysplastic syndromes and associated with higher expression and activation of Focal Adhesion Kinase. 2012 , 3, 1158-68	17
259	Clinical implications of TP53 mutations in myelodysplastic syndromes treated with hypomethylating agents. 2016 , 7, 14172-87	59
258	Azacytidine (Vidaza(R)) in the treatment of myelodysplastic syndromes. 2006 , 2, 377-88	65
257	Basic ferritin content of red cells of patients with anemia and polycythemia vera. 1984 , 16, 419-23	3
256	The myelodysplastic syndromes: diagnostic criteria and laboratory evaluation. 1993 , 25, 297-304	4
255	Myelodysplastic syndromes: moving towards personalized management. 2020 , 105, 1765-1779	21
254	Survey on Recommended Health Care for Adult Patients with Myelodysplastic Syndromes Identifies Areas for Improvement. 2020 , 17,	0
253	Telomerase Activity and MDS/EVI Gene Fusion in Myelodysplastic Syndrome. Correlation to the Immunohistochemical Expression of Ki-67, Bcl-2 and p53 in Bone Marrow Biopsy Samples. 2008 , 1, 17-24	1
252	A CASE OF AORTIC VALVE REPLACEMENT IN A PATIENT WITH MYELODYSPLASTIC SYNDROME AND AORTIC VALVE STENOSIS. 2010 , 71, 2825-2829	1
251	Decreased CD10-positive mature granulocytes in bone marrow from patients with myelodysplastic syndrome. 2000 , 124, 1152-6	19
250	CD34/QBEND10 immunostaining in the bone marrow trephine biopsy: a study of CD34-positive mononuclear cells and megakaryocytes. 2002 , 126, 823-8	15
249	Myelodysplastic syndromes: clinicopathologic features, pathobiology, and molecular pathogenesis. 2005 , 129, 1299-310	21
248	Myelodysplastic syndromes in children: a critical review of issues in the diagnosis and classification of 887 cases from 13 published series. 2007 , 131, 1110-6	31
247	Revisiting use of growth factors in myelodysplastic syndromes. 2012 , 13, 1081-91	10

- 246 Pancytopenia—diagnostic challenge?. **2021**, 14, 355 0
- 245 Myelodysplastische Syndrome. **2000**, 910-922
- 244 Myelodysplasia and Acute Leukemia Following High-Dose Chemotherapy. **2000**, 261-277
- 243 Myelodysplastic Syndromes. **2000**, 147-156
- 242 Paraneoplastic Arthritis. **2000**, 133-140 1
- 241 Acute Leukemia and Myelodysplastic Syndromes. **2000**, 193-221
- 240 Therapy-related acute myeloid leukemia and myelodysplasia after high-dose chemotherapy and autologous stem cell transplantation. **2000**, 95, 3273-3279 1
- 239 Risk of colorectal cancer in patients with hematologic disease. **2000**, 15, 1272-1276
- 238 Intensive Chemotherapy Followed by Stem Cell Transplantation for the Treatment of Myelodysplastic Syndromes. **2001**, 649-654
- 237 Are there Two Main Categories of de Novo Acute Myeloid Leukemias with a Normal Karyotype?. **2001**, 54-60
- 236 Colony Stimulating Factors in Myelodysplastic Syndromes. **2001**, 210-217
- 235 Chronic myelomonocytic leukemia revealed by uncontrollable hematuria. **2001**, 125, 657-9 6
- 234 Mitochondrial Featurig in Kidney Disorders and Myelodysplastic Syndromes. **2002**, 295-303
- 233 Myelodysplastisches Syndrom und akute myeloische Leukämie. **2002**, 389-419
- 232 Response Criteria for Myelodysplastic Syndromes. **2002**, 237-246
- 231 The Role of Apoptosis in the Myelodysplastic Syndromes. **2002**, 171-193
- 230 Hypocellular Myelodysplastic Syndromes and Hypocellular Acute Myeloid Leukemia: Relationship to Aplastic Anemia. **2002**, 123-138
- 229 Allogeneic Bone Marrow Transplantation in the Myelodysplastic Syndromes. **2002**, 398-425

- 228 Treatment of Anemia in Myelodysplastic Syndromes. **2002**, 321-344
- 227 The Cytogenetics and Molecular Biology of Myelodysplastic Syndromes. **2002**, 95-122
- 226 New Investigational Strategies in Patients with Myelodysplastic Syndromes. **2002**, 368-386
- 225 Protocol for the examination of specimens from patients with hematopoietic neoplasms of the bone marrow: a basis for checklists. **2002**, 126, 1050-6 12
- 224 Allogeneic Hematopoietic Cell Transplantation for Adult Patients with Acute Myelogenous Leukemia. **2003**, 13-27
- 223 Myelodysplastische Syndrome. **2003**, 1038-1046
- 222 Myelodysplastic Syndromes. **2003**, 243-253
- 221 Myelodysplastische Syndrome. **2003**, 268-311
- 220 Anämien. **2003**, 1013-1027 2
- 219 The New WHO Classification for Akute Myeloid Leukemias and Myelodysplastic Syndromes. **2003**, 3-6
- 218 Relationship between immunologic abnormalities and paroxysmal nocturnal hemoglobinuria-associated clones in myelodysplastic syndromes. **2003**, 263-269
- 217 Peculiarities of myelodysplasia syndrome course of children. **2003**, 2, 67-71
- 216 Myelodysplastische Syndrome. **2004**, 1815-1846
- 215 Allogeneic and Autologous Stem Cell Transplantation for Acute Leukemia and Myelodysplasia in the Adult. **2004**, 3-24
- 214 Blut und Knochenmark. **2004**, 27-291
- 213 Myelodysplastisches Syndrom (MDS). **2004**, 51-60
- 212 Einteilung und Klassifikation maligner Erkrankungen. **2004**, 17-44
- 211 Myelodysplastic Syndromes. **2004**, 151-178

210 Allogeneic stem cell transplantation. **2004**, 423-465

209 Myelodysplastic Syndrome Risk Class Analysis by Microarray. **2004**, 881-884

208 Molecular Biology of Myelodysplasia. **2006**, 23-38

207 Hematopoietic Growth Factors. **2006**, 99-109

1

206 Myelodysplastisches Syndrom (MDS). **2006**, 2724-2748

205 Hämoblastosen. **2006**, 630-713

204 Hemopoietic Cell Transplantation. **2006**, 123-134

203 Myelodysplastische Syndrome (MDS). **2007**, 359-376

202 Myelodysplastic/Myeloproliferative Diseases (Overlap Syndromes). **2007**, 211-218

201 Myelodysplastic/Myeloproliferative Diseases (Overlap Syndromes). **2007**, 211-218

200 Myelodysplastic Syndromes. **2008**, 529-534

199 Citoquímica eritrocitaria y leucocitaria. **2008**, 267-286

198 Childhood Leukemia. **2008**, 2139-2169

1

197 Recombinant human erythropoietin (rhEPO) therapy in myelodysplasia. **2008**, 531-539

196 Molecular Basis of Lymphoid and Myeloid Diseases. **2009**, 265-290

195 Allogeneic Transplantation for Myelodysplastic Syndromes. **2010**, 203-217

194 Molecularly Targeted Therapies in Pediatric Myelodysplastic Syndromes. **2010**, 155-176

193 Prognostic Significance of CEBPA Mutations and BAALC Expression in Acute Myeloid Leukemia Patients with Normal Karyotype. **2010**, 7,

- 192 The Myelodysplastic Syndromes. **2010**, 606-609
- 191 The Myelodysplastic Overlap Syndromes. **2011**, 159-173
- 190 The Myelodysplastic Syndromes. **2011**, 656-671
- 189 Bone marrow. **2011**, 1927-2012
- 188 Diagnostic Criteria and Classification of Myelodysplastic Syndromes. **2011**, 43-53 1
- 187 Myelodysplastic Syndromes/Neoplasms: Morphological and Immunohistochemical Features and Standard Evaluation. **2011**, 25-41 2
- 186 Myelodysplastic Syndrome. **2011**, 35-42
- 185 Myelodysplastic Syndromes. 99-114
- 184 Myelodysplastic Syndromes: The Role of Cytogenetic and Molecular Abnormalities for Classification and Risk Assignment. 87-98
- 183 Flow Cytometry in Myelodysplastic Syndromes. **2011**, 121-143 1
- 182 The History of the Myelodysplastic Syndromes. **2011**, 1-4 1
- 181 Cytokines in MDS: Abnormalities and Treatment. **2011**, 205-218
- 180 The Myelodysplastic Syndromes. 219-260
- 179 Supportive Care in Myelodysplastic Syndrome. 172-190
- 178 The Nature of Leukaemia, Cytology, Cytochemistry and the FAB Classification of Acute Leukaemia. 1-63 1
- 177 Use of rHuG-CSF in Myelodysplastic Syndromes. **2012**, 183-193 1
- 176 A case of synchronous double cancer of the stomach and the ascending colon associated with myelodysplastic syndrome. **2012**, 73, 502-508 2
- 175 Facharzt Hämatologie Onkologie - Pages e1-e61. **2012**, e1-e61

174 Molecular Biology of Myelodysplastic Syndromes. **2012**, 117-127

173 Myelodysplastic Syndromes. **2012**, 523-546

172 Hematology. **2012**, 767-871

171 Myelodysplastic/Myeloproliferative Neoplasms. **2013**, 111-126

170 Epidemiology and Etiology. **2013**, 9-38

169 Management of High-Risk Myelodysplastic Syndrome. **2013**, 189-210

168 Immunophenotyping in Myelodysplastic Syndromes. **2013**, 141-152

167 Classification and Staging of Myelodysplastic Syndromes. **2013**, 127-139

166 CHAPTER 7: The Diagnosis of Myelodysplastic Syndromes. **2013**, 182-200

165 The Myelodysplastic Syndromes: Pathophysiology, Care and Management. 171-182

164 Sobrevida e evoluçã leucêmica de portadores de síndromes mielodisplásicas. **2013**, 21, 154-159

163 PTK2 and PTPN11 expression in myelodysplastic syndromes. **2013**, 68, 1371-5

162 WHO Classification of Hematologic Malignancies. **2014**, 219-225.e2

161 Diagnosis of myelodysplastic syndromes. **2014**, 32-46

160 Myelodysplastic Syndromes. **2014**, 1907-1928.e8

159 Myelodysplastisches Syndrom. **2014**, 51-59

158 Features of Therapy-Related Leukemia and their Comparison with Leukemia de Novo and with the Blast Phase of Chronic Granulocytic Leukemia. **1984**, 159-171

157 Epidemiologic Studies of Chemotherapy-Related Acute Leukemia. **1985**, 499-514

- 156 Akute Leukämien des Erwachsenen. **1985**, 257-279
- 155 Clinical Trials and in Vitro Studies of 13 CIS Retinoic Acid in the Myelodysplastic Syndrome. **1986**, 453-469
- 154 Myelodysplasie [Ein neu definiertes Vorstadium akuter Leukämien. **1986**, 85-89
- 153 Low-Dose Ara-C by Continuous Infusion in the Treatment of Acute Non-Lymphocytic Leukemia (ANLL) and Myelodysplastic Syndrome (MDS). **1986**, 95-100
- 152 Cytogenetics of the Leukemias and Lymphomas. **1986**, 1-41
- 151 Low-dose Ara-C in myelodysplastic syndromes and acute nonlymphoid leukemia. Experience with seven patients. **1987**, 30, 315-21
- 150 Therapeutic Effects of Low-Dose Cytosine Arabinoside, β -Interferon, 1,25-Dihydroxyvitamin D3 and Retinoic Acid in Myelodysplastic Syndromes and Acute Leukemia. **1987**, 205-212
- 149 Prognostic significance of morphologic and cytogenetic findings for progression in myelodysplastic syndromes. **1987**, 30, 365-8
- 148 Natural Killer Activity in Preleukemic States. **1987**, 132-135
- 147 Therapiekonzepte. **1987**, 1-899
- 146 Myelodysplastische Syndrome (MDS). **1988**, 322-324
- 145 Cytogenetic Findings in Myeloproliferative Disorders. **1988**, 1-18 3
- 144 Cytobiology and clinical findings of myelodysplastic syndromes. **1988**, 106, 172-9 1
- 143 Akute Leukämie. **1988**, 325-337
- 142 Primary acquired myelodysplastic syndromes. **1988**, 56, 129-58 1
- 141 Cytogenetics of preleukemic stages in experimental and human leukemogenesis. **1988**, 106, 152-8
- 140 A Modern View of Histopathological Diagnosis and Classification of Cancer. **1989**, 62-83
- 139 Hematologic Complications of Cancer from the Species Specific View. **1989**, 87-97

138 Vermehrung und Verminderung der Leukozyten. **1989**, 60-70

137 Cytogenetics and Human Neoplasia. **1989**, 231-246

136 Primary and Secondary Myelodysplastic Syndromes. **1990**, 67-80

135 Diagnosis of Leukaemia. **1990**, 5-13

134 Myelodysplastic syndromes: preleukemic or early leukemic conditions?. **1990**, 33, 3-7

133 Low-Dose Aclacinomycin A in Myelodysplastic Syndromes and Subsequent Acute Myelogenous Leukemia: A Phase II Study. **1990**, 41-50

132 Risk of leukemic transformation in two types of acquired idiopathic sideroblastic anemia. **1990**, 33, 374-81

131 Prognostic significance of the karyotype in patients with primary myelodysplastic syndrome. **1990**, 33, 166-8

130 Hematopoietic Malignancies During the Perinatal Period. **1991**, 169-173

129 Myelodysplastische Syndrome (MDS). **1991**, 385-389

128 Sweet's Syndrome Accompanied by Myelodysplastic Syndrome.. **1991**, 53, 535-540

3

127 Literatur. **1991**, 446-467

0

126 Regulation of Erythropoietin Production in Patients with Myelodysplastic Syndromes. **1992**, 163-168

125 Effect of Interleukin-3 on Human Hematopoietic Progenitor and Precursor Cells in Patients with Myelodysplastic Syndromes. **1992**, 179-184

124 Differential Response of Cytogenetically Abnormal Cell Clones in Myelodysplastic Syndromes to Cytokines in Vitro. **1992**, 185-193

123 Differentialdiagnose der primären Knochenmarkinsuffizienz. **1992**, 166-222

122 Conversion of Myelodysplastic Subtypes to Acute Leukemia: A Follow-Up Study. **1992**, 114-120

121 The Therapeutic Effect of Recombinant Human Cytokines (GM-CSF, Interleukin-3, Erythropoietin) in Patients with Myelodysplastic Syndromes. **1992**, 299-306

- 120 Chronic Myelomonocytic Leukemia with Lymphadenopathy. **1992**, 140-145
- 119 The Classification of Myelodysplastic Syndromes. **1992**, 3-10
- 118 Classification of Myelodysplastic Syndromes in Clinical Practice: Frequency of Subtypes. **1992**, 15-19
- 117 Recombinant α 2b-Interferon in the Management of Myelodysplastic Syndromes. **1992**, 291-293
- 116 Results of Low-Dose Cytosine Arabinoside and Aggressive Chemotherapy in Patients with Advanced Myelodysplastic Syndromes. **1992**, 274-281
- 115 Pediatric Experiences in Myelodysplastic Syndrome. **1992**, 31-37 1
- 114 Supportive Therapy and Bone Marrow Transplantation in MDS. **1992**, 240-247
- 113 Differentiation inducers and their potential use in the treatment of acute myelogenous leukaemia. **1992**, 163-181
- 112 A Phase II Clinical Trial of Recombinant Interferon- α in Myelodysplastic Syndromes. **1992**, 294-299
- 111 Low-Dose Cytosine Arabinoside Regimen Adapted to the FAB Classifications of Myelodysplastic Syndromes: Is it Superior to Uniform Treatment for all Types of MDS?. **1992**, 268-273
- 110 Phase III Evaluation of Low-Dose Cytosine Arabinoside Versus Supportive Care in the Treatment of Adults With Myelodysplastic Syndrome: An Intergroup Study by the Eastern Cooperative Oncology Group and the Southwest Oncology Group Preliminary Results. **1992**, 253-258
- 109 Evolution of Myelodysplastic Syndromes. **1992**, 107-113
- 108 Impaired Monocyte/Macrophage Differentiation in the Myelodysplastic Syndromes. **1992**, 155-158
- 107 Treatment of Patients with Myelodysplastic Syndromes with Recombinant Human Granulocyte/Macrophage Colony-Stimulating Factor: A Phase I/II Trial. **1992**, 300-314
- 106 Study of the Rearrangement of Proto-oncogene MET in 88 Cases of Myelodysplastic Syndromes. **1992**, 193-197
- 105 Serum Erythropoietin in Myelodysplastic Syndromes. **1992**, 233-237
- 104 Maturation Pattern and Evolution of Leukemia in the Myelodysplastic Syndrome. **1992**, 81-89
- 103 Primary Myelodysplastic Syndromes and Chronic Myelofibrosis. **1992**, 121-124

- 102 Myelodysplastic Syndromes: Cytogenetic Anomalies and Their Clinical Significance. **1992**, 165-177
- 101 Immunological Phenotyping of Blood and Bone Marrow Cells From Patients with Myelodysplastic Syndromes. **1992**, 60-66
- 100 Clinical, Biochemical and Cytokinetic Parameters for Distinguishing Smouldering and Rapidly Proliferating Variants of Acute Leukemia. **1993**, 27-32
- 99 Megakaryocytopoiesis in Patients with Myelodysplastic Syndromes. **1993**, 5-9
- 98 Myelodysplastic Syndromes: Response to Aggressive Chemotherapy and Prognostic Factors for Treatment Outcome. **1994**, 633-637
- 97 Descriptive Epidemiology of Myelodysplastic Syndromes. **1994**, 628-632
- 96 Blutbildendes und lymphatisches Gewebe einschließlich Milz und Thymus. **1994**, 157-169
- 95 Myelodysplastic Syndromes: Treatment Indication and Choice of Therapy. **1994**, 185-200
- 94 Myelodysplastische Syndrome (MDS). **1995**, 545-548
- 93 Neutrophilic Dermatitis Associated with Myelodysplastic Syndrome.. **1996**, 58, 756-759 1
- 92 Bone Marrow. **1996**, 661-680
- 91 The Role of Hemopoietic Cytokines in the Myelodysplastic Syndromes. **1996**, 541-547
- 90 Chromosome Abnormalities and Karyotype Evolution in the Stem Cell Compartments of AML and MDS. **1997**, 17-23
- 89 Secondary Myelodysplastic Syndromes: Morphological Findings, Cytogenetics, and Clinical Course in 55 Patients. **1997**, 923-927
- 88 Myelodysplastic Syndromes or Leukemia Following MDS Treated with Allogeneic Bone Marrow Transplantation: A Survey of the Working Party on Chronic Leukemia of the European Cooperative Group for Blood and Marrow Transplantation. **1997**, 928-933
- 87 Childhood Myelodysplastic Syndromes Treated with Acute Myeloid Leukemia Regimens. **1997**, 912-917
- 86 Genetic Instability and Evolution of Karyotype in Secondary Acute Myeloid Leukemia. **1997**, 889-892
- 85 Erythropoietin-Induced Activation of STAT5 Is Impaired in the Myelodysplastic Syndrome. **1997**, 89, 1690-1700 1

- 84 The Karyotype in MDS [Cytogenetic Profile, Clinical Correlations and Prognostic Implications in 362 Patients with MDS. **1998**, 269-277
- 83 Myelodysplastic Syndromes in Children: Clinical and Morphological Analysis. **1998**, 214-216
- 82 Knochenmark und myelogene Neoplasien. **1999**, 429-517
- 81 Zyto- und Histotechnologie in der hämatopathologischen Diagnostik. **1999**, 689-739
- 80 Myelodysplastic Syndromes. **1999**, 382-398
- 79 Myelodysplastische Syndrome. **1999**, 953-957
- 78 Cytokines for the Treatment of Myelodysplastic Syndromes and Other Bone Marrow Failure States. **1999**, 326-339
- 77 Ulcérations buccales et vésiculaires d'une leucémie aiguë myéloïde de type 4. **2015**, 21, 37-41 1
- 76 E28 Literaturhinweise und Internetadressen. **2015**, e1-e79
- 75 Myelodysplastic syndromes. 126-152
- 74 Myelodysplastic syndromes in 2016. **2016**, 10, 114-119
- 73 CLINICO-HEMATOLOGICAL PROFILE OF PAEDIATRIC PATIENT ADMITTED WITH ACUTE LEUKEMIA IN TERTIARY CARE CENTRE OF CENTRAL INDIA. **2016**, 03, 308-310
- 72 Myelodysplastic Syndrome (MDS) and Juvenile Myelomonocytic Leukemia (JMML). **2017**, 87-108
- 71 Myelodysplastic Syndromes. **2017**, 1-4
- 70 Pathophysiology of Chronic Myelomonocytic Leukemia New Insights from Molecular and Biologic Characterization. **2017**, 3, 1-10
- 69 Chronic Myelomonocytic Leukemia: Clinical and Pathologic Features. **2018**, 233-247
- 68 Pathology of the Chronic Myeloid Leukemias. **2018**, 19-28
- 67 The Myelodysplastic Syndromes. **2018**, 483-508

- 66 Myelodysplastic Syndromes. **2018**, 239-242
- 65 Morphology and Flow Cytometry. **2018**, 3-13
- 64 Myelodysplastic Syndromes. **2019**, 913-942
- 63 Myelodysplastic Syndrome. **2019**, 1-21
- 62 A case of therapy-related myelodysplastic syndrome after chemoradiation for advanced tongue carcinoma. **2019**, 31, 91-96
- 61 Myelodysplastic Syndrome: An Overview. **2019**, 149-161
- 60 Acute Leukemia and Myelodysplastic Syndromes. **2019**, 193-222
- 59 Myelodysplastic Syndrome. **2020**, 479-499
- 58 Epidemiology, Etiology, and Clinical Presentation of Myelodysplastic Syndromes. **2020**, 3-17
- 57 A Case of Myelodysplastic Syndrome Diagnosed after Colectomy for Colon Cancer with a Poor Prognosis. **2020**, 81, 2297-2302
- 56 Myelocytic Cell Lines. **2002**, 207-236
- 55 Anämien. **2005**, 1063-1077
- 54 Myelodysplastische Syndrome. **2005**, 1090-1098
- 53 Myelodysplastische Syndrome und juvenile myelomonzytäre Leukämie. **2006**, 715-723
- 52 Myelodysplastic Syndrome. **2006**, 41-49
- 51 Myelodysplastic Syndromes. **2007**, 195-205
- 50 Targeted Therapy in Myelodysplastic Syndrome. **2008**, 237-260
- 49 Diagnosis and Classification of the Acute Myeloid Leukemias (with Discussion of the Role of the Myelodysplastic Syndromes in AML Pathogenesis). **2008**, 21-46

- 48 Flow cytometry shows recurrent aneuploid clone after remission in megakaryocytic leukemia. **1988**, 296, 327-31
- 47 The WHO 2016 diagnostic criteria for Acute Myeloid leukemia with myelodysplasia related changes (AML-MRC) produce a very heterogeneous entity: A retrospective analysis of the FAB subtype RAEB-T. **2021**, 112, 106757 ○
- 46 Hybrid or Mixed Myelodysplastic/Myeloproliferative Disorders - Epidemiological Features and Overview. **2021**, 11, 778741
- 45 How do herbal medicines tonify the kidney and ameliorate the marrow microenvironment work on hemopoiesis. **1995**, 1, 47-51
- 44 Myelodysplastic Syndromes. **2020**, 107-126
- 43 Significance of WT1 and multiparameter flow cytometry assessment in patients with chronic myelomonocytic leukemia receiving allogeneic hematopoietic stem cell transplantation.. **2022**, ○
- 42 A Rare Case of Ankylosing Spondylitis Coexisting with Relapsing Polychondritis, Antiphospholipid Syndrome, and Myelodysplastic Syndrome.. **2022**,
- 41 Amsacrine, cytarabine and etoposide in the treatment of bad prognosis acute myeloid leukemia. **1989**, 6, 199-205 5
- 40 Impact of in vivo T-cell depletion in patients with myelodysplastic syndromes undergoing allogeneic hematopoietic stem cell transplant: a registry study from the Chronic Malignancies Working Party of the EBMT.. **2022**, ○
- 39 Prognostic value of a new clinically-based classification system in patients with CMML undergoing allogeneic HCT: a retrospective analysis of the EBMT-CMWP.. **2022**,
- 38 Feline pancytopenia: a review of causes, investigation and treatment. **2022**, 27, 1-11
- 37 Response to azacitidine in patients with chronic myelomonocytic leukemia according to overlap myelodysplastic/myeloproliferative neoplasms criteria.. **2022**, 116, 106836 ○
- 36 Incidence of myelodysplastic syndromes in Finland 1997-2016.. **2022**, 116, 106839 ○
- 35 A Case of Untreated Myeloid Sarcoma of the Pancreas Head Region: Diagnostic Process of AML Subtyping in an Autoptic Case.. **2021**, 2021, 7439148
- 34 Morphology of blood cells. **2022**, 64-197
- 33 Clinical, immunophenotypic, and cytogenetic characteristics of high-grade myelodysplastic syndromes with CD41-positive progenitor cells.. **2021**,
- 32 Bone marrow. 813-942
- 31 Myelodysplastic syndromes (MDS). 103-115

- 30 The iatrogenic leukaemias induced by radio- and/or chemotherapy. **1987**, 4, 245-57 6
- 29 Evolution of multiple cytogenetic clones and leukemic transformation in a case of myelodysplastic syndrome. **1989**, 6, 233-8 2
- 28 Different distribution of DNA polymerases alpha and beta in bone marrow and peripheral blood from human leukemia. **1988**, 5, 181-6 1
- 27 Prognostic impacts of serum levels of C-reactive protein, albumin, and total cholesterol in patients with myelodysplastic syndromes.. **2022**, 1
- 26 Prospective comparison of 5- and 7-day administration of azacitidine for myelodysplastic syndromes: a JALSG MDS212 trial.. **2022**, 1 1
- 25 Hematological Diseases. **2022**, 73-120
- 24 Case 314. **2012**, 636-637
- 23 Past, present and future in low-risk myelodysplastic syndrome. 9,
- 22 ASXL1 mutations with serum EPO levels predict poor response to darbepoetin alfa in lower-risk MDS: W-JHS MDS01 trial.
- 21 Haematological Improvement with Conservative Management in an Infant with Myelodysplasia. **1992**, 85, 495-496
- 20 Real-World Data on Chronic Myelomonocytic Leukemia: Clinical and Molecular Characteristics, Treatment, Emerging Drugs, and Patient Outcomes. **2022**, 14, 4107
- 19 A Current View on Pathogenesis, Diagnosis, and Treatment of Some Rare Acute Leukemia Variants. **2022**, 15, 307-326 0
- 18 SF3B1, RUNX1 and TP53 Mutations Significantly Impact the Outcome of Patients With Lower-Risk Myelodysplastic Syndrome. **2022**, 1 1
- 17 Extramedullary Hematopoiesis in Myelodysplastic Syndromes: A Systematic Literature Review. **2022**, 3, 569-573 0
- 16 Significance of abnormal blood coagulation in patients with chronic myelomonocytic leukemia. 0
- 15 Navigating the contested borders between myelodysplastic syndrome and acute myeloid leukemia. 12, 0
- 14 Treatment options and survival in real life during the past three decades in patients with chronic myelomonocytic leukemia. 0
- 13 Significance of reduced renal function in patients with chronic myelomonocytic leukemia. 0

- 12 MODERN PRINCIPLES OF CLASSIFICATION, PROGNOSIS AND TREATMENT OF PRIMARY MYELODYSPLASTIC SYNDROMES. **2011**, 34-41 ○
- 11 Myelodysplastic syndromes. **2022**, 8, ○
- 10 Outcomes of transplant-eligible patients with myelodysplastic syndrome with excess blasts registered in a prospective observational study: The JALSG-CS11-MDS-SCT. ○
- 9 Significance of cardiovascular comorbidity in patients with chronic myelomonocytic leukemia. ○
- 8 Significance of C-reactive protein in patients with chronic myelomonocytic leukemia. ○
- 7 Significance of hypergammaglobulinemia in patients with chronic myelomonocytic leukemia. ○
- 6 Flow cytometry in the diagnosis of myelodysplastic syndromes. ○
- 5 Pathogenic role of 25-hydroxycholesterol in cancer development and progression. ○
- 4 Impact of gene alterations on clinical outcome in young adults with myelodysplastic syndromes. **2023**, 13, ○
- 3 Molecular Drivers of Myelodysplastic Neoplasms (MDS) Classification and Prognostic Relevance. **2023**, 12, 627 ○
- 2 The Secondary Myelodysplastic Neoplasms (MDS) Jigsaw. **2023**, 15, 1483 ○
- 1 Allogeneic transplantation of bone marrow versus peripheral blood stem cells from HLA-identical relatives in patients with myelodysplastic syndromes and oligoblastic acute myeloid leukemia: a propensity score analysis of a nationwide database. **2023**, 102, 1215-1227 ○